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Abstract 
Background: 
Lewy body dementia (LBD), which comprises dementia with Lewy bodies (DLB) and 
Parkinson’s disease dementia (PDD), is characterised by transient clinical symptoms such as 
cognitive fluctuations which may be caused by alterations of intrinsic brain dynamics. The 
aim of this thesis is to investigate how dysfunctional brain connectivity and dynamics relate to 
the cognitive LBD phenotype, especially to attentional impairment and cognitive fluctuations. 
Methods: 
In order to investigate behavioural aspects of cognitive fluctuations in LBD, reaction time 
(RT) data from an attention task were analysed to study how attentional impairment in LBD 
differs from Alzheimer’s disease (AD) and healthy controls. Additionally, brain structural 
correlates of attentional dysfunction were assessed using voxel-based morphometry. 
Subsequently, resting-state fMRI data were analysed using static and dynamic functional 
connectivity and dynamic network analyses. Faster brain dynamics were assessed by EEG 
microstate analysis. 
Results:  
AD and LBD patients exhibited slower and more variable RTs than controls, with greater 
impairment in LBD than AD. Extremely slow responses occurred with comparable frequency 
in both dementia groups. There were widespread correlations between RT abnormalities and 
structural changes in AD patients, but not LBD.  
Functional connectivity was decreased in DLB patients compared to controls, mainly in 
motor, temporal, and frontal networks with sparing of the DMN. Differences between AD and 
DLB were subtle. Considering time-varying connectivity, AD and DLB patients spent more 
time in sparse connectivity configurations than controls and switched less often into more 
highly connected states. Compared to controls, variability of global network efficiency was 
reduced in patients with DLB.  
Microstate analysis revealed a marked and generalised increase in microstate duration in LBD 
patients compared to controls, which was not seen in AD and was related to a loss of dynamic 
connectivity between basal ganglia/thalamic and large-scale cortical networks. Microstate 
slowing was correlated with fluctuation severity in the DLB group and with RT slowing and 
variability across all participants. 
Conclusions: 
Different aspects of RT performance are differentially affected by AD and LBD, with a 
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difference in structural neural correlates. The dynamic connectivity and microstate results 
indicate a loss of brain dynamics in LBD which might lead to a breakdown of the intricate 
dynamic properties of the brain, thereby causing loss of flexibility that is crucial for healthy 
brain function. This might lead to a network configuration which gives rise to the cognitive 
LBD phenotype characterised by attentional impairment and cognitive fluctuations.  
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Chapter 1. Introduction 
1.1 Lewy Body Dementia 
Lewy body dementia (LBD) is an umbrella term describing two common forms of 
neurodegenerative dementia in older age that present with a similar clinical phenotype and 
which share the same underlying neuropathology: dementia with Lewy bodies (DLB) and 
Parkinson’s disease dementia (PDD) (McKeith et al., 2017, 2005). Accounting for 
approximately 10-15% of all neuropathologically defined dementia cases, LBD is the second 
most common form of neurodegenerative dementia after Alzheimer’s disease (AD) (McKeith 
et al., 1996; Vann Jones and O’Brien, 2014). 
1.1.1 Clinical features 
The central requirement for a diagnosis of DLB or PDD is dementia which is defined as a 
progressive decline in cognition of sufficient severity to interfere with normal social or 
occupational functions (McKeith et al., 2017). In addition, there are a number of clinical 
symptoms associated with LBD including (1) complex and recurrent visual hallucinations, (2) 
rapid eye movement (REM) sleep behaviour disorder (RBD), (3) spontaneous Parkinsonism, 
and (4) cognitive fluctuations (McKeith et al., 2017, 2005). These are core diagnostic features 
of DLB, but frequently occur in PDD as well (Emre et al., 2007).  
Visual hallucinations occur in up to 80% of LBD patients and typically present in the form of 
well-formed and detailed images of people, animals, and objects (Aarsland et al., 2001; 
Mosimann et al., 2006). RBD is characterised by an absence of normal REM sleep atonia 
leading to dream enactment behaviour, and can precede the onset of other symptoms by many 
years (Ferman et al., 2011). Parkinsonism in DLB and PDD is often associated with postural 
instability, gait, and speech disturbances. Rest tremor is not as common as in Parkinson’s 
disease (PD) patients without dementia (Burn et al., 2003). Apart from motor disturbances, 
Parkinsonism in LBD is also commonly associated with a slowness of thinking referred to as 
bradyphrenia (Firbank et al., 2018). Cognitive fluctuations are characterised by pronounced 
variations in attention and alertness over time. They will be discussed in more detail in 
Section 1.2.  
Other features that are associated with LBD and that can help inform a clinical diagnosis 
include autonomic dysfunction, syncope, repeated falls, neuroleptic sensitivity, delusions, 
apathy, anxiety, and depression (McKeith et al., 2017). From a neuropsychological 
perspective, both DLB and PDD are characterised by marked deficits in executive, 
visuospatial, visuoperceptual, and attentional function (Emre et al., 2007; Ferman et al., 2006; 
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Walker et al., 2015).  
Currently, there are no disease-modifying treatments for LBD. However, acetylcholinesterase 
inhibitors have been used in LBD patients with positive effects on overall cognition, visual 
hallucinations and other neuropsychiatric symptoms, as well as attentional impairment 
(Aarsland et al., 2004; McKeith et al., 2000b; Stinton et al., 2015; Wang et al., 2015; Wesnes 
et al., 2002). Similarly, memantine has been shown to improve overall cognition, attention, 
and episodic memory in DLB and PDD (Aarsland et al., 2009a; Emre et al., 2010; Wesnes et 
al., 2015). Furthermore, dopaminergic medication is used to treat motor symptoms in LBD 
(Bonelli et al., 2004; Molloy et al., 2005). 
1.1.2 Neuropathology 
A definitive diagnosis of LBD is dependent on the presence of Lewy body pathology at 
autopsy which is characterised by abnormal aggregations of the presynaptic protein alpha-
synuclein in the form of Lewy bodies (found in the neuronal cytoplasm) or Lewy neurites 
(found inside dystrophic neurons) (Dickson, 2002; McKeith et al., 2005). These can be widely 
distributed throughout the peripheral and central nervous system and are found in the 
brainstem, basal forebrain, limbic regions, and the neocortex (Beach et al., 2009; Braak et al., 
2003). Lewy body pathology is also characteristic of other neurodegenerative disorders 
including PD and multiple system atrophy which together with LBD are collectively referred 
to as alpha-synucleinopathies (Jellinger, 2003) (see Figure 1.1). In the context of PD, it has 
been suggested that accumulation of Lewy bodies follows an ascending pathway, starting in 
the lower brainstem and progressing to limbic and subsequently to neocortical regions in a 
caudo-rostral distribution (Braak et al., 2003). This is also thought to reflect the clinical 
phenotype with brainstem-predominant pathology being associated with PD without dementia 
and the accumulation of pathology in higher-order regions being related to a clinical 
presentation with more severe cognitive impairment (Braak et al., 2004; Halliday and 
McCann, 2010). However, many DLB cases do not necessarily follow this staging system, i.e. 
Lewy body pathology may be found in neocortical areas with sparing of lower brain regions 
(Frigerio et al., 2011; Parkkinen et al., 2005; Zaccai et al., 2008) and significant Lewy body 
pathology may be present without the development of cognitive or motor impairment 
(Colosimo, 2003; Parkkinen et al., 2008). A further pathological finding that is characteristic 
of both DLB and PDD is the loss of midbrain dopaminergic neurons and cholinergic neurons 
in the ventral forebrain nuclei (Kövari et al., 2009), leading to marked dopaminergic and 
cholinergic deficits (Lippa et al., 1999).  
In many LBD cases, especially those with DLB, significant concurrent AD pathology is  
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Figure 1.1. Overview of diseases that are characterised by Lewy body pathology.  
present in the form of neuritic plaques (extracellular amyloid-beta aggregations) and 
neurofibrillary tangles (intraneuronal accumulation of hyperphosphorylated tau) (Dugger et 
al., 2014; Howlett et al., 2015). Conversely, Lewy body pathology can also be present in 
cases with clinical AD and is typically found in the amygdala (Lippa et al., 2005; Popescu et 
al., 2004). 
While it is still unclear how Lewy body and other pathologies lead to the clinical 
manifestation of the disease, several studies have identified possible clinicopathological 
correlations. In PD, the development of dementia has been associated with the presence of 
cortical and limbic Lewy bodies (Hurtig et al., 2000; Kövari et al., 2003) as well as 
cholinergic deficits (Klein et al., 2010), and the level of cognitive impairment in DLB has 
been related to the severity of Lewy body pathology (Beach et al., 2009). Furthermore, Lewy 
bodies in the hippocampus have been shown to be associated with memory impairment in 
DLB (Adamowicz et al., 2017). Neuronal loss in the substantia nigra is the strongest correlate 
of Parkinsonism in LBD (McKeith et al., 2017). The presence of visual hallucinations has 
been related to Lewy body pathology in limbic regions (Ferman et al., 2013a) and the 
4 
 
temporal lobe (Harding et al., 2002) (with relative sparing of early visual areas (Erskine et al., 
2015)) and to disturbances in cholinergic neurotransmission (Ballard et al., 2000). The 
relation between pathological changes and cognitive fluctuations is less clear (Harding et al., 
2002). There is, however, evidence that higher binding of nicotinic receptors in the temporal 
cortex and thalamus may be associated with fluctuating cognition (Ballard et al., 2002b; 
Pimlott et al., 2006). Additionally, it has been suggested that cognitive fluctuations are more 
prevalent in patients with neocortical Lewy bodies as opposed to patients with predominantly 
striatal or limbic pathology (Schneider et al., 2012). The effect of concomitant AD pathology 
on the clinical presentation of LBD will be discussed in more detail in Section 1.1.4. 
1.1.3 DLB vs PDD 
DLB and PDD are differentiated clinically based on the time-course of symptom 
development: DLB is diagnosed if dementia occurs before or simultaneously with 
Parkinsonism whereas PDD is diagnosed if dementia develops in the context of well-
established PD. For practical purposes the one-year rule is applied where DLB is diagnosed in 
patients who develop cognitive symptoms before or within one year of the onset of 
Parkinsonism and where PDD is diagnosed if the onset of motor symptoms precedes the 
development of cognitive symptoms by more than a year (Aarsland et al., 2009b; McKeith et 
al., 2017, 2005). Numerous studies have investigated similarities and differences between 
DLB and PDD in terms of behavioural, clinical, morphological, and neurochemical 
characteristics. However, it is still debated whether they represent distinct disease entities or 
merely different points on the same disease spectrum (e.g. Friedman, 2018; Jellinger and 
Korczyn, 2018) (see Table 1.1 for a comparison of clinical and pathological characteristics 
between DLB and PDD). 
Table 1.1. Comparison of clinical and pathological characteristics between DLB and PDD.  
 DLB PDD 
Attention +++ +++ 
Executive dysfunction +++ +++ 
Cognitive fluctuations +++ ++ 
Parkinsonism variable present 
Visual hallucinations +++ ++ 
Delusions +++ ++ 
Responsiveness to levodopa +/- + 
Nigrostriatal loss + +++ 
Cortical/striatal pathology +++ ++ 
Amyloid deposition moderate – high low 
DLB, dementia with Lewy bodies; PDD, Parkinson’s disease dementia. 
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From a neuropathological and neurochemical perspective, DLB and PDD are difficult to 
discriminate, with no hallmark pathological feature that distinguishes the two (Harding and 
Halliday, 2001; Klein et al., 2010; Tsuboi and Dickson, 2005). Neuronal loss in the substantia 
nigra might be more severe in PDD relative to DLB (Tsuboi and Dickson, 2005), whereas 
pathological burden in the striatum has been found to be higher in DLB than in PDD 
(Jellinger and Attems, 2006). Additionally, more severe Lewy body pathology in the temporal 
lobe has been reported in DLB than in PDD (Harding et al., 2002). Nevertheless, similar 
striatal dopaminergic deficits have been observed in both conditions (Klein et al., 2010). 
Some studies report a higher prevalence of AD pathology in DLB than in PDD (Edison et al., 
2008; Gomperts et al., 2008; Harding and Halliday, 2001; van Steenoven et al., 2016) 
whereas others have failed to find such differences (Tsuboi and Dickson, 2005).  
Studies of grey and white matter differences between DLB and PDD have found conflicting 
results. While one study did not find any differences in white matter hyperintensities (Burton 
et al., 2006), others have found more severe white matter abnormalities in DLB than in PDD 
which has been hypothesised to be due to concurrent AD pathology in DLB patients (Joki et 
al., 2018; Lee et al., 2010). Similarly, for grey matter atrophy some studies described more 
pronounced loss in DLB compared to PDD (Beyer et al., 2007; Joki et al., 2018; Lee et al., 
2010) whereas other studies could not identify differences between the groups (Burton et al., 
2004; Hattori et al., 2012; Janzen et al., 2012; Kenny et al., 2008; Tam et al., 2005). DLB and 
PDD show similar deficits in blood perfusion across the brain with slightly more pronounced 
hypoperfusion in DLB than in PDD (Hattori et al., 2012; Mito et al., 2005). Additionally, 
functional connectivity has been shown to be comparable between the two conditions, with 
only subtle differences in motor- and attention-related networks (Peraza et al., 2015a). 
Overall, cognitive and neuropsychological profiles have been shown to be similar (Aarsland 
et al., 2003; Aldridge et al., 2018; Noe et al., 2004), with slight differences in verbal learning 
and memory which may be more impaired in DLB than in PDD (Brønnick, 2015; Filoteo et 
al., 2009; Mondon et al., 2007; Park et al., 2011). Sleep and motor abnormalities are 
comparable in DLB and PDD (Boddy et al., 2007; McKeith et al., 2005) as are 
visuoperceptual impairment and neuropsychiatric symptoms (Fields, 2017; Mosimann et al., 
2004). The phenomenology of visual hallucinations and delusions is similar in the LBD 
subgroups (Aarsland et al., 2001; Mosimann et al., 2006). However, both delusions and 
hallucinations have been shown to be more prevalent in DLB than in PDD (Aarsland et al., 
2001; Savica et al., 2013). While cognitive fluctuations are clinically indistinguishable 
between DLB and PDD (Ballard et al., 2002a; Varanese et al., 2010) they occur with a higher 
prevalence in DLB (Savica et al., 2013). Furthermore, attentional and executive impairment 
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has been reported to be comparable in both conditions (Ballard et al., 2002a; Firbank et al., 
2016; Mondon et al., 2007), with one study reporting slightly worse deficits in DLB than in 
PDD (Park et al., 2011). In particular, a functional neuroimaging study of attentional 
dysfunction in LBD did not find any behavioural and only subtle neuroimaging differences 
between DLB and PDD, indicating that similar processes underlie attentional-executive 
impairment in both groups (Firbank et al., 2016). From an electrophysiological perspective, 
there are no differences between DLB patients and PDD patients with cognitive fluctuations 
(Bonanni et al., 2008). Further support comes from a meta-analysis of attention and executive 
dysfunction in DLB and PDD in which the authors did not find statistical evidence for a 
difference between the two groups (Brønnick, 2015).  
In summary, while some clinical and neuropsychological studies have found subtle 
differences between DLB and PDD, the overall presentation of the two patient groups seems 
to be similar, especially with respect to attentional impairment and cognitive fluctuations. 
DLB and PDD patients were therefore combined into one Lewy body dementia group for 
most analyses in this thesis. Nevertheless, since the exact relationship between DLB and PDD 
is still unclear and previous studies have reported conflicting results, additional analyses were 
performed to investigate potential differences between the two groups in terms of the clinical, 
behavioural, and neuroimaging measures presented in this thesis. 
1.1.4 LBD vs AD 
While the specificity of the clinical diagnostic criteria for LBD is high, i.e. most patients with 
a clinical diagnosis of LBD will show significant Lewy body pathology at autopsy (McKeith 
et al., 2000a), their sensitivity can be low which is mainly due to patients being misdiagnosed 
with AD (Litvan et al., 2003, 1998; Lopez et al., 2002; Rizzo et al., 2017). This prevents 
misdiagnosed patients from receiving appropriate treatment, can have potentially adverse 
effects due to neuroleptic sensitivity in LBD (McKeith et al., 1992a), and constitutes a 
problem when stratifying patients for research studies or clinical trials. While LBD and AD 
are in theory characterised by different phenotypes, there is often considerable clinical overlap 
(Thomas et al., 2018). While AD is characterised by more pronounced impairment in episodic 
memory relative to LBD in the early stages (Calderon, 2001; Economou et al., 2016; Kraybill 
et al., 2005; Noe et al., 2004), memory impairment usually develops with disease progression 
in LBD (McKeith et al., 2017). In contrast, LBD patients show more severe attentional and 
executive impairment than AD patients (Kraybill et al., 2005; Noe et al., 2004), and cognitive 
fluctuations (Ferman et al., 2004) as well as visual hallucinations (Thomas et al., 2018) seem 
to be the most distinguishing features. 
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Many LBD cases, especially those with DLB, exhibit significant concurrent AD pathology 
(Dugger et al., 2014; Howlett et al., 2015) which can be assessed at autopsy or in vivo using 
positron emission tomography (PET) imaging or analysis of cerebrospinal fluid (CSF) 
markers (Donaghy et al., 2015). This additional pathological burden has been related to higher 
global atrophy rates in LBD (Nedelska et al., 2015; Sarro et al., 2016; Shimada et al., 2013) 
and to medial temporal lobe atrophy which is typically seen in clinical AD (Elder et al., 2017; 
van der Zande et al., 2018). Amyloid-beta deposition has also been associated with lower 
medial temporal lobe perfusion in DLB (Donaghy et al., 2018). From a clinical point of view, 
the severity of AD pathology is inversely related to the LBD clinical phenotype (Ballard et al., 
2004; Fujishiro et al., 2008; McKeith et al., 2005), and LBD patients with mixed pathology 
show more severe memory impairment than pure Lewy body cases (Kraybill et al., 2005). 
Furthermore, coexisting AD pathology in LBD is associated with a more severe manifestation 
of the disease (van Steenoven et al., 2016), a higher risk of institutionalisation and mortality 
(Graff-Radford et al., 2016; Lemstra et al., 2017), lower cognitive performance (Foster et al., 
2010), and a more rapid cognitive decline (Blanc et al., 2017; Howlett et al., 2015; Kraybill et 
al., 2005; Sarro et al., 2016).  
Based on these considerations, the reasons for including an AD group in the analyses of this 
thesis are two-fold. Firstly, AD patients were included so as to get a better understanding of 
commonalities and differences between these two common forms of dementia which may be 
important in the context of a differential diagnosis. Secondly, AD patients were included as a 
disease-comparator group to disentangle which of the differences that were observed in the 
comparison between patients with LBD and healthy controls might be a general dementia 
phenomenon and which might be specific LBD-related changes. 
1.2 Cognitive Fluctuations 
Even though the recognition of DLB as a distinct diagnostic entity is relatively recent 
(McKeith et al., 1992b), cognitive fluctuations have long been recognised as a salient feature 
of the phenotype, as described in early clinicopathological series (Forno et al., 1978; Gibb et 
al., 1987; Woodard, 1962). This culminated in the identification of cognitive fluctuations as a 
key feature of the disease in the first consensus criteria (McKeith et al., 1996). They are now 
regarded as one of the most characteristic features of the condition and form an important 
element in differential diagnosis (McKeith, 2002; McKeith et al., 1992b). However, accurate 
identification of cognitive fluctuations can pose a clinical challenge (Cummings, 2004; Litvan 
et al., 1998; Mega et al., 1996). 
Data pertaining to the prevalence of cognitive fluctuations in DLB are heterogeneous, with 
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rates of 45-90% reported (Bradshaw et al., 2004; Byrne et al., 1989; Lee et al., 2012; 
Varanese et al., 2010; Verghese et al., 1999). They are also common in PDD, albeit being 
slightly less prevalent than in DLB (Ballard et al., 2002a; Savica et al., 2013). 
While some data suggest that cognitive fluctuations are a late manifestation of the disease, 
occurring on average 4.5 years after onset of cognitive symptoms (Molano et al., 2010), 
others have identified cognitive fluctuations in the prodromal phase in 30% (Jicha et al., 
2010) to 60% (Cagnin et al., 2015) of patients. Furthermore, the presence of cognitive 
fluctuations in non-amnestic mild cognitive impairment (MCI) cohorts has been shown to be 
predictive of conversion to DLB (Ferman et al., 2013b; Sadiq et al., 2017), and it has been 
described as one of the most characteristic features of prodromal DLB (Donaghy et al., 2017).  
Cognitive fluctuations are associated with impaired quality of life and inability to perform 
activities of daily living (Brønnick et al., 2006; Sun et al., 2018). They contribute to greater 
disability and caregiver burden (Ballard et al., 2001b; Lee et al., 2013), and can present the 
clinician with significant challenges in the assessment of decision-making capacity (Shulman 
et al., 2015; Trachsel et al., 2015). Cognitive fluctuations therefore constitute an important 
therapeutic target. However, their aetiology is still poorly understood. 
1.2.1 Clinical and behavioural manifestation of cognitive fluctuations 
Qualitatively, the clinical manifestation of cognitive fluctuations in LBD is primarily that of 
an altered level of alertness and attention with a marked amplitude between best and worst 
performances ranging from episodes of switching off or going blank, to spontaneous 
remission to normal or near-normal performance (Ballard et al., 2002a; McKeith, 2002; 
McKeith et al., 1996) (see Figure 1.2). This is described as having a spontaneous, periodic, 
and transient quality, as opposed to the fluctuations in cognitive performance seen in AD in 
response to inter-current environmental demands; informants in the latter circumstance more 
frequently cite episodes of memory failure rather than significant alterations in alertness 
(Bradshaw et al., 2004). As such, cognitive fluctuations in LBD are largely an internally-
mediated process, whilst fluctuations in AD are more frequently a consequence of an altered 
external environment. While fluctuations in LBD are classically transient, clinical experience 
has long suggested that there may be a spectrum of severity, from periods of altered attention 
or drowsiness – lasting seconds or minutes – to days of obtundation (McKeith et al., 1996, 
1992b). However, there does not seem to be a clear diurnal pattern, and mild diurnal/nocturnal 
variations that occur in other dementia subtypes should not be considered to support a clinical 
diagnosis of cognitive fluctuations (McKeith et al., 1996). 
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Figure 1.2. Cognitive fluctuations in LBD. 
Behaviourally, cognitive fluctuations have been associated with impairments in reaction time 
(RT) performance on tests of sustained attention. LBD patients with a higher severity of 
cognitive fluctuations show slower RTs, impaired vigilance, and higher variability in RT 
performance than those with less severe fluctuations (Ballard et al., 2002a, 2001b; Onofrj et 
al., 2003; Walker et al., 2000a). Furthermore, the severity of cognitive fluctuations as assessed 
by clinical fluctuation scores has been shown to correlate with variability in attentional 
performance across 90 seconds (Walker et al., 2000a, 2000b, 2000c). These results highlight 
the relationship between cognitive fluctuations and fluctuations in attention and alertness, and 
indicate that cognitive fluctuations might be associated with perturbations in attentional 
circuitry. Furthermore, it has been suggested that measures of attentional variability might 
represent an objective and accurate tool to characterise and quantify cognitive fluctuations in 
LBD (Walker et al., 2000a). 
In addition to attentional impairment, there seems to be a sleep/arousal dimension 
contributing to cognitive fluctuations. Patients with advanced LBD have extremely poor sleep 
efficiency and may demonstrate profound distortions in sleep-wake architecture (Pao et al., 
2013). Hypersomnolence has been incorporated as a supportive feature in the most recent 
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DLB diagnostic criteria (McKeith et al., 2017), and one of the clinical tools to investigate 
cognitive fluctuations specifically enquires as to the presence of excessive daytime 
somnolence (Ferman et al., 2004). The presence of RBD appears to correlate with cognitive 
fluctuations in DLB (Escandon et al., 2010), and some studies suggest that sleep disturbances 
and cognitive fluctuations may reciprocally potentiate each other (Cagnin et al., 2016). 
However, this may also represent concomitant pathological involvement of anatomically 
related structures in brainstem-thalamo-cortical networks (Antelmi et al., 2016; Terzaghi et 
al., 2013). Additionally, other studies do not find any correlations between polysomnography 
parameters as well as multiple sleep latency tests and cognitive fluctuations in DLB (Bliwise 
et al., 2014; Ferman et al., 2014). Nevertheless, certain findings suggest that there may be two 
distinct dimensions to fluctuations, one related to attention and one related to 
arousal/alertness. 
1.2.2 Clinical assessment tools 
A number of clinical assessment tools have been devised in an effort to better identify 
cognitive fluctuations and distinguish fluctuations in LBD from those seen in other dementia 
subtypes (Ferman et al., 2004; Lee et al., 2014; Walker et al., 2000b).  
The Clinician Assessment of Fluctuation (CAF), a series of questions administered to an 
informant by an experienced clinician, assesses the severity and duration of fluctuations in 
cognition and levels of confusion during the month prior to the assessment (Walker et al., 
2000b). Cognitive fluctuations are considered to be present, if the informant is able to provide 
a clear example. If present, severity and duration of the cognitive fluctuations are rated on a 
scale from 0-4; both scores are then multiplied to obtain a total score ranging from 0-12 with a 
score of 0 representing no fluctuations and a score of 12 representing severe fluctuations (a 
score of 16 would indicate a continuously confused state and hence no fluctuations). This 
scale showed fair inter-rater reliability with excellent reliability in scoring severe fluctuations 
(Van Dyk et al., 2016) as well as good sensitivity and specificity at distinguishing DLB from 
AD and vascular dementia (Walker et al., 2000b); however, it needs to be administered by an 
experienced clinician which makes its application in clinical trials challenging.  
Similarly, the Mayo fluctuations scale is a 19-item questionnaire delivered to the patient’s 
caregiver to evaluate fluctuating cognition during the month prior to the assessment (Ferman 
et al., 2004). A total score is calculated; additionally, a cognitive and an arousal subscore can 
be derived by focussing on questions related to cognitive and arousal aspects of fluctuations, 
respectively (Bliwise et al., 2014). It can reliably differentiate DLB from AD (Ferman et al., 
2004), however, its utility in distinguishing DLB from other dementia subtypes remains 
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unclear (Lee et al., 2012).  
The One Day Fluctuation Assessment Scale is a brief clinician-rated scale to evaluate 
cognitive fluctuations over a period of 24 hours prior to the assessment (Walker et al., 2000b). 
While Walker et al. (2000b) have reported good sensitivity at differentiating DLB from AD 
and healthy controls, Bradshaw et al. (2004) have only found low sensitivity for detecting 
cognitive fluctuations in DLB patients. 
Building on these fluctuation scales, the Dementia Cognitive Fluctuation Scale is a more 
recently developed scale aiming to address some of the difficulties associated with previous 
fluctuation measures (Lee et al., 2014). It demonstrates good test-retest and inter-rater 
reliability and accurately distinguishes between LBD, AD, and vascular dementia, especially 
in patients with mild to moderate dementia (Lee et al., 2014). While the full version can be 
applied in research studies, a shorter four-item clinician version is envisaged to facilitate its 
use in clinical practice (Lee et al., 2014). 
However, many challenges regarding the accurate clinical assessment of fluctuations still 
remain, and several studies have underscored the importance of developing more objective 
measures of cognitive fluctuations (Bonanni et al., 2015; Lee et al., 2012; Walker et al., 
2000a). 
1.2.3 Symptomatic treatment of cognitive fluctuations  
The prevalence of cognitive fluctuations in LBD patients and their negative impact on patient 
and carer quality of life highlights the need for targeted therapies; however, in the therapeutic 
armoury for LBD, they are something of a neglected symptom.  
Acetylcholinesterase inhibitors have shown some efficacy in treating cognitive fluctuations. 
There is evidence for a role of donepezil (Onofrj et al., 2003) and galantamine (Edwards et 
al., 2007) in ameliorating clinical features of cognitive fluctuations and associated 
electroencephalogram (EEG) abnormalities, while the benefit of rivastigmine and memantine 
in this regard is less certain (Stinton et al., 2015). Similarly, the finding that deep brain 
stimulation of the nucleus basalis of Meynert (NBM) stabilises alertness and other cognitive 
features in a PDD patient with cognitive fluctuations (Freund et al., 2009) suggests that this 
may be a potential therapeutic option. However, a more recent randomised clinical trial of 
NBM stimulation in patients with PDD did not find the same effects on cognition (Gratwicke 
et al., 2018). Following the conjecture that fluctuating cognition might be related to a disorder 
of sleep or arousal, there is encouraging preliminary evidence for the efficacy of modafinil 
and armodafinil even though numbers are limited (Varanese et al., 2013). 
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1.2.4 Neural correlates of cognitive fluctuations in LBD 
Cognitive fluctuations in LBD are likely to be attributable to a separate pathophysiological 
process from that driving the progressive cognitive decline, as these fluctuations, by nature, 
are transient and reversible. This hypothesis has been investigated using structural and 
functional neuroimaging, as well as electrophysiological techniques. Tables 1.2 - 1.5 show an 
overview of studies that examined possible neural correlates of cognitive fluctuations in LBD 
using different neuroimaging methods. 
Structural neuroimaging (Table 1.2) 
DLB and PDD are generally characterised by less severe structural abnormalities than AD 
with a relative preservation of the medial temporal lobe (Barber et al., 2000; Beyer et al., 
2007; Burton et al., 2009, 2004, 2002; Mak et al., 2014; Takahashi et al., 2010; Tam et al., 
2005; Watson et al., 2012). Nevertheless, a recent meta-analysis of voxel-based morphometry 
(VBM) studies identified consistent grey matter atrophy in the basal ganglia (putamen and 
globus pallidus), insular cortex, and lateral temporal areas in patients with DLB compared to 
controls (Zhong et al., 2014). There does not, however, appear to be a clear-cut structural 
correlate for cognitive fluctuations. No association was found between hippocampal (Elder et 
al., 2017; Kantarci et al., 2012), cerebellar (Colloby et al., 2014), anterior cingulate or insular 
(Blanc et al., 2016) grey matter volume and the severity of cognitive fluctuations. A possible 
contribution of thalamic structural abnormalities has been suggested based on the finding that 
thalamic atrophy is associated with the severity of attentional deficits in DLB (Watson et al., 
2017). Suggesting an involvement of cholinergic structures in cognitive fluctuations, several 
studies have identified structural abnormalities within the substantia innominata of patients 
with DLB, which are more pronounced than in patients with AD (Colloby et al., 2017; Hanyu 
et al., 2007, 2005; Whitwell et al., 2007) and which are related to the severity of cognitive 
fluctuations (Colloby et al., 2017).  
Subcortical and cortical white matter lesions are common in DLB patients (Bozzali et al., 
2005; Kantarci et al., 2010; Sarro et al., 2017); however, there appears to be no correlation 
between the burden of white matter lesions and cognitive fluctuations (Kantarci et al., 2010; 
Sarro et al., 2017). White matter degeneration in the anterior thalamic radiation which has 
been observed in DLB is not correlated with fluctuation severity (Delli Pizzi et al., 2015a). 
Similarly, disturbances in the projections from thalamus to prefrontal and parieto-occipital 
cortices present in DLB do not correlate with cognitive fluctuation severity (Delli Pizzi et al., 
2015b). 
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Table 1.2. Structural MRI studies of cognitive fluctuations. 
 Methods Participants Fluctuation 
measure 
Results  
Kantarci et al. (2010) DTI 30 DLB, 30 
AD, 60 HC 
Mayo Elevated MD in amygdala and decreased FA in inferior longitudinal 
fasciculus in DLB compared to HC, but no difference between 
fluctuating and non-fluctuating DLB patients for these measures 
Kantarci et al. (2012) VBM 21 DLB, 21 
AD, 42 HC 
Mayo No difference in hippocampal volume between DLB patients with and 
without cognitive fluctuations  
Colloby et al. (2014) VBM 41 DLB, 48 
AD, 39 HC 
CAF Cerebellar grey matter loss in DLB compared to HC, but no significant 
correlations with CAF 
Delli Pizzi et al. (2015a) DTI 14 DLB, 14 
AD, 15 HC 
CAF Degeneration of anterior thalamic radiation in DLB compared to HC, 
but no correlation with CAF 
Delli Pizzi et al. (2015b) DTI 16 DLB, 16 
AD, 13 HC 
CAF Increased MD in thalamic regions projecting to prefrontal and parieto-
occipital cortices in DLB compared to HC, but not correlated with 
CAF in DLB 
Blanc et al. (2016) VBM 28 pDLB, 
27 pAD, 33 
HC 
CAF Grey matter atrophy in insulae and anterior cingulate cortex in 
prodromal DLB compared to HC, but not correlated with CAF in DLB 
Colloby et al. (2017) VBM 41 DLB, 47 
AD, 39 HC 
CAF Bilateral grey matter atrophy in substantia innominata (SI) in DLB and 
AD compared to HC; negative correlation between right SI volume 
and CAF in DLB 
Elder et al. (2017) cortical 
thickness 
65 DLB, 76 
AD, 63 HC 
CAF Hippocampal atrophy less severe in DLB than in AD and not 
correlated with CAF in DLB 
Sarro et al., (2017) cerebrovascular 
lesions 
81 DLB, 
240 AD 
Mayo No difference in white matter hyperintensities between DLB patients 
with and without cognitive fluctuations 
Watson et al. (2017) thalamic atrophy 35 DLB, 35 
HC 
attention 
task 
Atrophy of left pulvinar and ventral lateral nucleus of the thalamus 
associated with impaired attentional function in DLB 
AD, Alzheimer’s disease; CAF, Clinician Assessment of Fluctuation; DLB, dementia with Lewy bodies; DTI, diffusion tensor imaging; FA, fractional anisotropy; HC, healthy 
controls; Mayo, Mayo Fluctuation scale; MD, mean diffusivity; MRI, magnetic resonance imaging; pAD, prodromal AD; pDLB, prodromal DLB; SI, substantia innominata; 
VBM, voxel-based morphometry. 
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The lack of a clear structural correlate of cognitive fluctuations is not surprising given their 
transient and reversible nature, and the fact that Lewy body pathology has been shown to have 
little direct involvement in cerebral atrophy (Burton et al., 2009; Mak et al., 2015a, 2015b). It 
has therefore been suggested that cognitive fluctuations might arise from large-scale 
functional network perturbations within the brain. These can be assessed by functional 
neuroimaging and electrophysiological methods as discussed in the following paragraphs. 
Functional neuroimaging (Table 1.3) 
A potential involvement of attentional networks in cognitive fluctuations has been 
investigated through functional connectivity analyses at rest and during task performance 
using functional magnetic resonance imaging (fMRI). In patients with DLB, Peraza et al. 
(2014) have identified a desynchronisation of several cortical and subcortical areas related to 
the left fronto-parietal attention network which was associated with the severity and 
frequency of cognitive fluctuations. Similarly, Franciotti et al. (2013) have found that 
functional connectivity between right middle frontal gyrus and right lateral parietal cortex was 
negatively correlated with fluctuation severity in DLB. Furthermore, attention network 
connectivity has been found to be decreased in LBD compared to control participants during 
the execution of an attention task; however, this was not related to the severity of cognitive 
fluctuations in the patient groups (Kobeleva et al., 2017). A possible relation between 
cognitive fluctuations and aberrant connectivity in basal ganglia and limbic networks has also 
been reported (Lowther et al., 2014). 
Another neural network potentially involved in cognitive fluctuations is the default mode 
network (DMN) which is active in resting conditions, but deactivated during task performance 
(Binder et al., 1999; Buckner, 2005; Gusnard and Raichle, 2001). However, data to support 
this concept are conflicting. One resting-state fMRI study reported reductions in DMN 
functional connectivity in patients with DLB compared to AD patients and controls (Lowther 
et al., 2014) whereas others showed increased DMN connectivity (Kenny et al., 2012) or did 
not find any evidence for connectivity alterations within the DMN (Galvin et al., 2011; Peraza 
et al., 2014). In particular, Franciotti et al. (2013) have found no evidence for a correlation 
between DMN abnormalities and cognitive fluctuations in DLB; even in patients with severe 
fluctuations, the DMN appeared to be intact, indicating that changes within the DMN alone 
cannot account for cognitive fluctuations in DLB. 
A more intricate explanation may lie in the interplay between attentional and default mode 
networks which is important for attentional performance (Sonuga-Barke and Castellanos, 
2007; Weissman et al., 2006). In support of this, several studies have found 
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Table 1.3. Functional MRI and MRS studies of cognitive fluctuations. 
 Methods Participants Fluctuation 
measure  
Results  
Sauer et al. (2006) Attention task-
fMRI 
9 DLB, 10 
AD, 13 HC 
attention 
task 
Reduced attention task-related deactivation of the DMN in both 
AD and DLB 
Franciotti et al. (2013) Rest-fMRI, 
seed analysis  
18 DLB, 18 
AD, 15 HC 
CAF No evidence of resting-state DMN disruption in presence of 
cognitive fluctuations 
Lowther et al. (2014) Rest-fMRI, 
dual regression 
15 DLB, 13 
AD, 40 HC 
CAF Positive correlation between basal ganglia and limbic network 
connectivity and CAF in DLB 
Peraza et al. (2014) Rest-fMRI, 
dual regression 
16 DLB, 17 
HC 
CAF Positive correlation of connectivity within left fronto-parietal 
network clusters in pallidum, lingual gyrus, and putamen with CAF 
in DLB 
Peraza et al. (2015b) Rest-fMRI, 
graph theory 
18 DLB, 19 
AD, 17 HC 
CAF Positive correlation between normative path length and CAF in 
DLB 
Peraza et al. (2016) Rest fMRI, 
ReHo 
19 DLB, 18 
AD, 16 HC 
CAF No significant correlations between ReHo abnormalities and CAF 
in DLB 
Kobeleva et al. (2017) Attention task-
fMRI 
30 LBD, 20 
AD, 21 HC 
CAF, 
Mayo 
Attention network connectivity reduced in LBD compared to HC, 
but no significant correlations with CAF or Mayo scores in LBD 
Chabran et al. (2018) Visuoperceptual 
task-fMRI 
26 DLB, 29 
AD, 22 HC 
CAF Positive correlation between DMN synchronisation with task 
paradigm and CAF in DLB 
Graff-Radford et al. (2014) MRS 34 DLB, 35 
AD, 148 HC 
Mayo No difference in metabolites in frontal, posterior cingulate, and 
occipital regions between DLB with and without fluctuations  
Delli Pizzi et al. (2015b) MRS 16 DLB, 16 
AD, 13 HC 
CAF Increase in tCho/tCr in right thalamus in DLB compared to AD, 
this increase positively correlates with CAF 
Su et al. (2016) MRS 35 DLB, 36 
AD, 35 HC 
CAF Negative correlation between hippocampal NAA/Cr levels and 
CAF in DLB 
AD, Alzheimer’s disease; CAF, Clinician Assessment of Fluctuation; CRT, choice reaction time; DLB, dementia with Lewy bodies; DMN, default mode network; fMRI, 
functional magnetic resonance imaging; HC, healthy controls; LBD, Lewy body dementia; Mayo, Mayo Fluctuation scale; MRS, magnetic resonance spectroscopy; NAA/Cr, N-
acetyl-aspartate/total creatine ratio; ODFAS, One Day Fluctuation Assessment Scale; ReHo, regional homogeneity; rest-fMRI, resting-state fMRI; RT, reaction time; tCho/tCr, 
total choline/total creatine ratio. 
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abnormalities in the dynamic synchronisation between default mode and attention networks 
during the execution of an attention task in patients with LBD (Chabran et al., 2018; Firbank 
et al., 2018, 2016; Kobeleva et al., 2017; Sauer et al., 2006). In particular, Chabran et al. 
(2018) have shown that disturbances in the task-related modulation of DMN activity are 
associated with the severity of cognitive fluctuations, suggesting that a disturbance of the 
dynamic switching between task-positive and default mode networks might be related to 
cognitive fluctuations in DLB. 
Global network measures, analysing the brain’s functional connectivity by means of graph 
theory, have identified a correlation between the severity of cognitive fluctuations and an 
increase in path length (i.e. less efficient network topography) in DLB (Peraza et al., 2015b). 
However, this might be a more general marker of disease severity given the relationship 
between these graph measures and more general markers of cognitive impairment (Peraza et 
al., 2015b). A study of regional homogeneity measuring local functional connectivity 
identified DLB-related changes in sensory-motor and temporal regions (Peraza et al., 2016); 
however, no correlation was found between these regional abnormalities and cognitive 
fluctuation severity, supporting, indirectly, the hypothesis that cognitive fluctuations might be 
related to perturbations in large-scale functional networks rather than local changes in 
connectivity. 
Magnetic resonance spectroscopy (Table 1.3) 
Magnetic resonance spectroscopy (MRS) can be used to characterise biochemical changes in 
the brain quantitatively assessing in-vivo levels of several metabolites such as N-
acetylaspartate/creatine (NAA/Cr) which is considered to be a marker of neuronal integrity 
and is commonly reduced in AD patients (Kantarci and Graff-Radford, 2013). While NAA/Cr 
levels have been found to be reduced in occipital regions in patients with DLB, there does not 
appear to be a difference in NAA/Cr levels between DLB patients with fluctuations compared 
to DLB patients without fluctuations in frontal, posterior cingulate, and occipital regions 
(Graff-Radford et al., 2014a). However, using a whole-brain approach instead of restricting 
their analysis to a priori defined regions, Su et al. (2016) identified a negative correlation 
between hippocampal NAA/Cr levels and cognitive fluctuation severity in DLB, indicating 
that neuronal changes within the hippocampus might play a role in cognitive fluctuations in 
DLB. Furthermore, higher choline/creatine levels as measured by MRS have been observed in 
the thalamus of DLB patients compared to controls. This increase correlated with fluctuation 
frequency and severity, suggesting that neurochemical imbalances within the thalamus might 
be involved in the aetiology of cognitive fluctuations in DLB (Delli Pizzi et al., 2015b). 
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Radionuclide imaging (Table 1.4) 
Occipital hypoperfusion/hypometabolism has been consistently shown in patients with DLB 
compared to patients with AD and healthy controls (Colloby et al., 2002; Imamura et al., 
1999; Ishii et al., 1998; Kantarci et al., 2012; Lobotesis et al., 2001; Minoshima et al., 2001; 
Perneczky et al., 2008; Sato et al., 2007; Shimizu et al., 2005; Yoshida et al., 2015). This 
deficit in blood perfusion and energy metabolism affects primary visual as well as visual 
association areas and the precuneus (Kemp et al., 2005; Mito et al., 2005), and can already be 
identified at the prodromal stage of DLB (Fujishiro et al., 2013). Several studies suggest that 
metabolic and perfusion changes might be related to the severity of cognitive fluctuations in 
LBD: Osaki et al. (2005) have found hypoperfusion in bilateral parietal association areas, 
medial parietal, and dorsal occipital lobes in PDD patients with cognitive fluctuations 
compared with non-fluctuators. Similarly, a reduction in occipital metabolism was reported 
for fluctuating compared to non-fluctuating DLB patients (Kantarci et al., 2012). In a 
longitudinal study, O’Brien et al. (2005) have found a decrease in occipital perfusion and an 
increase in thalamic perfusion to be associated with an increase in fluctuation severity over 
the course of one year.  
Metabolism within the posterior cingulate cortex which is markedly affected in AD is 
normally preserved in DLB (the so-called cingulate island sign) (Graff-Radford et al., 2014b; 
Iizuka and Kameyama, 2016; Lim et al., 2009; O’Brien et al., 2014), suggesting that this does 
not affect cognitive fluctuations (Iizuka and Kameyama, 2016). In addition to the fMRI 
studies discussed above, more evidence for an involvement of complex functional network 
perturbations in cognitive fluctuations is provided by a perfusion single photon emission 
computed tomography (SPECT) study observing aberrant perfusion in an interconnected 
series of structures mainly in parietal and motor areas (including basal ganglia) which was 
found to be correlated with the severity of cognitive fluctuations (Taylor et al., 2013). 
Even though PET and SPECT studies have consistently identified a relative loss of 
dopaminergic neurons within the substantia nigra in LBD (Colloby et al., 2004; Marquie et 
al., 2014; McKeith et al., 2007; O’Brien et al., 2004; Walker et al., 2002), results regarding an 
association between dopamine abnormalities and fluctuation severity in LBD are conflicting. 
While two studies did not see a difference in striatal dopamine transporter density between 
DLB patients with cognitive fluctuations compared to those without fluctuations (Shimizu et 
al., 2017; Ziebell et al., 2013), a third study identified a significant negative correlation 
between striatal dopamine transporter density and cognitive fluctuation severity in DLB 
(Iizuka and Kameyama, 2016). However, cognitive fluctuations are generally considered to be  
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Table 1.4. PET and SPECT studies of cognitive fluctuations. 
 Methods Participants Fluctuation 
measure 
Results  
O’Brien et al. (2005) Perfusion SPECT 14 DLB, 15 
PDD 
CAF Increase in CAF over one year associated with increased thalamic 
and decreased inferior occipital perfusion  
Osaki et al. (2005) Perfusion SPECT 10 PDD, 20 
PD 
absent/ 
present 
Hypoperfusion in bilateral parietal association areas, medial 
parietal, and dorsal occipital lobes in fluctuators compared to non-
fluctuators 
Foster et al. (2010) Amyloid PET 6 DLB, 15 
PDD, 9 PD-
MCI, 9 HC 
Mayo No difference in Mayo fluctuation score between amyloid-positive 
compared to amyloid-negative LBD patients 
Kantarci et al. (2012) Amyloid PET, 
FDG-PET 
21 DLB, 21 
AD, 42 HC 
Mayo No difference in amyloid burden between fluctuating and non-
fluctuating DLB patients; occipital FDG uptake lower in fluctuating 
than in non-fluctuating DLB patients 
Taylor et al. (2013) Perfusion SPECT 19 DLB, 23 
AD 
CAF, CRT 
task 
Positive correlation between DLB-cognitive motor pattern 
(characterised by increased perfusion in cerebellum, basal ganglia, 
and supplementary motor area and decreased perfusion in parietal 
regions) and CAF and CRT task variability 
Ziebell et al. (2013) DAT-SPECT 51 DLB, 28 
HC 
absent/ 
present 
No difference between fluctuating and non-fluctuating DLB 
patients in DAT density in striatum, caudate, and putamen 
Iizuka and Kameyama 
(2016) 
FDG-PET, DAT-
SPECT 
24 DLB, 24 
AD 
CAF Negative correlation between striatal DAT density and CAF in 
DLB; no correlation between cingulate island sign ratio and CAF in 
DLB  
Shimizu et al. (2017) DAT-SPECT 133 DLB, 95 
AD 
absent/ 
present 
No difference in striatal DAT binding between fluctuating and non-
fluctuating DLB patients 
Donaghy et al. (2018) Amyloid PET 37 DLB, 20 
AD, 20 HC 
CAF  No difference in CAF between amyloid-positive and amyloid-
negative DLB patients and no correlation between amyloid burden 
and CAF in DLB 
AD, Alzheimer’s disease; CAF, Clinician Assessment of Fluctuation; CRT, choice reaction time; DAT, dopamine transporter; DLB, dementia with Lewy bodies; FDG-PET; 
fluorodeoxyglucose PET; HC, healthy controls; LBD, Lewy body dementia; Mayo, Mayo Fluctuation scale; MCI, mild cognitive impairment; PDD, Parkinson’s disease 
dementia; PET, positron emission tomography; SPECT, single photon emission computed tomography. 
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a non-dopaminergic phenomenon as levodopa does not seem to exert a significantly beneficial 
effect on cognitive performance in patients or animal models (Kulisevsky et al., 1996; Molloy 
et al., 2006; Schneider et al., 2013). Finally, there does not seem to be an association between 
amyloid burden and cognitive fluctuations in LBD (Donaghy et al., 2018; Foster et al., 2010; 
Kantarci et al., 2012). 
Electrophysiology (Table 1.5) 
In addition to fMRI and nuclear imaging techniques, electrophysiological methods have 
provided insights into the functional perturbations underlying cognitive fluctuations. Evoked 
potential paradigms suggest that delayed P300 latency and reduced amplitude, which are 
associated with impaired stimulus detection and attention, are related to cognitive fluctuation 
severity in DLB (Bonanni et al., 2010; Onofrj et al., 2003).  
Early resting-state EEG studies in DLB patients have found a correlation between the 
variability of mean and delta-band EEG frequency and cognitive fluctuation severity as 
measured by clinical  scales as well as trial-to-trial variability on a choice RT test (Walker et 
al., 2000a, 2000b). These correlations were observed across different timescales, ranging from 
90 s to 1 hour to 1 week (Walker et al., 2000b). These early EEG findings suggest that 
instabilities of  oscillatory EEG activity might be related to cognitive fluctuations.  
Furthermore, the presence of prominent posterior slow wave activity has strong 
discriminatory value over AD and correlates with the presence of cognitive fluctuations in 
LBD (Bonanni et al., 2008, 2016; Stylianou et al., 2018). In addition, temporal slow wave 
activity has been associated with a history of loss of consciousness in DLB (Briel et al., 
1999). The dominant EEG rhythm which is normally within the alpha range, is thought to be 
slowed down towards pre-alpha/fast theta in LBD patients and the variability of dominant 
frequency over time has been shown to be increased (Babiloni et al., 2017; Bonanni et al., 
2016; Cromarty et al., 2015; Onofrj et al., 2003; Peraza et al., 2018; Stylianou et al., 2018). 
These EEG abnormalities correlate with the severity of cognitive fluctuations in DLB and can 
already be identified at the MCI stage, indicating that they might even precede the clinical 
manifestation of cognitive fluctuations (Bonanni et al., 2015). A slowing of the EEG rhythm 
has been suggested to be related to cholinergic neurodegeneration (Jeong, 2004; Stoffers et 
al., 2007), which further highlights the possible involvement of the cholinergic system in the 
aetiology of cognitive fluctuations.  
An analysis of EEG network structure has found a decrease in brain efficiency and impaired 
neural synchronisation in patients with DLB and PDD compared to patients with AD and 
controls; however, these abnormalities did not correlate with cognitive fluctuation severity in  
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Table 1.5. EEG studies of cognitive fluctuations. 
 Methods Participants Fluctuation 
measure 
Results  
Briel et al. (1999) Rest-EEG 14 DLB, 11 AD loss of 
consciousness  
Relation between temporal lobe slow wave activity and clinical 
history of loss of consciousness 
Walker et al. (2000a) Rest-EEG 37 DLB, 61 AD, 22 
VaD, 35 HC 
CAF, CRT 
task 
Positive correlation between variability of mean EEG frequency 
across 90 s and CAF and CRT variability  
Walker et al. (2000b) Rest-EEG 15 DLB, 15 AD, 10 
HC 
CAF, ODFAS CAF, ODFAS, and CRT variability positively correlated with 
variability in delta-band EEG frequency  
Walker et al. (2000c) Rest-EEG 15 DLB, 15 AD, 10 
HC 
CAF, CRT 
task 
CAF positively associated with greater RT variability across 
different timescales (90 s, 1 hour, 1 week) and greater variability 
of slow-wave delta EEG across 1 hour 
Onofrj et al. (2003) Rest-EEG, 
ERP 
11 dementia with 
CF, 12 dementia 
without CF, 20 HC 
CAF, ODFAS Fluctuating dementia patients show higher P300 trial-to-trial 
variability, more slow-wave activity, and greater dominant 
frequency variability than non-fluctuating dementia patients; 
donepezil has a larger effect in fluctuating compared to non-
fluctuating patients 
Bonanni et al. (2008) Rest-EEG 50 DLB, 40 PDD, 
50 AD 
CAF, ODFAS Correlation between CAF and dominant frequency, dominant 
frequency variability, and degree of residual alpha in DLB and 
PDD 
Bonanni et al. (2010) ERP 36 DLB, 40 AD, 50 
HC 
CAF, ODFAS CAF correlated with delayed P300 latency and reduced P300 
amplitude in DLB 
Bonanni et al. (2015) Rest-EEG 20 MCI-DLB, 14 
MCI-AD, 8 HC 
CAF Correlation between CAF and reduced dominant frequency and 
increased dominant frequency variability in MCI-DLB 
Peraza et al. (2018) Rest-EEG, 
graph theory 
25 DLB, 21 PDD, 
26 AD, 17 HC 
CAF No correlations between EEG network measures and CAF in DLB 
and PDD 
Stylianou et al. (2018) Rest-EEG 17 DLB, 17 PDD, 
18 AD, 21 HC 
CAF Positive correlation between CAF and dominant frequency 
variability in the theta range and slow-theta frequency prevalence 
AD, Alzheimer’s disease; CAF, Clinician Assessment of Fluctuation; CF, cognitive fluctuations; CRT, choice reaction time; DLB, dementia with Lewy bodies; EEG, 
electroencephalography; ERP, event-related potential; HC, healthy controls; Mayo, Mayo Fluctuation scale; MCI, mild cognitive impairment; ODFAS, One Day Fluctuation 
Assessment Scale; PDD, Parkinson’s disease dementia; rest-EEG, resting-state EEG; RT, reaction time. 
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the LBD groups (Peraza et al., 2018). Overall, EEG findings in LBD suggest that cognitive 
fluctuations might be related to instabilities in brain oscillations and a slowing of the EEG 
background rhythm, indicating that temporal aspects of brain functioning might also be 
related to the emergence of cognitive fluctuations in LBD. 
Further evidence 
A role of the cholinergic system in the aetiology of cognitive fluctuations mentioned above is 
further supported by studies showing that anticholinergic medication can induce a symptom 
similar to cognitive fluctuations (Perry et al., 1999) as well as by studies showing that 
acetylcholinesterase inhibitors ameliorate the clinical features of cognitive fluctuations 
(Edwards et al., 2007; McKeith et al., 2000b; Onofrj et al., 2003; Wesnes et al., 2002). 
Lesional work in primates identified a deleterious impact on attention upon targeting basal 
forebrain cholinergic nuclei such as the NBM (Voytko et al., 1994). The NBM is important 
for relaying “bottom-up” signals of attention and is particularly vulnerable to alpha-synuclein 
pathology (Liu et al., 2015). Pathological series in DLB have demonstrated a correlation 
between neuronal loss in the NBM and reduced cortical choline acetyltransferase levels 
(Lippa et al., 1999). Evidence for a hypocholinergic aetiology is further provided by a highly 
selective animal lesioning model (Cyr et al., 2015). Cyr and colleagues demonstrated  a 
behavioural correlate of cognitive fluctuations – variable response latencies on an attention 
task – in rats subjected to cholinergic denervation of the pedunculopontine tegmental nucleus. 
Furthermore, as mentioned above, alterations in nicotinic receptor binding in temporal cortex 
(Ballard et al., 2002b) and thalamus (Pimlott et al., 2006) have been described in relation to 
cognitive fluctuations in DLB. 
The thalamus is another subcortical structure which has been shown to be involved in the 
aetiopathogenesis of cognitive fluctuations. Pathological data implicates a predilection for 
alpha-synuclein pathology in thalamic centres, which are integral to the reticulo-thalamo-
cortical activating system and therefore the mediation of consciousness (Braak et al., 2003; 
Henderson et al., 2000; Rüb et al., 2002). Subcortical thalamic cholinergic denervation has 
been established in DLB (Kotagal et al., 2012) and imbalances within this system could thus 
contribute to cognitive fluctuations (Ballard et al., 2002b; Pimlott et al., 2006). 
Given the importance of noradrenaline for the integrity of the attentional system (Buschman 
and Miller, 2007; Gratwicke et al., 2015), a noradrenergic deficit may also be an important 
player in the aetiopathogenesis of cognitive fluctuations in LBD. This is supported by reports 
of cell loss within the locus coeruleus in Lewy body diseases (Del Tredici and Braak, 2013), 
and by evidence that noradrenaline re-uptake inhibitors increase sustained attention in PD 
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(Kehagia et al., 2014; Rae et al., 2016). However, there remains little research into the role of 
a direct relationship between deficiency of the noradrenergic system and cognitive 
fluctuations. 
1.2.5 Summary 
Collating evidence from different modalities, several theories have emerged regarding the 
possible aetiology of cognitive fluctuations in LBD.  
Firstly, there is evidence that cognitive fluctuations might be related to network perturbations 
in attentional circuitry. Evidence for this theory comes from studies relating cognitive 
fluctuations to RT performance on tests of sustained attention (Ballard et al., 2002a, 2001b; 
Onofrj et al., 2003; Walker et al., 2000a) and from fMRI and EEG studies showing an 
association between abnormalities in structures and networks related to attentional processing 
and fluctuation severity (Bonanni et al., 2010; Chabran et al., 2018; Kobeleva et al., 2017; 
Peraza et al., 2014; Sauer et al., 2006). 
Secondly, there is evidence for a relation between corticopetal deafferentiation and cognitive 
fluctuations, in particular with respect to disturbances within the cholinergic system and the 
thalamus. Support for the hypocholinergic theory comes from the beneficial effect of 
acetylcholinesterase inhibitors on the clinical manifestation of cognitive fluctuations 
(Edwards et al., 2007; McKeith et al., 2000b; Onofrj et al., 2003; Wesnes et al., 2002), from 
the observation of grey matter loss in subcortical cholinergic structures (Colloby et al., 2017), 
from animal studies (Cyr et al., 2015; Voytko et al., 1994), and from findings of biochemical 
changes within the cholinergic system (Ballard et al., 2002b; Pimlott et al., 2006). In regard to 
the thalamus, this has been implicated in cognitive fluctuations on structural (Watson et al., 
2017) as well as biochemical studies (Ballard et al., 2002b; Delli Pizzi et al., 2015b; Pimlott et 
al., 2006). 
Thirdly, there might be an association between disturbances in the sleep-wake cycle and 
cognitive fluctuations (Cagnin et al., 2016); however, the exact relationship between the two 
still remains to be elucidated. 
1.3 Resting-State Brain Dynamics 
This thesis will focus on the analysis of resting-state neuroimaging and electrophysiology 
data, i.e. participants were not asked to perform any task during data acquisition. In recent 
years, there has been an increasing interest in this kind of data. The following section will 
provide an overview of previous work in this field and present an argument for the importance 
of studying the brain at rest, especially with respect to cognitive fluctuations in LBD. 
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1.3.1 The resting state of the brain 
Traditionally, functional neuroimaging studies have focussed on analysing task-evoked brain 
activity, i.e. changes in brain signal that are associated with a specific task or stimulus 
(Raichle, 2009). This approach reflects a view of the brain that has dominated the field of 
cognitive neuroscience for a long time where the brain is seen as being a primarily reflexive 
organ which is mainly driven by momentary demands of the environment (Raichle, 2010). 
There is also a pragmatic benefit of task/stimulus data as this allows the use of time-locked 
averaging across repeated trials to ameliorate the inherently noisy nature of the fMRI and 
EEG signals by removing non-neuronal noise sources from the data in order to be able to 
visualise task-related changes in brain activity (Raichle, 2015). 
However, the focus on task-related brain activity largely ignores the fact that much of the 
brain’s energy is devoted to intrinsic brain activity and that task-evoked activity usually only 
adds a small increment to this continuously ongoing energy demand (Raichle and Mintun, 
2006). In this regard, it is therefore important to distinguish between the behavioural resting 
state – as defined by the absence of a specific task –  and the resting state of the brain which is 
by no means a resting state; in fact, the brain is never physiologically at rest and there is 
constant intrinsic activity at various levels of organisation (Faisal et al., 2008; Yuste et al., 
2005). 
The field of resting-state neuroimaging was greatly advanced by a chance discovery from 
early PET and fMRI studies, which found that there are brain regions that show a decrease in 
activity during many attention-demanding and goal-directed tasks (Binder et al., 1999; 
Shulman et al., 1997). This set of brain regions was later labelled the default mode network 
(DMN) and provided first neuroimaging evidence for a functional significance of brain 
activity during the resting state (Gusnard and Raichle, 2001; Raichle et al., 2001). 
Furthermore, it was shown that the different areas of the DMN do not only show consistent 
task-related decreases, but they also show coherent activity during rest, suggesting a 
systematic network organisation of the brain at rest (Greicius et al., 2003). This network 
organisation is not unique to the DMN and many other brain regions exhibit correlated 
activity during rest (Biswal et al., 1995; Fox and Raichle, 2007; Lowe et al., 1998). These so-
called resting-state networks (RSNs) have been linked to different cognitive functions based 
on the involvement of brain regions that are known to be related to certain functions including 
visual, motor, executive, salience, and attention networks (Beckmann et al., 2005; 
Damoiseaux et al., 2006; Smith et al., 2009). While there is some degree of overlap between 
structural connectivity, as assessed by diffusion tensor imaging, and functional connectivity 
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within RSNs (Greicius et al., 2009), these functional networks are not necessarily constrained 
by anatomical connections (Honey et al., 2009). Furthermore, there is not only an intricate 
functional organisation within each network, but interrelations exist between different 
networks (Fox et al., 2009, 2005). This is particularly important with regards to the intricate 
anti-correlated interplay between the DMN and task-positive attentional networks (Fox et al., 
2005) which has been related to the efficiency of stimulus processing on attention tasks thus 
showing its behavioural relevance (Weissman et al., 2006). 
The study of resting-state data comes with certain challenges. This is due to the fact that one 
is interested in neuronal “noise” (i.e. task- or stimulus-independent changes in brain activity) 
which can be hidden by non-neuronal noise (e.g. due to movement or physiological artefacts). 
Furthermore, resting-state data show large heterogeneity across participants due to the 
unconstrained nature of the respective experiment. While the analysis of brain activity in 
response to external stimuli can be rigorously controlled, the analysis of spontaneous brain 
activity is more elusive (Raichle, 2010).  
However, resting-state scans are easy and relatively fast to acquire, they do not depend on a 
person’s cognitive abilities, and the signal is not directly confounded by individual 
differences in behavioural performance. This makes resting-state studies especially suitable 
for older patient populations and patients who might not be able to perform a cognitive task 
while lying in the scanner (Raichle, 2010; Zhang and Raichle, 2010). 
1.3.2 The importance of resting-state brain dynamics 
Most resting-state studies have focussed on average connectivity over the duration of a scan 
of several minutes, thereby implicitly assuming that the functional architecture of the brain 
remains stationary over time. However, it has recently been shown that functional 
connectivity can vary substantially in both strength and directionality on a timescale of 
seconds to minutes (Chang and Glover, 2010; Hutchison et al., 2013b). Studying these 
dynamics can provide important complementary information to the analysis of stationary 
functional connectivity (Calhoun et al., 2014; Hutchison et al., 2013a). Several studies have 
furthermore provided support for a cognitive role of dynamic connectivity by showing that 
changes in connectivity are related to changes in behavioural or vigilance states (Jia et al., 
2014; Kucyi et al., 2017; Thompson et al., 2013).  
However, moment-to-moment signal variability cannot only be observed on the level of large-
scale RSNs; it is rather a universal feature of the brain that is present at different levels of the 
nervous system (Faisal et al., 2008; McDonnell and Ward, 2011). More generally, the brain 
can be considered a nonlinear dynamical system in which the intrinsic activity and 
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connectivity structure varies over time and which operates at a point of criticality (Garrett et 
al., 2013b; Hesse and Gross, 2014). In such a system, fluctuations are important because they 
allow an exploration of the state space (Ghosh et al., 2008) and provide greater dynamical 
range, i.e. a larger range of possible responses to incoming stimuli (Deco and Jirsa, 2012). 
Brain variability has also been related to more optimal and efficient network structure (Garrett 
et al., 2018; Mišić et al., 2011), and higher signal variability indicates a system that operates 
closer to a critical state (He, 2011). Additionally, it has been shown that disturbances to these 
intricate dynamics can cause the system to lose its optimal network properties (Van De Ville 
et al., 2010). 
In addition, various studies have provided evidence for a behavioural relevance of intrinsic 
brain dynamics by relating more dynamic brain activity to faster, more accurate, and more 
consistent performance on a wide range of cognitive tasks (Garrett et al., 2011; McIntosh et 
al., 2008; Mišić et al., 2010). Ageing has been shown to be associated with a reduction in 
brain variability (Garrett et al., 2013a, 2011) and a loss of complexity within the brain 
network (Takahashi et al., 2009), and different diseases have also been related to a loss of 
brain variability and complexity (Garrett et al., 2013b). 
Brain dynamics can be assessed with different methodologies and on different timescales: 
while dynamic connectivity analysis from fMRI data allows the characterisation of slower 
brain dynamics with high spatial resolution (see Chapter 5), dynamic changes on a sub-second 
timescale can be studied using EEG. One method that is particularly suitable to study the 
dynamic properties of the EEG signal is microstate analysis (Michel and Koenig, 2017) where 
the EEG signal is segmented into short, non-overlapping states whose temporal characteristics 
can provide insight into the brain’s dynamic properties (see Chapter 6). 
1.3.3 Resting-state brain dynamics in LBD 
An important characteristic of cognitive fluctuations in LBD is that they occur spontaneously 
and in the absence of a specific situational demand or external explanation, i.e. they can occur 
while the patient is at rest. This stands in contrast to AD where cognitive fluctuations seem to 
be related to difficulties when responding to a specific task or certain situational demands 
(Bradshaw et al., 2004). Furthermore, fluctuations in LBD by their nature are transient and 
reversible and remission to near-normal levels of cognitive functioning can occur (McKeith, 
2002; McKeith et al., 1996) making it unlikely that they are primarily driven by progressively 
worsening structural changes. Instead, it has been suggested that they might be related to 
transient functional changes in the brain, i.e. dynamic changes in the brain’s activity and its 
functional network organisation (Sourty et al., 2016; Taylor et al., 2013). Therefore, a better 
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characterisation of resting-state brain dynamics in patients with LBD compared to patients 
with AD and healthy controls might provide important insight into the aetiology of cognitive 
fluctuations and might, more generally, provide a better understanding of the LBD cognitive 
phenotype. Furthermore, it might help reveal details of differences and similarities between 
AD and LBD and the changes in brain dynamics that might underlie the clinically observed 
differences. 
1.4 Description of Study Cohort 
1.4.1 Study data 
Data from several previous dementia research studies conducted at Newcastle University were 
used in the different analyses comprising this thesis. RT, EEG, and fMRI data from AD, 
DLB, and PDD patients as well as healthy controls were obtained from the CATFieLD study. 
Participants in this study were assessed using an RT based attention test while undergoing 
high-density EEG and fMRI recordings on two separate occasions. Additionally, resting-state 
EEG and fMRI data were acquired. This thesis will focus on the analysis of the RT and 
resting-state EEG and fMRI data while the task-based EEG and fMRI data have been 
analysed previously (Cromarty, 2016; Firbank et al., 2016; Kobeleva et al., 2017). Additional 
resting-state fMRI data from AD and DLB patients and healthy controls were obtained from 
the ARThippo study. This study did not collect RT or EEG data and did not involve PDD 
patients. For the creation of the fMRI resting-state network templates (Chapter 4), healthy 
control data from an independent cohort was required which was taken from two additional 
independent studies, the ICICLE and VEEG-Stim studies. All studies were approved by the 
local ethics committee and written informed consent was obtained from each participant prior 
to study participation. Patients were recruited from the local community-dwelling population 
who had been referred to old-age psychiatry and neurology services. Dementia diagnoses 
were performed independently by two experienced clinicians in alignment with consensus 
criteria for probable DLB (McKeith et al., 2017, 2005), PDD (Emre et al., 2007), and AD 
(McKhann et al., 1984, 2011). Age-matched healthy controls were recruited from 
friends/acquaintances of the patients with no history of psychiatric or neurological illness. 
Participants from all included studies underwent detailed clinical and cognitive assessments. 
Clinical scores that were of interest for this thesis were scores of global cognition as well as 
measures of the core LBD symptoms of Parkinsonism, visual hallucinations, and cognitive 
fluctuations (see Section 1.4.2 for a more detailed description of the included scores). 
Furthermore, detailed information about medication usage was available for all participants; 
for this thesis information on the use of acetylcholinesterase inhibitors and dopaminergic 
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medication in the dementia patients was extracted given the potential impact of these on the 
dynamic measures of interest in this thesis.  
A more detailed description of each study group and reasons for inclusion/exclusion of 
participants are provided in the methods sections of the respective chapters. 
1.4.2 Clinical measures 
Global cognition 
Global cognitive functioning was assessed using the Mini Mental State Examination (MMSE) 
and Cambridge Cognitive Examination (CAMCOG) in patients and healthy control 
participants in all studies. The MMSE is designed to measure different aspects of cognitive 
functioning including short-term memory, immediate recall, calculation, language, 
construction, and orientation, with a total score of 30 points (Folstein et al., 1975). It is widely 
used to assess cognitive impairment in dementia cohorts and a total score of <24 points in 
addition to impairments in activities of daily living is usually considered to support a 
diagnosis of dementia. Similarly, the CAMCOG is designed to assess different cognitive 
domains such as orientation, language, memory, attention, calculation, perception, and 
executive function with a total score of 105 points (Roth et al., 1986). A cut-off of <80 points 
is usually considered to indicate dementia. 
Parkinsonism 
The motor subsection of the Unified Parkinson’s Disease Rating Scale (UPDRS III) was 
administered to all healthy control and dementia participants (Fahn and Elton, 1987). The 
UPDRS III is used to assess five aspects of motor functioning: rigidity, tremor at rest, 
bradykinesia, action tremor, and facial expression. Scores from the five subsections are 
summed to obtain a total score with a score of ≥8 indicating the presence of Parkinsonism.  
Visual hallucinations 
The carer-administered Neuropsychiatric Inventory (NPI) was used to assess psychiatric 
symptoms in all dementia patients (Cummings et al., 1994). It is designed to measure 
presence, frequency, and severity of symptoms in ten behavioural domains over the month 
prior to the assessment, including delusions, hallucinations, agitation/aggression, dysphoria, 
anxiety, euphoria, apathy, disinhibition, irritability, and aberrant motor behaviour. The 
hallucination subscale was of particular interest for the analyses described in this thesis as, 
when this domain was assessed there was a specific focus on visual hallucination occurrence 
in the dementia patients.  
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Cognitive fluctuations 
The severity and duration of cognitive fluctuations was assessed by the CAF scale in all 
dementia patients (Walker et al., 2000b). Additionally, for all dementia patients included in 
the CATFieLD study the Mayo fluctuations scale was used (Ferman et al., 2004) (see Section 
1.2.2 for a more detailed description and discussion of clinical fluctuation scales). 
1.5 Aims and Hypotheses 
1.5.1 Aims 
The objective of this thesis is to integrate behavioural and neuroimaging data from patients 
diagnosed with dementia in order to study their brain dynamics as well as behavioural and 
clinical correlates, especially with respect to attentional impairment and cognitive 
fluctuations. 
More specifically, the aims of the thesis are: 
 to analyse how different aspects of RT performance are differentially affected by AD 
and LBD and how these map onto clinical measures in LBD, particularly to clinical 
measures of cognitive fluctuations (Chapter 2 and 3), 
 to analyse disruptions in functional connectivity of RSNs in LBD patients compared to 
AD and healthy controls, and relate these to the clinically observed cognitive 
fluctuations (Chapter 4), and 
 to compare the dynamics of fMRI functional connectivity as well as EEG dynamics in 
LBD, AD, and healthy controls to study associations between the dynamic properties 
of the brain network and the clinical LBD phenotype, especially with respect to 
cognitive fluctuations (Chapter 5 and 6). 
1.5.2 Hypotheses: RT data 
 Response times in an attention task will be slower and show higher intraindividual 
variability in both dementia groups compared to healthy controls and this will be more 
pronounced in LBD than in AD. 
 Compared to AD and healthy controls, LBD will be characterised by an increase in 
attentional lapses and this will correlate with the severity of cognitive fluctuations. 
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 There will be a relation between structural brain changes and different aspects of 
attention in the AD group which will be less pronounced in the LBD group given less 
atrophic changes in this condition compared to AD. 
1.5.3 Hypotheses: fMRI data 
 Compared to controls, there will be a reduction in functional connectivity in the 
motor, basal ganglia, attentional, and possibly visual RSNs in patients with LBD.  
 The overall dynamics of functional connectivity will be reduced in both dementia 
groups compared to controls, with greater impairment in LBD compared to AD. 
 Disturbances within the dynamic architecture of the functional brain network will be 
related to cognitive fluctuation severity in LBD. 
1.5.4 Hypotheses: EEG data 
 There will be a slowing of microstate dynamics in LBD which will be related to the 
cognitive phenotype, and in particular, cognitive fluctuations. 
 Disturbances in microstate dynamics in LBD will be contingent upon a loss of 
dynamics within cortical-basal ganglia-thalamic connections. 
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Chapter 2. Analysis of Attention Components and Brain Structural 
Correlates  
2.1 Introduction 
Previous investigations using attention tasks have found that LBD patients show slower RTs 
and higher intra-individual variability than AD patients (Ballard et al., 2001a; Bradshaw et al., 
2004), and that this difference is accentuated when the task involves an executive or spatial 
aspect (Bradshaw et al., 2004). This deficit in RT performance has also been related to the 
severity of cognitive fluctuations; patients with more severe fluctuations show more impaired 
RT performance and higher trial-to-trial variability (Ballard et al., 2002a, 2001b; Onofrj et al., 
2003; Walker et al., 2000a). 
It has been proposed that attention can be modelled as three anatomically distinct, but 
functionally inter-related systems: alerting, orienting, and executive control or conflict 
(Posner and Petersen, 1990). The efficiency of these three attention systems is commonly 
assessed using the Attention Network Test (ANT) (Fan et al., 2002) combining elements of 
the Posner cueing paradigm (Posner and Petersen, 1990) and the Eriksen flanker task (Eriksen 
and Eriksen, 1974) to test all three components in a single session. The significance and size 
of the alerting, orienting, and executive conflict effects is measured by differences in RT 
performance between different cue and target conditions. First, the alerting effect is assessed 
as the benefit of a simple warning cue (compared to no cue) on subsequent RT performance. 
The size of this effect is therefore an indicator for the ability to achieve and maintain a 
vigilant or alert state (Posner and Petersen, 1990). Second, the orienting effect is measured by 
the difference in RT when presenting stimuli in a previously cued location in space compared 
to an uncued location. Its size therefore indicates how efficient a participant can select 
information from sensory input (Fan et al., 2005). Finally, the size of the executive conflict 
effect is tested using a flanker task, i.e. by measuring the effect of distracting targets on RT 
performance (Eriksen and Eriksen, 1974). An increase in the executive conflict effect thus 
indicates an impairment in resolving conflict amongst responses.  
To date, very little research has been conducted to investigate how the efficiency of the 
different attentional systems is affected by dementia, and the findings of previous studies are 
inconsistent (Fernandez-Duque and Black, 2006; Fuentes et al., 2010). The aim of this chapter 
is to determine the extent to which the efficiency of the attentional systems is differentially 
affected in LBD patients relative to AD patients and age-matched healthy participants. The 
alerting component is purported to be modulated by noradrenergic projections from the locus 
coeruleus (Coull et al., 2001; Raz, 2004). Given that LBD patients have been found to have a 
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paucity of noradrenergic neurons in the locus coeruleus (Szot, 2006), my first hypothesis was 
that there will be an impairment in alerting efficiency in LBD patients. Secondly, as the 
orienting component has been suggested to be modulated by the basal forebrain cholinergic 
system (Fan et al., 2005) which is more markedly affected in LBD patients than in AD 
patients (Ballard et al., 2013), I hypothesised that LBD patients will exhibit differentially 
reduced orienting efficiency compared to AD patients and controls. Thirdly, based on 
previous studies I also hypothesised that AD patients will exhibit reduced executive conflict 
efficiency relative to healthy controls (Fernandez-Duque and Black, 2006). Given that deficits 
in executive functioning are also a common feature of LBD, I expected that the LBD group 
will also exhibit reduced executive conflict processing efficiency. Furthermore, executive 
control has been shown to be modulated by the dopaminergic and cholinergic systems 
(Noudoost and Moore, 2011) which are more affected in LBD compared to AD (Ballard et al., 
2013; O’Brien et al., 2004; Walker et al., 2002). Thus, I hypothesised that the impairment in 
executive conflict efficiency will be greater in LBD compared to AD.  
Previous studies have also investigated how inter-individual differences in the efficiency of 
the attentional systems, as measured by the ANT, are related to differences in brain structure 
in healthy participants (Hao et al., 2015; Westlye et al., 2011) and amnestic MCI (Borsa et al., 
2016). However, to date, no studies have examined the relationship between the efficiency of 
these attentional systems and structural alterations in more severe neurodegenerative disease. 
A further aim of this chapter is therefore to study macrostructural neural correlates of 
attentional dysfunction in AD and LBD using a VBM analysis. Previously, Borsa et al. (2016) 
found an association between impairment in the executive conflict component in MCI patients 
and decreased grey matter volume in the anterior cingulate cortex (ACC). Given that MCI is 
associated with a high conversion rate to AD (Petersen, 2004), I hypothesised that there might 
be a similar or possibly even stronger relationship between conflict monitoring and brain 
volume in the ACC in the AD group. However, given the general paucity of previous research 
in this area, the analysis of brain structural correlates of the attentional systems was conducted 
in a more exploratory manner, using a whole-brain approach rather than restricting the 
analysis to a priori defined regions. 
Finally, as cognitive fluctuations have been correlated with other RT measures in DLB 
(Bradshaw et al., 2006; Walker et al., 2000a), it is of interest to know how the efficiency of 
the different ANT systems may relate to the clinical symptoms of LBD. The association 
between the ANT components and cognitive fluctuation severity will be explored. 
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2.2 Methods 
2.2.1 Participants 
This analysis involved 104 participants from the CATFieLD study, including 49 patients 
diagnosed with probable LBD (26 DLB and 23 PDD), 33 with probable AD, and 22 age-
matched healthy controls (HC). 
DLB and PDD patients were combined into one LBD group a priori for this analysis as 
previous studies have shown similar attentional and executive impairment in DLB and PDD 
(Ballard et al., 2002a; Firbank et al., 2016) and similar patterns of brain structural alterations 
(Burton et al., 2004). 
2.2.2 Modified Attention Network Test 
The CATFieLD study used a modified version of the ANT (Cromarty, 2016; Firbank et al., 
2016) based on the version described by Fan et al. (2007). The main rationale for adapting the 
ANT was to make it suitable for older adults and dementia patients. This was achieved by 
increasing the size of the stimuli to account for participants with poor visual acuity and by 
adjusting the timings to account for slower cognitive processing speed in older adults. 
Furthermore, an additional level of executive conflict complexity was added to create a more 
graded task difficulty (see below).  
The computerised task was programmed by Dr Michael Firbank using the Cogent toolbox in 
Matlab (http://www.vislab.ucl.ac.uk/cogent_2000.php). Participants completed between 3 and 
14 runs of the task (median=8), each run consisting of 36 trials. Throughout the task a central 
fixation cross and three boxes were presented on a screen (Figure 2.1). At the beginning of 
each trial, one of three possible cues (no, neutral, or spatial cue) was presented for 200 ms. In 
the no cue condition, the boxes remained unchanged. During the neutral cue condition, the 
central box flashed and during the presentation of a spatial cue, one of the boxes either above 
or below the central box flashed (to indicate the box in which a subsequent target would 
appear). The disappearance of the cue was followed by a target comprising four arrowheads in 
a row, either in the box above or below the central fixation. The time between the 
disappearance of the cue and the appearance of the target was one of the following 
exponentially distributed times: 700, 770, 850, 960, 1080, 1240, 1430, 1660, 1940, 2300, 
2700, 3200 ms. The target stimuli could be congruent or incongruent; congruent targets were 
arrowheads which were all pointing in the same direction (left or right), whereas for 
incongruent targets one arrowhead was pointing in the opposite direction. In the incongruent 
condition, the incongruent arrowhead appeared either on the end of the row (easy  
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Figure 2.1. Depiction of a single trial of the modified Attention Network Test. 
incongruent) or as one of the two arrowheads in the middle (hard incongruent). The target was 
presented on screen until the participant made a response by squeezing a right or left hand air 
pressure bulb to indicate the direction in which the majority of arrowheads were facing, or 
until 3000 ms had elapsed. The intertrial interval was one of the following: 4300, 4500, 4750, 
5000, 5350, 5700, 6100, 6400, 6800, 7200, 7700, 8300 ms, with each time occurring three 
times during each run in random order.  
During each run, the six trial types were presented in a predetermined counterbalanced order; 
each cue appeared 12 times and there were 18 congruent and 18 incongruent target trials (9 
easy incongruent and 9 hard incongruent). All trials from runs with less than 2/3 correct 
responses were excluded from further analysis as performance below this was not different 
from chance (Firbank et al., 2016). 
2.2.3 Analysis of ANT effects 
Mean RTs for each cue and target condition were calculated in Matlab (R2015b), using only 
the trials in which the participants gave correct responses in alignment with previous studies. 
The ANT effects were calculated as defined by Fan et al. (2002): 
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Alerting effect = no cue - neutral cue  
Orienting effect = neutral cue - spatial cue  
Executive conflict effect = incongruent target - congruent target  
The alerting effect is therefore a measure of the extent to which response speed is facilitated 
by the presence of a warning, indicating that a response is imminently required. The orienting 
effect is the extent to which responses are further facilitated when the actual spatial location 
of the oncoming target is cued, rather than a simple warning that a response is imminent. 
Finally, the executive conflict effect pools all types of cued conditions and examines the 
impairing/interfering effect of having conflicting information regarding the target stimuli (in 
terms of the direction in which each of the arrowheads are pointing), compared to the 
facilitative effect of having target stimuli which are all pointing in the same direction. 
To calculate the alerting and orienting effects, mean RTs from congruent and incongruent 
trials were averaged. Similarly, the executive conflict effect was calculated by averaging 
mean RTs across the cue conditions. For the purpose of this thesis, easy and hard incongruent 
conditions were not analysed separately. Error rates were also determined for each task 
condition by dividing the number of incorrect and missed response trials by the number of 
recorded trials for each participant. 
2.2.4 MR imaging and analysis 
Structural MR images were acquired with a 3 T Philips Intera Achieva scanner with a 
magnetisation prepared rapid gradient echo (MPRAGE) sequence, sagittal acquisition, echo 
time 4.6 ms, repetition time (TR) 8.3 ms, inversion time 1250 ms, flip angle = 8°, SENSE 
factor = 2, and in-plane field of view 240 x 240 mm2 with slice thickness 1.0 mm, yielding a 
voxel size of 1.0 x 1.0 x 1.0 mm3.  
A VBM analysis was performed in SPM12 (Statistical Parametric Mapping, 
www.fil.ion.ucl.ac.uk/spm/) to assess voxel-wise correlations between the ANT results and 
mean RT and grey matter and white matter volume. Images were first segmented into grey 
matter, white matter, and CSF. The segmented grey and white matter images were then co-
registered and normalised to MNI space using SPM’s DARTEL algorithm (Ashburner, 2007) 
and modulated. Finally, images were smoothed with an 8 mm full width at half maximum 
Gaussian kernel. 
2.2.5 Statistics 
Statistical analyses were carried out in IBM SPSS Statistics version 22 and R version 3.5.1 
(http://www.R-project.org/). For the mean RT data for each cue and target condition, a 
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repeated measures (cue x target) analysis of variance (ANOVA) was conducted with a 
between-subject factor of group (HC, AD, LBD). Subsequently, separate repeated measures 
(cue x target) ANOVAs were conducted for each group; post- hoc pairwise comparisons were 
used to calculate RT differences between the cue and target conditions, thus determining the 
significance of the ANT effects. The magnitude of the ANT effects was compared between 
groups using univariate ANOVAs; the dependent variable being the ANT effect with group as 
a fixed factor. For each ANOVA analysis Mauchly's sphericity test was used and F-values 
were adjusted accordingly. Post-hoc pairwise comparisons were corrected for multiple 
comparisons using Bonferroni correction. The same analysis was repeated for the error rates.  
Additionally, to control for the effect of overall processing speed and to test whether between-
group differences in overall processing speed influenced the analyses of the ANT effects, I 
repeated all analyses using normalised RTs; for each participant, the mean RT for each 
condition was divided by the participant’s overall mean RT in alignment with previous 
studies (Faust and Balota, 1997; Fernandez-Duque and Black, 2006). 
Spearman’s correlations were calculated to investigate associations between the behavioural 
data (overall mean RT and the ANT effects) and clinical variables in the dementia groups. In 
the LBD group, correlations were calculated for cognitive fluctuation scores (Mayo and CAF 
total and subscores); supplementary analyses were performed for measures of overall 
cognition (MMSE, CAMCOG), the UPDRS motor subscale, and the NPI hallucination scale. 
In the AD group, correlations were calculated for MMSE and CAMCOG. P-values were false 
discovery rate (FDR)-corrected for multiple comparisons.  
Correlations between the ANT behavioural data and grey and white matter volume were 
assessed using a general linear model (GLM) in SPM12. The GLM combined all three ANT 
effects (alerting, orienting, and executive) as variables of interest in one design matrix and a 
separate model was used for mean RT. Covariates of no interest for age, sex, total intracranial 
volume, and UPDRS motor scores (in LBD) were included. An explicit mask was estimated 
to restrict the statistical analysis to voxels which represented grey and white matter, 
respectively (Ridgway et al., 2009). Significant results are reported at a voxel-level p-
value<0.001. Additionally, the minimum cluster size for a multiple comparison corrected 
threshold of p<0.05 was determined by Monte Carlo simulations using the REST software 
(www.restfmri.net). 
To study the possible influence of dopaminergic medication on the ANT effects in the LBD 
group, the repeated-measures (cue x target) ANOVA was repeated including a covariate for 
levodopa equivalent daily dose (LEDD) (Tomlinson et al., 2010). This was tested for both 
raw and normalised RT. 
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2.3 Results 
2.3.1 Demographics  
Two AD, one DLB, and three PDD patients were excluded from the analysis because they did 
not meet the minimum performance criteria (Section 2.2.2). Thus, 31 AD, 45 LBD (25 DLB 
and 20 PDD), and 22 HC participants were further analysed (Table 2.1). All groups were 
matched for age and sex. LBD patients were slightly less impaired in terms of overall 
cognition (MMSE and CAMCOG) and had had a shorter duration of cognitive symptoms 
compared to AD patients. The proportion of patients taking acetylcholinesterase inhibitors did 
not differ between the dementia groups. As expected, many LBD patients were taking 
dopaminergic medication (none of the AD patients took dopaminergic medication). 
Furthermore, compared to the AD group, LBD patients were more impaired in terms of the 
core LBD symptoms of Parkinsonism, cognitive fluctuations, and visual hallucinations.  
To ensure that differences between the dementia groups in terms of behavioural data were not 
due to differences in MMSE, all analyses reported below were repeated with matched 
dementia groups. To create these matched dementia groups, four AD patients with MMSE<16 
and ten LBD patients (six DLB and four PDD) with MMSE>26 were excluded from the 
analysis. Subsequently, the two groups did not differ with respect to duration of dementia 
(Mann-Whitney U test, U=358, p=0.10), MMSE (Student’s t-test, t60=0.38, p=0.71) or 
CAMCOG (Student’s t-test, t60=0.39, p=0.70). 
There were no significant differences between DLB and PDD subgroups in terms of age, 
overall cognition, and dementia duration whereas PDD patients had more severe 
Parkinsonism, psychiatric symptoms, and cognitive fluctuations than DLB patients (Table 
2.1). To ensure that combining DLB and PDD patients into one LBD group was appropriate, 
mean RT, error rates, and the ANT effects were compared between the two groups, revealing 
no significant differences (Table 2.2). 
2.3.2 Reaction time analysis  
The number of recorded trials per participant did not differ significantly between the groups 
(mean (SD) HC: 301.1 (17.7), AD: 290.3 (41.5), LBD: 304.8 (37.3); univariate ANOVA, 
F(2,95)=1.56, p=0.22). Overall, the error rate was lower in the control group than in AD and 
LBD but did not significantly differ between the dementia groups (Table 2.4 and 2.7). In AD 
and LBD, there was a significant negative correlation between overall error rate and MMSE 
and CAMCOG scores (Table 2.8 and Figure 2.3B).
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Table 2.1. Demographics and clinical information; mean (standard deviation). 
 HC  
(N=22) 
AD  
(N=31) 
LBD  
(N=45) 
Group differences DLB  
(N=25) 
PDD  
(N=20) 
Group differences 
Male: female 15:7 24:7 38:7 χ2=2.36, p=0.31a  19:6 19:1 χ2=3.05, p=0.08h  
Age 75.9 (5.4) 77.1 (7.9) 74.5 (6.3) F2,95=1.41, p=0.25
b  76.1 (6.2) 72.6 (5.9) t43=1.95, p=0.06
j  
AChEI - 28 39 χ2=0.24, p =0.63c  23 16 χ2 =1.39, p =0.24h  
PD meds - 0 33 χ2=40.2, p<0.001c  13 20 χ2 =13.09, p<0.001h  
Duration  - 3.9 (2.1) 3.1 (2.1) U=509, p=0.043d  3.6 (2.4) 2.6 (1.5) U =1.14, p=0.29
k  
MMSE 29.2 (0.9) 21.1 (3.7) 23.3 (3.8) t74=2.5, p =0.01
e  23.0 (4.2) 23.7 (3.2) t43 =0.54, p =0.60
j  
CAMCOG 96.7 (3.7) 68.8 (13.3) 75.9 (12.6) t74=2.4, p =0.02
e  74.5 (14.7) 77.7 (9.3) t43 =0.85, p =0.40
j  
UPDRS 1.1 (1.4) 2.4 (2.2) 20.5 (9.3) t74=10.6, p<0.001
e 15.6 (7.2) 26.6 (7.9) t43 =4.86, p<0.001
j 
CAF total - 0.8 (1.7)f 5.1 (4.5)g t71=4.9, p<0.001
e 4.00 (4.4) 6.6 (4.3)l t41 =1.89, p=0.07
j 
Mayo total - 9.1 (4.1)f 13.5 (5.8)g t71=3.6, p=0.001
e 12.3 (6.2) 15.2 (5.0)l t41=1.67, p=0.10
j 
Mayo cogn - 1.8 (1.8)f 2.8 (1.9)g t71=2.4, p=0.02
e 2.2 (1.8) 3.7 (1.8)l t41=2.59, p=0.01
j 
NPI total - 6.9 (6.2)f 13.4 (9.7) t73 =3.3, p=0.002
e  9.1 (4.9) 18.8 (11.6) t43=3.78, p<0.001
j  
NPI hall - 0.03 (0.2)f 1.8 (2.0) t73 =4.8, p<0.001
e  1.4 (1.7) 2.2 (2.2) t43=1.37, p=0.18
j  
AChEI, number of patients taking acetylcholinesterase inhibitors; AD, Alzheimer’s disease; CAF total, Clinician Assessment of Fluctuations total score; 
CAMCOG, Cambridge Cognitive Examination; DLB, Dementia with Lewy bodies; Duration, duration of cognitive symptoms in years; HC, healthy controls; 
LBD, Lewy body dementia; Mayo Fluctuations, Mayo Fluctuations cognitive subscale; MMSE, Mini Mental State Examination; PDD, Parkinson’s disease 
dementia; PD meds, number of patients taking dopaminergic medication; UPDRS, Unified Parkinson’s Disease Rating Scale III; NPI, Neuropsychiatric Inventory; 
NPI hall, NPI hallucination subscore. 
a Chi-square test HC, AD, LBD; b One-way ANOVA HC, AD, LBD; c Chi-square test AD, LBD; d Mann Whitney U test AD, LBD; e Student’s t-test AD, LBD; 
fN=30, gN=43  
h Chi-square test DLB, PDD; j Student’s t-test DLB, PDD; k Mann Whitney U test DLB, PDD; l N=18. 
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Table 2.2. Mean RT, error rates, and ANT effects for DLB and PDD subgroups (standard 
deviations are presented in brackets). Comparison between groups were conducted using 
Student’s t-tests. 
 DLB  PDD  Between-group 
differences 
Mean RT 1483.6 (382.3) 1651.7 (391.0) t43=1.45, p=0.15 
Mean error rate (%) 14.2 (8.4) 12.2 (10.0) t43=0.74, p=0.47 
Alerting    
 Raw RT 10.9 (87.7) -11.2 (101.7) t43=0.78, p=0.44 
 Normalised RT 0.01 (0.06) -0.0006 (0.05) t43=0.65, p=0.52 
Orienting    
 Raw RT 85.0 (98.8) 82.5 (131.1) t43=0.07, p=0.94 
 Normalised RT 0.06 (0.06) 0.05 (0.07) t43=0.19, p=0.85 
Executive    
 Raw RT 548.9 (281.6) 596.7 (219.4) t43=0.62, p=0.54 
 Normalised RT 0.35 (0.12) 0.36 (0.10) t43=0.32, p=0.75 
DLB, dementia with Lewy bodies; PDD, Parkinson’s disease dementia; RT, reaction time 
 
 
Table 2.3. Mean RTs from correct trials (ms) for each task condition (cue x target), for the 
controls, AD and LBD patients. Standard deviations are presented in brackets. 
  HC AD  LBD  
Mean RT (ms)   
All trials  964.6 (147.5) 1319.8 (322.6) 1558.3 (391.0) 
No Cue 
Overall 1025.1 (162.6) 1363.2 (325.3) 1587.0 (377.4) 
Congruent 806.7 (110.2) 1059.8 (270.2) 1280.4 (288.4) 
Incongruent 1243.4 (241.4) 1666.6 (402.4) 1893.6 (491.9) 
Neutral 
Overall 978.9 (147.3) 1334.1 (309.5) 1585.9 (413.0) 
Congruent 795.7 (98.8) 1072.0 (267.7) 1293.7 (302.6) 
Incongruent 1162.0 (222.4) 1596.1 (383.6) 1878.2 (553.6) 
Spatial 
Overall 900.00 (136.4) 1262.0 (342.9) 1502.0 (395.8) 
Congruent 710.5 (89.5) 989.1 (314.1) 1245.7 (355.7) 
Incongruent 1069.5 (203.5) 1534.9 (411.0) 1758.4 (478.9) 
Congruent Overall 771.0 (97.6) 1040.3 (278.0) 1273.3 (302.8) 
Incongruent Overall 1158.3 (220.8) 1599.2 (393.0) 1843.4 (496.4) 
ANT effects (ms)   
Alerting 46.2 (37.0)* 29.14 (80.84)  1.1 (93.7) 
Orienting 88.9 (35.0)* 72.07 (74.62)* 83.9 (112.9)* 
Executive conflict 387.4 (171.9)* 558.88 (217.13)* 570.1 (254.2)* 
AD, Alzheimer’s disease; HC, healthy controls; LBD, Lewy body dementia; RT, reaction time. 
*Significant ANT effect, p-value<0.05 for normalised RTs. 
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Figure 2.2. Group comparison of reaction times for the different ANT effects. A) Overall 
mean RT and mean RT for the different cue and target conditions of the ANT within each 
group. B) ANT effects from raw RTs. C) ANT effects from normalised RTs. In each boxplot 
the central line corresponds to the sample median, the upper and lower border of the box 
represent the 25th and 75th percentile, respectively, and the length of the whiskers is 1.5 times 
the interquartile range. Corresponding results from statistical comparisons between the three 
groups are presented in Table 2.5. 
AD, Alzheimer’s disease; HC, healthy controls; LBD, Lewy body dementia; RT, reaction 
time. 
Overall mean RT 
There was a main effect of group across all cue and target conditions; control participants had 
faster overall mean RT relative to AD and LBD patients, and the LBD mean RT was slower 
than the AD mean RT (Tables 2.3 and 2.5 and Figure 2.2A). Mean RT was significantly 
negatively correlated with overall cognition (MMSE and CAMCOG) in AD (Table 2.8 and 
Figure 2.3A). In LBD patients, mean RT was positively correlated with the UPDRS motor 
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score and the Mayo cognitive subscale (Table 2.8); however, these correlations in the LBD 
group did not survive correction for multiple comparisons. 
Alerting and orienting effects 
There was a main effect of cue; across all groups, mean RT for neutral cue trials was faster 
than no cue trials for both raw and normalised RT, i.e. there was an overall significant alerting 
effect. Furthermore, there was an overall significant orienting effect (difference between 
spatial and neutral cue trials) for raw and normalised RT (Table 2.5).  
When considering raw RT, the group x cue interaction was not significant, however it was 
significant for normalised RT. Subsequent post-hoc tests of normalised RT at the individual 
group level revealed that controls had significant alerting and orienting effects. In AD and 
LBD participants, the alerting effect was not significant, however, both dementia groups 
demonstrated a significant orienting effect (Table 2.5 and Figure 2.2B and 2.2C). Restricting 
the analysis to matched dementia subgroups did not change the results significantly (Table 
2.6). The analysis of error rates did not show any difference between the different cue 
conditions with no significant cue x group interaction (Table 2.7). 
Comparing the magnitude of the alerting effect between groups did not reveal a significant 
difference for raw RT, whereas there was a significantly smaller alerting effect in LBD 
patients compared to controls when considering normalised RT (Table 2.5). The orienting 
effect was not different in magnitude between groups for raw and normalised RT. 
Additionally, there were no group differences in the magnitude of the alerting and orienting 
effects on error rates (Table 2.7). 
Finally, there were no significant correlations between the alerting and orienting effects and 
any clinical variables after correcting for multiple comparisons (Table 2.8). 
Executive conflict effect 
There was a main effect of target; across all groups, mean RT for congruent trials was faster 
than for incongruent trials (Table 2.5). Additionally, there was a significant target x group 
interaction (albeit only marginally significant for normalised RT) and post-hoc tests revealed 
that the executive conflict effect was significant in all three groups (Figure 2.2B and 2.2C). 
Comparing the magnitude of the effect between groups, gave a larger conflict effect in both 
dementia groups than in healthy controls with no difference between AD and LBD patients 
for raw RT. In contrast, for normalised RT there was no significant difference in the executive 
conflict effect between controls and either dementia group, although there was a trend for a 
larger effect in AD patients than in LBD patients. Again, analysing matched dementia 
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subgroups did not change the results significantly (Table 2.6). Considering error rates, the 
executive conflict effect was significant in all groups, and compared to controls, it was 
significantly larger in both AD and LBD patients (Table 2.7). There were no significant 
correlations between the executive conflict effect RT and clinical variables even for 
uncorrected p<0.05. While there was a significant interaction between cue and target for both 
raw and normalised RT (Table 2.5), this interaction did not differ between groups and was not 
analysed further. 
Table 2.4. Mean error rates (%) for each task condition (cue x target), for the controls, AD 
and LBD patients. Standard deviations are presented in brackets. 
  HC AD LBD 
Mean error rates (%)   
All trials  1.8 (1.7) 9.7 (8.6) 13.3 (9.1) 
No Cue 
Overall 1.9 (2.4) 9.8 (7.5) 14.1 (10.3) 
Congruent 1.1 (2.1) 4.3 (6.0) 5.8 (6.0) 
Incongruent 2.8 (3.8) 15.3 (11.6) 22.4 (17.5) 
Neutral 
Overall 2.1 (1.8) 9.5 (9.1) 12.8 (9.1) 
Congruent 1.1 (1.5) 5.4 (5.8) 7.6 (8.1) 
Incongruent 3.1 (2.6) 13.7 (13.4) 18.0 (14.2) 
Spatial 
Overall 1.5 (1.8) 9.8 (9.9) 13.0 (9.5) 
Congruent 0.7 (1.7) 5.2 (7.6) 6.4 (7.5) 
Incongruent 2.3 (2.5) 14.5 (15.0) 19.6 (14.2) 
Congruent Overall 0.9 (1.5) 4.9 (6.0) 6.6 (6.2) 
Incongruent Overall 2.7 (2.4) 14.5 (12.8) 20.0 (14.3) 
ANT effects (%)   
Alerting -0.2 (2.2) 0.2 (3.5) 1.3 (3.5) 
Orienting 0.6 (1.3) -0.3 (3.7) -0.3 (3.7) 
Executive 1.78 (2.1)* 9.7 (10.2)* 9.6 (10.2)* 
AD, Alzheimer’s disease; HC, healthy controls; LBD, Lewy body dementia;  
*Significant ANT effect, p-value<0.05 for error rates. 
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Table 2.5. Results from statistical tests for raw and normalised RT. Repeated measures (cue x 
target) ANOVA effects with group (HC, AD, LBD) as between-subject factor (F value, 
degrees of freedom (df), error df, and p-value), and post-hoc tests ([95% confidence interval 
of the mean difference], Bonferroni-corrected p-values). 
  Effect significance,  
raw RT 
Effect significance,  
normalised RT 
Main effects 
Group  F(2,95)=24.19, p<0.001  
Post-hoc 
HC-AD [-578.9, -131.4], p=0.001  
HC-LBD [-802.5, -384.9], p<0.001  
AD-LBD [-425.9, -51.2], p=0.008  
Cue  F(2,190)=73.97, p<0.001 F(2,190)=131.81, p<0.001 
Post-hoc 
Alerting [4.9, 46.1], p=0.01 [0.011, 0.038], p<0.001 
Orienting [58.7, 104.5], p<0.001 [0.055, 0.085], p<0.001 
Target F(1,95)=448.04, p<0.001 F(1,95)=981.64, p<0.001 
Interactions 
Cue x group F(4,190)=1.64, p=0.17 F(4,190)=6.97, p<0.001 
HC Cue  F(2,42)=167.0, p<0.001 
  Alerting  [0.026, 0.068], p<0.001 
  Orienting   [0.073, 0.111], p<0.001 
AD Cue   F(2,60)=33.33, p<0.001 
  Alerting  [-0.003, 0.047], p=0.10 
  Orienting  [0.037, 0.089], p<0.001 
LBD Cue  F(2,88)=24.89, p<0.001 
  Alerting  [-0.015, 0.026], p=1.0 
  Orienting  [0.03, 0.080], p<0.001 
Target x group F(2,95)=5.30, p=0.007 F(2,95)=3.01, p=0.054 
HC Executive F(1,21)=111.68, p<0.001 F(1,21)=227.05, p<0.001 
AD Executive F(1,30)=205.38, p<0.001 F(1,30)=370.25, p<0.001 
LBD Executive F(1,44)=226.33, p<0.001 F(1,44)=443.46, p<0.001 
Cue x target F(1.7,157.1)=6.51, p=0.002 F(1.9,177.8)=14.53, p<0.001 
Cue x target x group F(3.3,157.1)=0.9, p=0.46 F(3.7,177.8)=1.44, p=0.22 
Magnitude group differences 
Alerting ANOVA F(2,95)=2.63, p=0.08 F(2,95)=4.85, p=0.01 
 HC-AD  [-0.010, 0.060], p=0.25 
Post-hoc HC-LBD  [0.009, 0.074], p=0.008 
 AD-LBD  [-0.013, 0.046], p=0.52 
Orienting ANOVA F(2,95)=0.27, p=0.77 F(2,95)=3.06, p=0.052 
Executive ANOVA F(2,95)=5.30, p=0.007 F(2,95)=3.01, p=0.054 
 HC-AD [-325.5, -17.55], p=0.02 [-0.111, 0.049], p=1.0 
Post-hoc HC-LBD [-326.4, -39.1], p=0.008 [-0.039, 0.111], p=0.73 
 AD-LBD [-140.2, 117.7], p=1.0 [-0.0001, 0.134], p=0.05 
AD, Alzheimer’s disease; HC, healthy controls; LBD, Lewy body dementia; RT, reaction time. 
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Table 2.6. Results from statistical tests for raw and normalised RT analysing matched 
dementia subgroups (see Section 2.3.1). Repeated measures (cue x target) ANOVA effects 
with group (HC, AD, LBD) as between-subject factor (F value, degrees of freedom (df), error 
df, and p-value), and post-hoc tests ([95% confidence interval of the mean difference], 
Bonferroni-corrected p-values). 
  Effect significance,  
raw RT 
Effect significance,  
normalised RT 
Main effects 
Group  F(2,81)=29.6, p<0.001  
Post-hoc 
HC-AD [-557.0, -118.7], p=0.001  
HC-LBD [-857.5, -442.3], p<0.001  
AD-LBD [-507.4, -116.6], p=0.001  
Cue  F(2,162)=63.3, p<0.001 F(2,162)=115.9, p<0.001 
Post-hoc 
Alerting [-4.2, 37.6], p=0.16 [0.006, 0.032], p=0.002 
Orienting [59.9, 109.1], p<0.001 [0.073, 0.106], p<0.001 
Target F(1,81)=440.1, p<0.001 F(1,81)=978.0, p<0.001 
Interactions 
Cue x group F(4,162)=2.00, p=0.10 F(4,162)=8.4, p<0.001 
HC Cue  F(2,42)=167.0, p<0.001 
  Alerting  [0.026, 0.068], p<0.001 
  Orienting   [0.073, 0.111], p<0.001 
AD Cue   F(2,52)=27.3, p<0.001 
  Alerting  [-0.012, 0.037], p=0.62 
  Orienting  [0.044, 0.113], p<0.001 
LBD Cue  F(2,68)=16.4, p<0.001 
  Alerting  [-0.025, 0.020], p=1.0 
  Orienting  [0.024, 0.078], p<0.001 
Target x group F(2,81)=6.4, p=0.003 F(2,81)=3.10, p=0.051 
HC Executive F(1,21)=111.68, p<0.001 F(1,21)=227.05, p<0.001 
AD Executive F(1,26)=187.8, p<0.001 F(1,26)=428.5, p<0.001 
LBD Executive F(1,34)=194.6, p<0.001 F(1,34)=361.2, p<0.001 
Cue x target F(1.6,132.9)=4.7, p=0.01 F(1.9,150.5)=10.7, p<0.001 
Cue x target x group F(3.3,132.9)=1.1, p=0.37 F(3.7,150.4)=1.39, p=0.24 
Magnitude group differences 
Alerting ANOVA F(2,81)=3.58, p=0.03 F(2,81)=7.0, p=0.002 
 HC-AD [-21.5,86.5], p=0.44 [0.000, 0.068], p=0.047 
Post-hoc HC-LBD [4.8,107.1], p=0.03 [0.017, 0.081], p=0.001 
 AD-LBD [-24.7,71.7], p=0.71 [-0.016, 0.045], p=0.72 
Orienting ANOVA F(2,81)=0.15, p=0.87 F(2,81)=3.0, p=0.055 
Executive ANOVA F(2,81)=6.4, p=0.003 F(2,81)=3.1, p=0.051 
 HC-AD [-341.6, -29.7], p=0.01 [-0.120, 0.039], p=0.65 
Post-hoc HC-LBD [-353.3, -57.7], p=0.003 [-0.044, 0.107], p=0.93 
 AD-LBD [-159.0, 119.3], p=1.0 [0.001, 0.143], p=0.05 
AD, Alzheimer’s disease; HC, healthy controls; LBD, Lewy body dementia; RT, reaction time. 
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Table 2.7. Results from statistical tests for error rates. Repeated measures (cue x target) 
ANOVA effects with group (HC, AD, LBD) as between-subject factor (F value, degrees of 
freedom (df), error df, and p-value), and post-hoc tests ([95% confidence interval], 
Bonferroni-corrected p-values). 
  Effect significance, error rates 
Main effects 
Group F(2,95)=15.59, p<0.001 
Post-hoc 
HC-AD [-13.3, -2.5], p=0.002 
HC-LBD [-16.5, -6.5], p<0.001 
AD-LBD [-8.1, 0.9], p=0.17 
Cue  F(1.8,172.4)=0.67, p=0.51  
Target F(1,95)=57.70, p<0.001 
Cue x group F(3.6,172.4)=0.65, p=0.63 
Interactions 
Target x group F(2,95)=9.38, p<0.001 
HC Executive F(1,21)=15.98, p=0.001 
AD Executive F(1,30)=27.10, p<0.001 
LBD Executive F(1,44)=51.82, p<0.001 
Cue x target F(1.9,176.2)=3.87, p=0.02 
Cue x target x group F(3.7,176.2)=1.76, p=0.14 
Magnitude group differences  
Alerting ANOVA F(2,95)=0.79, p=0.46 
Orienting ANOVA F(2,95)=0.44, p=0.65 
Executive ANOVA F(2,95)=9.38, p<0.001 
 HC-AD [-14.8, -0.8], p=0.02 
Post-hoc HC-LBD [-18.1, -5.1], p<0.001 
 AD-LBD [-9.6, 2.0], p=0.35 
AD, Alzheimer’s disease; HC, healthy controls; LBD, Lewy body dementia. 
  
Table 2.8. Spearman’s correlations between clinical scores and ANT effects using raw and 
normalised RT in the dementia groups. All correlations are shown that have uncorrected p-
values<0.05. Correlations surviving FDR-correction are marked with an asterisk. 
  Raw RT Normalised RT 
AD  
Mean RT MMSE ρ=-0.52 (p=0.002, pFDR=0.02)* / 
 CAMCOG ρ=-0.47 (p=0.007, pFDR=0.02)* / 
Error rate MMSE ρ=-0.47 (p=0.007, pFDR=0.02)* / 
 CAMCOG ρ=-0.45 (p=0.01, pFDR=0.02)* / 
LBD    
Mean RT UPDRS ρ=0.32 (p=0.03, pFDR=0.20) / 
 Mayo cogna ρ=0.30 (p=0.05, pFDR=0.50) / 
Error rate MMSE ρ=-0.60 (p<0.001, pFDR<0.001)* / 
 CAMCOG ρ=-0.68 (p<0.001, pFDR<0.001)* / 
Orienting CAF freq ρ=0.32 (p=0.03, pFDR=0.50) ρ=0.30 (p=0.05, pFDR=0.62) 
AD, Alzheimer’s disease; CAF freq, Clinician Assessment of Fluctuation frequency subscale; CAMCOG, 
Cambridge Cognitive Examination; LBD, Lewy body dementia; Mayo cogn, Mayo Fluctuations cognitive 
subscale; MMSE, Mini Mental State Examination; RT, reaction time; UPDRS, Unified Parkinson’s Disease 
Rating Scale 
aN=43. 
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Figure 2.3. A) Spearman’s correlations between global cognition and mean RT in the AD 
group. B) Spearman’s correlation between global cognition and error rates in in the LBD 
group. All p-values are FDR-corrected for multiple comparisons.  
MMSE, Mini Mental State Examination; CAMCOG, Cambridge Cognitive Examination; RT, 
reaction time. 
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2.3.3 Effect of dopaminergic medication in the LBD group 
For raw RT, there was no interaction between LEDD and cue (F(2,84)=0.15, p=0.86) or target 
(F(1,42)=0.003, p=0.96). There was a main effect of cue (F(2,84)=9.34, p<0.001) with post-
hoc tests revealing no alerting effect (no cue compared to neutral cue, 95% confidence 
interval (CI)=[-34.4, 37.5], p=1.0), but a significant orienting effect (neutral cue compared to 
spatial cue, 95% CI=[39.7, 126.4], p<0.001). Furthermore, there was a main effect of target 
with slower RTs in incongruent compared to congruent trials (F(1,42)=104.1, p<0.001).  
For normalised RT, there was no interaction between LEDD and cue (F(2,84)=0.08, p=0.92) 
and no target by LEDD interaction (F(1,42)=0.85, p=0.36). There was a main effect of cue 
(F(2,84)=12.20, p<0.001) with no alerting effect (95% CI=[-0.02, 0.03], p=1.0), but a 
significant orienting effect (95% CI=[0.03, 0.08], p<0.001). There was also a significant main 
effect of target (F(1,42)=224.01, p<0.001).  
These results indicate that dopaminergic medication dose does not significantly influence the 
ANT effects in LBD. 
2.3.4 VBM analysis 
Four DLB and two AD patients did not have structural scans and were therefore excluded 
from the VBM analysis.  
In AD patients, a significant negative correlation was found between mean RT and grey 
matter volume in a large cluster at the lingual gyrus (Figure 2.4A). All other results in the AD 
group did not survive correction for multiple comparisons and are therefore reported as an 
exploratory analysis at a voxel-level threshold of p<0.001 in Tables 2.9 and 2.10. The alerting 
effect negatively correlated with grey matter volume in parietal regions and positively 
correlated with white matter volume in occipital regions. For the orienting effect there were 
positive correlations with grey matter volume in occipital and white matter volume in 
temporal regions. Additionally, grey matter volume in different parts of the cerebellum in the 
AD group correlated with the executive conflict effect. 
In LBD patients, a significant negative correlation was found between the white matter 
volume in a large cluster at the lateral occipital cortex and the orienting effect (Figure 2.4B). 
Other results did not survive correction for multiple comparisons and are therefore reported at 
p<0.001 in Tables 2.11 and 2.12. There were positive correlations between grey matter 
volume in temporal and parietal regions and the alerting effect in patients with LBD. The 
orienting effect was positively correlated with grey matter volume in the parietal lobe and the 
executive conflict effect was negatively correlated with small grey matter clusters in temporal 
regions.  
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Table 2.9. Correlations between mean RT and ANT effects and grey matter volume in AD. 
All clusters are larger than five voxels and significant at p<0.001, uncorrected. Correction for 
multiple comparisons was performed with AlphaSim at p<0.05 resulting in minimum cluster 
sizes of 223 voxels for mean RT and 256 voxels for the ANT effects. Clusters surviving 
correction are highlighted with an asterisk. Locations were estimated from the Harvard-
Oxford atlas in FSL. 
Cluster location size MNI (X,Y,Z) 
Mean RT, negative correlation 
L lingual gyrus 805* -21,-58,-9 
L angular gyrus 74 -45,-50,22 
L paracingulate gyrus 56 -12,52,-6 
R cerebellum Crus I 43 20,-86,-22 
L middle frontal gyrus 31 -34,14,36 
L post. supramarginal gyrus 30 -58,-46,30 
L superior lateral occipital cortex 14 18,-62,50 
L cerebellum Crus I 13 -24,-87,-28 
R occipital pole 9 36,-93,9 
L superior lateral occipital cortex 7 -18,-69,40 
Alerting, negative correlation 
L anterior supramarginal gyrus 129 -51,-27,36 
L posterior cingulate cortex 26 -9,-22,44 
R postcentral gyrus 20 66,-10,14 
L anterior supramarginal gyrus 14 -60,-34,45 
L frontal orbital cortex 11 -22,32,-26 
R occipital pole 9 26,-87,32 
Orienting, negative correlation 
R frontal pole 7 52,39,15 
Orienting, positive correlation 
R occipital pole 74 33,-92,20 
R lateral occipital cortex 47 34,-76,39 
L sup. lateral occipital cortex 23 -27,-80,32 
R frontal pole 19 34,57,22 
R superior lateral occipital cortex 16 34,-72,20 
R superior lateral occipital cortex 15 26,-68,50 
Executive, negative correlation 
R paracingulate gyrus 22 6,40,34 
R cerebellum Crus I 20 48,-74,-30 
R cerebellum Crus I 11 34,-82,-21 
Executive, positive correlation 
R cerebellum V 24 8,-57,-27 
R cerebellum Crus II 19 32,-63,-42 
MNI, Montreal Neurological Institute coordinates; RT, reaction time. 
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Table 2.10. Correlations between mean RT and ANT effects and white matter volume in AD. 
All clusters are larger than five voxels and significant at p<0.001, uncorrected. Correction for 
multiple comparisons was performed with AlphaSim at p<0.05 resulting in minimum cluster 
sizes of 233 voxels for mean RT and 228 voxels for the ANT effects. There were no clusters 
which survived correction. Locations were estimated from the Harvard-Oxford atlas in FSL 
and white matter regions were identified from the nearest grey matter structure. 
Cluster location size MNI (X,Y,Z) 
Mean RT, negative correlation 
R inferior frontal gyrus 193 51,33,8 
L postcentral gyrus 92 -54,-14,22 
L middle temporal gyrus 85 -56,-36,-14 
L lateral occipital cortex 49 -33,-69,0 
L occipital fusiform gyrus 41 -22,-66,-8 
R lateral occipital cortex 38 27,-82,21 
L lingual gyrus 8 -12,-72,-8 
L precentral gyrus 8 -46,-9,28 
R inferior temporal gyrus 3 57,-36,-21 
R frontal pole 2 45,40,-8 
Alerting, positive correlation 
L lateral occipital cortex 36 -38,-64,33 
Orienting, positive correlation 
R inferior temporal gyrus 7 56,-39,-18 
MNI, Montreal Neurological Institute coordinates; RT, reaction time. 
 
 
Table 2.11. Correlations between mean RT and ANT effects and grey matter volume in LBD. 
All clusters are larger than five voxels and significant at p<0.001, uncorrected. Correction for 
multiple comparisons was performed with AlphaSim at p<0.05 resulting in minimum cluster 
sizes of 230 voxels for mean RT and 242 voxels for the ANT effects. There were no clusters 
which survived correction. Locations were estimated from the Harvard-Oxford atlas in FSL. 
Cluster location size MNI (X,Y,Z) 
Mean RT, positive correlation 
L frontal pole 79 -24,58,27 
L superior parietal lobule 23 -44,-40,54 
L cerebellum X 7 -24,-40,-44 
Alerting, positive correlation 
R parahippocampal gyrus 120 18,3,-42 
L frontal pole 21 -8,44,51 
R posterior temporal fusiform gyrus 11 39,-15,-27 
Orienting, positive correlation 
L parahippocampal gyrus 81 -12,-38,-6 
R frontal pole 11 30,48,34 
R angular gyrus 11 46,-50,27 
Executive, negative correlation 
R temporal pole 38 39,15,-46 
Executive, positive correlation 
R frontal pole 7 42,54,18 
MNI, Montreal Neurological Institute coordinates; RT, reaction time. 
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Table 2.12. Correlations between mean RT and ANT effects and white matter volume in 
LBD. All clusters are larger than five voxels and significant at p<0.001, uncorrected. 
Correction for multiple comparisons was performed with AlphaSim at p<0.05 resulting in 
minimum cluster sizes of 257 voxels for mean RT and 262 voxels for the ANT effects. 
Clusters surviving correction are highlighted with an asterisk. Locations were estimated from 
the Harvard-Oxford atlas in FSL and white matter regions were identified from the nearest 
grey matter structure. 
Cluster location size MNI (X,Y,Z) 
Mean RT, positive correlation 
R cerebellum I-IV 6 9,-48,-21 
R temporal fusiform 2 39,-16,-22 
R temporal fusiform  1 39,-21,-22 
Orienting, negative correlation 
R lateral occipital  484* 24,-58,45 
R paracingulate gyrus 159 9,22,45 
R suppl. motor area 80 8,-10,54 
L suppl. motor area 80 -8,-12,54 
L frontal pole 79 -33,39,18 
L precuneus 74 -8,-64,46 
R angular gyrus 21 50,-46,18 
R inferior temporal  17 45,-28,-22 
R paracingulate gyrus 9 9,34,38 
Orienting, positive correlation 
R occipital pole 12 24,-93,15 
MNI, Montreal Neurological Institute coordinates; RT, reaction time. 
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Figure 2.4. Significant clusters from VBM analysis. A) Negative correlation between mean 
reaction time (RT) and grey matter volume at the left lingual gyrus in the AD group. B) 
Negative correlation between the size of the orienting effect and white matter volume at the 
right lateral occipital cortex in the LBD group. Information on all uncorrected results can be 
found in Tables 2.9 - 2.12. 
2.4 Discussion 
In this chapter, the efficiency of different attentional systems in patients with AD and LBD 
was compared to healthy controls, in addition to examining the relationship between 
attentional deficits and structural abnormalities in the dementia groups. 
2.4.1 Mean RT 
Both dementia groups showed slower overall mean RTs than controls, and the LBD group 
showed slower RTs than the AD group. This is comparable to previous ANT studies in 
dementia cohorts (Fernandez-Duque and Black, 2006; Fuentes et al., 2010) and more general 
RT studies comparing AD and LBD (Ballard et al., 2001a; Bradshaw et al., 2004). In AD, the 
observed RT slowing was related to diminished overall cognitive functioning, i.e. patients 
with poorer cognitive function demonstrated more impaired RT performance. This finding in 
AD patients is in agreement with a previous study showing that increased RT during a choice 
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RT task is associated with reduced global cognitive functioning in AD and DLB patients 
(Ballard et al., 2001a). In contrast, this relationship was not observed in the present LBD 
group. However, DLB patients in Ballard et al. (2001a) were cognitively more impaired than 
our LBD patients which may explain the lack of association in the present analysis. A 
significant correlation was found between mean RT and grey matter volume at the lingual 
gyrus in AD patients, suggesting that lower brain volume in this area is related to general RT 
slowing. The ANT involves visual processing and therefore RT slowing in AD might be 
related to occipital/visual structural abnormalities. This agrees with previous studies showing 
associations between occipital cortex and visual impairments in AD and LBD (Firbank et al., 
2003; Ossenkoppele et al., 2015; Taylor et al., 2012). 
Compared to controls, the accuracy with which participants performed the task was lower in 
both dementia groups; however, error rates seen in the LBD group did not exceed those in the 
AD patients, indicating that LBD-related deficits seem to be specific to response speed, with 
limited impact on accuracy. In both dementia groups, there was a significant negative 
correlation between mean error rate and measures of overall cognition, indicating that both in 
AD and in LBD the overall severity of cognitive impairment has an influence on the patients’ 
ability to accurately perform the task. 
2.4.2 Alerting effect 
With respect to the alerting effect, group differences only became apparent when studying 
normalised RT. This indicates that differences in alerting might have been obscured by 
overall differences in RT speed. The absence of a significant alerting effect in both dementia 
groups, i.e. the inability of patients to benefit from the cueing effect, is indicative of reduced 
efficiency of the alerting system which seems to be a general dementia phenomenon and not 
specific to LBD or AD. In LBD, this result is expected given the association between alerting 
efficiency and noradrenergic projections from the locus coeruleus which are affected by LBD 
(Coull et al., 2001; Raz, 2004). In AD, however, this result stands in contrast to a previous 
study which has found a significant alerting effect in this group (Fernandez-Duque and Black, 
2006). AD patients in the present study were cognitively more impaired compared to the AD 
patients in the afore-mentioned study, indicating that there might be a loss of alerting 
efficiency with dementia progression. The absence of a significant correlation between the 
size of the alerting effect and the severity of cognitive impairment in the AD group, however, 
indicates that this is not a linear relationship. Another explanation for the lack of a significant 
alerting effect in the present study might be the modified ANT version that was used here. 
While Fernandez-Duque and Black (2006) used a display consisting of only two boxes that 
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both lit up in case of a neutral cue, in the present version the neutral cue was conveyed by 
flashing the central box while the target was presented in one of the boxes either below or 
above the central box. Thus, participants were required to re-orient their attention following a 
neutral cue which seemed to have a detrimental effect on some participants’ RT performance, 
as suggested by negative alerting effects in some dementia patients (see Figure 2.2). 
There were no significant associations between the alerting effect and grey and white matter 
volume in either dementia group. Using participants from the CATFieLD study, an fMRI 
study of the efficiency of the different attentional components found LBD, AD, and healthy 
control groups to have comparable fronto-parietal-occipital activations associated with the 
alerting effect (Firbank et al., 2016). Together with the results presented here, this suggests 
that the lack of a behavioural alerting effect in the dementia groups is unlikely to be due to 
region-specific functional or structural deficits. 
2.4.3 Orienting effect 
The orienting effect did not show group differences. This is comparable to previous literature 
showing preservation of the orienting system in AD patients (Fernandez-Duque and Black, 
2006). However, given that the orienting system is postulated to be modulated by the basal 
forebrain cholinergic system (Fan et al., 2005), which is markedly affected in DLB (Clerici et 
al., 2007; Grothe et al., 2014), I expected the LBD group to exhibit reduced orienting 
efficiency. Given the marginally significant overall ANOVA for normalised RT and the prior 
hypothesis of reduced orienting efficiency in LBD, I conducted an exploratory post-hoc 
analysis which demonstrated a marginally significant lower orienting effect in LBD compared 
to controls (p=0.049), thus tentatively supporting the a priori hypothesis that this component 
of attention would be reduced in LBD, particularly when overall processing speed is 
considered. Orienting efficiency was related to white matter abnormalities in the occipital 
cortex in patients with LBD, indicating a relationship between less efficient use of the 
orienting cue and reduced white matter volume in the lateral occipital cortex. Previous fMRI 
studies have found brain activations for the orienting effect in occipital and parietal cortices 
(Fan et al., 2005; Firbank et al., 2016). The present results further suggest that structural 
alterations in these regions might also contribute to orienting inefficiency in LBD. 
Associations with occipital cortical volume were also found for alerting and orienting effects 
in patients with AD. Even though these clusters did not survive correction for multiple 
comparison, they nevertheless suggest a trend for involvement of occipital regions in the 
efficiency of the ANT effects in both dementia groups. 
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2.4.4 Executive conflict effect 
In agreement with previous studies (Fernandez-Duque and Black, 2006), the magnitude of the 
executive conflict effect was substantially greater in both dementia groups relative to controls, 
suggesting that dementia patients have a reduced ability to resolve conflict amongst 
responses. Executive dysfunction is characteristic of LBD patients (Noe et al., 2004). The 
reduced executive conflict efficiency in LBD patients fits with the notion of dopaminergic 
mediated frontal-striatal dysfunction being a contributory factor to the executive dysfunction 
in LBD (Fan et al., 2005; Kehagia et al., 2012). However, the group differences were greatly 
diminished when considering normalised RTs, indicating that this effect was partly due to 
differences in overall processing speed. No strong association between the efficiency of the 
executive conflict component and cortical volume was observed in either dementia group. In 
particular, contrary to a previous study in individuals with MCI (Borsa et al., 2016), there was 
no association between grey matter volume at the ACC and the executive conflict effect in 
patients with AD (even when considering uncorrected results). This might be due to higher 
inter-subject variability in ACC volume in MCI compared to AD. Furthermore, Borsa et al. 
(2016) restricted their analysis to relations between the ACC and the executive conflict effect 
which makes their approach more sensitive compared to the whole-brain approach across all 
attentional components applied here. Overall, the present results for the executive conflict 
effect suggest that the dementia-related inefficiency of this component might be related to 
functional or microstructural rather than macrostructural changes. 
2.4.5 Clinical correlations 
Contrary to the hypothesis, there were no significant correlations between cognitive 
fluctuation severity and attentional measures in patients with LBD. At an uncorrected 
threshold of p<0.05, there was a correlation between the size of the orienting effect and the 
CAF frequency score which indicates that in LBD, there might be a relationship between loss 
of orienting efficiency and more frequent cognitive fluctuations. This would be in line with 
previous reports in DLB showing associations between greater RT slowing and cognitive 
fluctuations (Bradshaw et al., 2006; Walker et al., 2000a). However, these results did not 
survive correction for multiple comparison and should therefore be interpreted with caution. 
2.4.6 Limitations 
Seeing as the orienting and executive conflict components are believed to be modulated by 
cholinergic and dopaminergic systems (Fan et al., 2005), a potential confound was the fact 
that most patients were taking cholinergic and/or dopaminergic medication. Regarding 
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dopaminergic medication, I showed that covarying for levodopa equivalent daily dose did not 
change the results (see Section 2.3.3). The small number of patients not taking 
acetylcholinesterase inhibitors did not allow for a more in-depth analysis of the effect of 
cholinergic medication on orienting and executive conflict effects; this remains a limitation of 
this work. A further limitation might be the fact that the two dementia groups were not 
completely matched in terms of overall cognitive impairment. Repeating the analysis using 
data from two subgroups of AD and LBD patients that were matched in terms of overall 
cognition, as measured by the MMSE, showed that results remained largely the same. 
2.4.7 Conclusion 
In contrast to previous studies in less impaired patients, this investigation did not find a 
significant alerting effect for either of the dementia groups. This might indicate that a loss of 
the facilitating cue effect occurs with dementia progression. In contrast, orienting was largely 
preserved with a slight impairment in patients with LBD that was not observed in the AD 
patients, and this might be related to structural abnormalities in occipital regions. Finally, the 
resolution of executive conflict was clearly impaired in both dementia groups but did not 
appear to be related to macrostructural changes in brain volume in either group.
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Chapter 3. Ex-Gaussian Analysis of Reaction Time Data and Brain 
Structural Correlates 
3.1 Introduction 
In studies utilising cognitive tests with outcomes based on RT, it is common to focus on 
analysing mean RT. However, RT is usually not normally distributed, but positively skewed 
(Balota and Yap, 2011). Describing this distribution by more than central tendency measures 
therefore provides a more detailed and accurate analysis method (Balota and Yap, 2011). One 
distribution that has been used successfully to model empirical RT distributions is the 
exponentially modified Gaussian (ex-Gaussian) distribution. This is a convolution of a 
Gaussian and an exponential distribution characterised by three parameters – mu, sigma, and 
tau – that represent different aspects of the ex-Gaussian distribution. Mu and sigma describe 
the mean and standard deviation of the Gaussian part, respectively, while tau quantifies the 
right tail of the distribution which describes the subset of extremely slow responses (Ratcliff, 
1979). The ex-Gaussian analysis therefore allows investigation of the effect of ageing and 
dementia on different aspects of RT distributions. An overall shift of the distribution to higher 
or lower values will be primarily reflected by a change in mu, whereas changes in skewness 
will be indicated by a change in tau. While ageing has been shown to affect all three 
parameters, AD has been shown to only affect the tau component compared to age-matched 
controls without dementia (Jackson et al., 2012; Tse et al., 2010). An increase in tau can also 
be observed when comparing individuals without dementia who later developed AD to those 
who did not, suggesting that these changes can be observed early in the course of the disease 
(Balota et al., 2010). 
Even though attentional dysfunction is a core feature of LBD, no previous investigation has 
analysed RT data in LBD with an ex-Gaussian analysis. The aim of this chapter is therefore to 
investigate how different aspects of RT distributions – as modelled by the ex-Gaussian 
distribution – are differentially affected in LBD compared to AD and healthy ageing. Based 
on previous studies, I hypothesised that there will be an increase in tau in the AD group 
compared to healthy controls, with little change in mu and sigma (Jackson et al., 2012; Tse et 
al., 2010). Given that attentional impairment is more pronounced in LBD than in AD, I 
hypothesised to see an increase in all three ex-Gaussian parameters in patients with LBD 
compared to healthy controls and patients with AD. In addition, I expected this difference to 
be especially pronounced for tau, given that tau represents extremely slow responses which 
can be seen as lapses in attention (Schmiedek et al., 2007). Furthermore, I also explored the 
relationship between the different ex-Gaussian parameters and clinical scores in the LBD 
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group to investigate associations between clinical symptoms and different aspects of RT 
performance. Here, I hypothesised a correlation between cognitive fluctuation severity and the 
ex-Gaussian parameters in LBD, especially with respect to tau.  
Previous studies have suggested that there might be an association between RT deficits and 
structural brain abnormalities in AD (Jackson et al., 2012). I therefore also investigated 
possible macrostructural neural correlates of RT deficits by analysing voxel-wise relations 
between the three ex-Gaussian parameters and grey and white matter volume in both dementia 
groups. I hypothesised to find correlations between grey and white matter volume loss and the 
ex-Gaussian parameters in AD, and that this relation would be less pronounced in LBD. 
3.2 Methods 
3.2.1 Participants 
Data for this analysis were the same as in Chapter 2 (Section 2.2.2) involving the same 
participants from the CATFieLD study; 49 were diagnosed with probable LBD (26 DLB and 
23 PDD patients), 33 with probable AD, and 22 were age-matched healthy controls. Again, all 
trials from runs with less than 2/3 correct responses were excluded from the analysis as 
performance below this was not different from chance (Firbank et al., 2016). Additionally, 
participants with fewer than 70 remaining correct trials were excluded to allow a robust fit of 
the ex-Gaussian distribution. 
3.2.2 Ex-Gaussian analysis 
Response times from the ANT were analysed by fitting an ex-Gaussian distribution to the RTs 
from all correct trials for each participant individually (combining all cue and target 
conditions). The ex-Gaussian distribution is a convolution of a Gaussian and an exponential 
distribution and can be described by three parameters: mu and sigma represent the mean and 
standard deviation of the Gaussian component, respectively, while tau is the decay parameter 
of the exponential component and characterises the slow tail of the distribution (Figure 3.1). 
Ex-Gaussian parameters for each participant were estimated using the DISTRIB toolbox in 
Matlab (R2015b) which applies a maximum likelihood approach with a bounded search 
(Lacouture and Cousineau, 2008). 
3.2.3 VBM analysis 
A VBM analysis was performed for all LBD and AD patients in SPM12 to assess voxel-wise 
correlations between the ex-Gaussian parameters and cortical volume, separately in each 
dementia group. Using the preprocessed images from Chapter 2 (Section 2.2.4),  
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Figure 3.1. A) Ex-Gaussian function as a convolution of a Gaussian function with mean mu 
and standard deviation sigma and an exponential function with decay parameter tau. B) 
Example fit of the ex-Gaussian function to an empirical reaction time (RT) distribution. 
correlations between grey and white matter volume and the ex-Gaussian parameters were 
assessed using a GLM in SPM for each parameter separately. Covariates of no interest for 
age, sex, total intracranial volume, and UPDRS motor scores (in LBD) were included in the 
design matrix. An explicit mask was estimated using the SPM Masking Toolbox (Ridgway et 
al., 2009) to restrict the statistical analysis to voxels that represent grey and white matter, 
respectively. An uncorrected voxel-level threshold of p<0.001 was chosen and the minimum 
cluster size for a corrected threshold of p<0.05 was determined by AlphaSim via Monte Carlo 
simulation using the REST software. 
3.2.4 Statistics 
Statistical analyses were carried out in IBM SPSS Statistics version 23 and R version 3.5.1. 
The three ex-Gaussian parameters were compared between the groups by a Kruskal-Wallis 
test and post-hoc Dunn’s tests with Bonferroni correction. Correlations between the ex-
Gaussian parameters and different clinical scores were assessed by Spearman’s rank 
correlations. In the LBD group, correlations were calculated for cognitive fluctuation scores 
(Mayo and CAF total and subscores); supplementary analyses were performed for measures 
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of overall cognition (MMSE, CAMCOG), the UPDRS motor subscale, and the NPI 
hallucination scale. In the AD group, correlations were calculated for MMSE and CAMCOG. 
P-values were FDR-corrected for multiple comparisons. 
To study possible effects of dopaminergic medication on the ex-Gaussian distribution in the 
LBD group, correlations between the three ex-Gaussian parameters and LEDD (Tomlinson et 
al., 2010) were investigated using Spearman’s correlations. 
3.3 Results 
3.3.1 Demographics 
Five AD, three DLB, and eight PDD patients were excluded because they did not meet the 
minimum RT performance criteria (Section 3.2.1). Therefore, 28 AD patients, 39 LBD 
patients (23 DLB and 16 PDD), and 22 healthy controls were included for further analysis. 
The lower number of included participants compared to Chapter 2 is due to the additional 
exclusion criterion (<70 correct trials) that was needed for a successful fit of the ex-Gaussian 
distribution (see Section 3.2.1).   
Demographic and clinical information for all included participants is presented in Table 3.1. 
All three groups were matched for age and sex. As expected, the LBD group had more 
frequent occurrence of the core LBD symptoms (cognitive fluctuations, visual hallucinations, 
and Parkinsonism) than the AD group. However, they were slightly less impaired in terms of 
overall cognition (MMSE and CAMCOG) and the time since onset of cognitive symptoms 
was shorter in the LBD group compared with the AD group. To ensure that group differences 
in overall cognition did not influence the results, all analyses were repeated on AD and LBD 
subgroups matched for overall cognition. These matched dementia groups were created by 
excluding one AD patient with MMSE<16 and seven LBD patients (five DLB and two PDD) 
with MMSE>27. Subsequently, the two groups did not differ with respect to either dementia 
duration (Mann-Whitney U test, U=329, p=0.11), MMSE (Student’s t-test, t57=0.49, p=0.63) 
or CAMCOG (Student’s t-test, t57=0.31, p=0.76). 
Similar to the standard RT analysis in Chapter 2, it was decided a priori to combine the DLB 
and PDD patients into one LBD group as previous studies have shown similar attentional and 
executive impairment in DLB and PDD (Ballard et al., 2002a; Firbank et al., 2016) as well as 
similar brain structural abnormalities (Burton et al., 2004). Both groups were matched in 
terms of age, overall cognition, and dementia duration. PDD patients were more impaired in 
terms of Parkinsonism, psychiatric symptoms, and cognitive fluctuations, and were more 
often on dopaminergic medication (Table 3.1).  
59 
 
Table 3.1. Demographics and clinical information, mean (standard deviation). 
 HC (N=22) AD (N=28) LBD (N=39) Group differences DLB (N=23) PDD (N=16) Group differences 
Male: female 15:7 22:6 34:5 χ2=3.18, p=0.20a  18:5 16:0 χ2=3.99, p=0.046g  
Age 75.9 (5.4) 76.6 (8.1) 75.5 (5.5) F2,86=0.22, p=0.80
b  76.4 (5.9) 74.2 (4.7) t37=1.27, p=0.21
h  
AChEI na 26 35 χ2=0.19, p=0.66c  21 14 χ2 =0.15, p =0.70g  
PD meds na 0 28 χ2=34.54, p<0.001c  12 16 χ2 =10.66, p=0.001g  
Duration  na 3.9 (2.1) 3.0 (1.9) U=395, p=0.05d  3.4 (2.1) 2.6 (1.5) U =142.50, p=0.22
j  
MMSE 29.2 (0.9) 21.8 (3.1) 23.5 (3.7) t65=1.94, p=0.06
e  23.5 (4.0) 23.4 (3.4) t37 =0.12, p =0.91
h  
CAMCOG 96.7 (3.7) 71.0 (11.5) 76.2 (12.5) t65=1.73, p=0.09
e  76.0 (14.4) 76.5 (9.6) t37 =0.13, p =0.90
h  
UPDRS 1.1 (1.4) 2.1 (2.0) 19.2 (8.4) t65=10.47, p<0.001
e 14.3 (5.3) 26.2 (7.0) t37 =6.08, p<0.001
h 
CAF total na 0.7 (1.7)f 5.0 (4.7) t64=4.46, p<0.001
e 3.8 (4.5) 6.6 (4.6) t37 =1.93, p=0.06
h 
Mayo total na 8.8 (4.0)f 13.2 (5.9) t64=3.39, p=0.001
e 11.9 (6.1) 15.0 (5.3) t37=1.65, p=0.11
h 
Mayo cogn na 1.8 (1.8)f 2.7 (1.9) t64=1.96, p=0.05
e 2.1 (1.8) 3.5 (1.8) t37=2.35, p=0.02
h 
NPI total na 6.9 (6.4)f 13.3 (10.4) t64=2.89, p=0.005
e  8.7 (4.8) 20.1 (12.5) t37=3.99, p<0.001
h  
NPI hall na 0.04 (0.2)f 1.7 (2.1) t64=4.14, p<0.001
e  1.4 (1.7) 2.1 (2.5) t37=1.09, p=0.28
h  
AChEI, number of patients taking acetylcholinesterase inhibitors; AD, Alzheimer’s disease; CAF total, Clinical Assessment of Fluctuations total score; CAMCOG, 
Cambridge Cognitive Examination; DLB, Dementia with Lewy bodies; Duration, duration of cognitive symptoms in years; HC, healthy controls; LBD, Lewy body 
dementia; Mayo cogn, Mayo Fluctuations cognitive subscale; Mayo total, Mayo Fluctuations Scale; Mayo arousal, Mayo Fluctuations arousal subscale; MMSE, Mini 
Mental State Examination; na, not applicable; PDD, Parkinson’s disease dementia; PD meds, number of patients taking dopaminergic medication; UPDRS, Unified 
Parkinson’s Disease Rating Scale III; NPI, Neuropsychiatric Inventory; NPI hall, NPI hallucination subscore 
a Chi-square test HC, AD, DLB; b One-way ANOVA HC, AD, DLB; c Chi-square test AD, DLB; d Mann Whitney U test AD, DLB; e Student’s t-test AD, DLB. 
f N=27 
g Chi-square test DLB, PDD; h Student’s t-test DLB, PDD; j Mann Whitney U test DLB, PDD. 
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The number of recorded trials did not differ between the three groups (mean HC: 301.1, mean 
AD: 295.7, mean LBD: 302.8; Kruskal-Wallis test, F2=1.07, p=0.59). The percentage of 
correct trials was higher in the control group than in the AD and LBD groups, but did not 
significantly differ between the two dementia groups (mean HC: 98%, mean AD: 90%, mean 
LBD: 85%; Kruskal-Wallis test, F2=33.04, p<0.001; post-hoc Dunn’s test, p(HC,AD)<0.001, 
p(HC,LBD)<0.001, p(AD,LBD)=0.27). 
3.3.2 Comparison of ex-Gaussian parameters 
Mu was significantly increased in the LBD group compared to both healthy controls and 
patients with AD. The difference between healthy controls and AD patients was not 
significant. The same effect was observed for sigma. Compared to controls, tau was 
significantly increased in both dementia groups, but there was no significant difference in tau 
between the two dementia groups (Figure 3.2 and Table 3.2). These results persisted when 
analysing matched dementia subgroups (Table 3.3). 
Table 3.4 shows a comparison of ex-Gaussian parameters when DLB and PDD were treated 
as separate groups. Overall, the PDD group seemed to be more impaired than the DLB group 
(higher mu, sigma, and tau); however, none of the differences between DLB and PDD were 
significant after correcting for multiple comparisons. 
Table 3.2. Ex-Gaussian parameters, mean (standard deviation). Between-group differences 
were assessed by Kruskal-Wallis tests with Dunn’s post-hoc tests, Bonferroni-corrected for 
multiple comparisons. 
 HC AD LBD Kruskal-
Wallis 
post-hoc tests 
HC vs 
AD 
HC vs 
LBD 
AD vs 
LBD 
Mu 649.43 
(73.88) 
748.90 
(139.38) 
930.73 
(166.22) 
F2=40.49, 
p<0.001 
p=0.06 p<0.001 p<0.001 
Sigma 59.85 
(22.87) 
78.57 
(46.98) 
125.03 
(62.75) 
F2=23.25, 
p<0.001 
p=0.86 p<0.001 p=0.001 
Tau 313.48 
(119.50) 
523.28 
(202.89) 
572.99 
(213.21) 
F2=24.16, 
p<0.001 
p<0.001 p<0.001 p=1.00 
AD, Alzheimer’s disease; HC, healthy controls: LBD, Lewy body dementia. 
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Table 3.3. Ex-Gaussian parameters, mean (standard deviation) for matched dementia 
subgroups. Between-group differences were assessed by Kruskal-Wallis tests with Dunn’s 
post-hoc tests, Bonferroni-corrected for multiple comparisons. 
 HC AD LBD Kruskal-
Wallis 
post-hoc tests 
HC vs 
AD 
HC vs 
LBD 
AD vs 
LBD 
Mu 649.43 
(73.88) 
738.21 
(129.81) 
958.61 
(162.50) 
F2=42.57, 
p<0.001 
p=0.10 p<0.001 p<0.001 
Sigma 59.85 
(22.87) 
76.34 
(46.34) 
127.80 
(65.09) 
F2=22.55, 
p<0.001 
p=1.0 p<0.001 p=0.001 
Tau 313.48 
(119.50) 
522.70 
(206.74) 
616.30 
(204.76) 
F2=27.62, 
p<0.001 
p=0.001 p<0.001 p=0.36 
AD, Alzheimer’s disease; HC, healthy controls: LBD, Lewy body dementia. 
 
 
 
Figure 3.2. A) Comparison of ex-Gaussian parameters between HC, AD, and LBD (see Table 
3.2 for more detailed statistics). B) Fitted ex-Gaussian distributions for three exemplary 
participants illustrating the effect of increased tau in AD compared to an increase in all three 
parameters in LBD. 
AD, Alzheimer’s disease; HC, healthy controls; LBD, Lewy body dementia. 
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Table 3.4. Mean (standard deviation), Kruskal-Wallis test for between-group differences with post-hoc Dunn's test (Bonferroni corrected for multiple 
comparisons), treating DLB and PDD as separate groups. 
 HC AD DLB PDD Kruskal-
Wallis 
post-hoc tests 
HC vs 
AD 
HC vs 
DLB 
HC vs 
PDD 
AD vs 
DLB 
AD vs 
PDD 
DLB vs 
PDD 
Mu 649.43 
(73.88) 
748.90 
(139.38) 
879.89 
(143.68) 
1003.81 
(173.36) 
F3=42.77, 
p<0.001 
p=0.11 p<0.001 p<0.001 p=0.039 p=0.001 p=0.79 
            
Sigma 59.85 
(22.87) 
78.57 
(46.98) 
104.92 
(46.69) 
153.94 
(72.57) 
F3=26.08, 
p<0.001 
p=1.0 p=0.009 p<0.001 p=0.128 p=0.001 p=0.554 
            
Tau 313.48 
(119.50) 
523.28 
(202.89) 
545.86 
(226.29) 
611.99 
(193.15) 
F3=25.29, 
p<0.001 
p=0.001 p=0.001 p<0.001 p=1.0 p=1.0 p=1.0 
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; HC, healthy controls; PDD, Parkinson’s disease dementia. 
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3.3.3 Clinical correlations 
In the LBD group, there was a trend for a positive correlation between the UPDRS and mu 
and sigma, however, this correlation did not survive correction for multiple comparisons. 
There were no significant correlations between any of the ex-Gaussian parameters and any 
clinical fluctuation score (Table 3.5). 
In the AD group, all three ex-Gaussian parameters were negatively correlated with both 
MMSE and CAMCOG, except for tau which only showed a significant correlation with 
MMSE (Table 3.5 and Figure 3.3). 
Table 3.5. Spearman’s correlations of ex-Gaussian parameters with clinical scores in the LBD 
and AD groups separately, correlation coefficient (p-value, FDR-corrected for multiple 
comparisons). 
 Mu Sigma Tau 
LBD  
CAF total ρ=0.09 
(p=0.60, pFDR=0.86) 
ρ=0.12 
(p=0.48, pFDR=0.86) 
ρ=0.04 
(p=0.83, pFDR=0.86) 
CAF duration ρ=0.03 
(p=0.86, pFDR=0.86) 
ρ=0.08 
(p=0.63, pFDR=0.86) 
ρ=0.05 
(p=0.74, pFDR=0.86) 
CAF freq ρ=0.12 
(p=0.45, pFDR=0.86) 
ρ=0.17 
(p=0.29, pFDR=0.76) 
ρ=0.03 
(p=0.85, pFDR=0.86) 
Mayo total ρ=0.23 
(p=0.15, pFDR=0.55) 
ρ=0.20 
(p=0.22, pFDR=0.65) 
ρ=0.26 
(p=0.11, pFDR=0.51) 
Mayo cogn ρ=0.31 
(p=0.06, pFDR=0.42) 
ρ=0.29 
(p=0.07, pFDR=0.42) 
ρ=0.32 
(p=0.04, pFDR=0.42) 
Mayo arousal ρ=0.07 
(p=0.67, pFDR=0.86) 
ρ=0.03 
(p=0.86, pFDR=0.86) 
ρ=0.07 
(p=0.66, pFDR=0.86) 
UPDRS ρ=0.34 
(p=0.03, pFDR=0.19) 
ρ=0.38 
(p=0.02, pFDR=0.19) 
ρ=0.23 
(p=0.15, pFDR=0.46) 
AD    
MMSE ρ=-0.59 
(p=0.001, pFDR=0.003)* 
ρ=-0.52 
(p=0.005, pFDR=0.009)* 
ρ=-0.42 
(p=0.03, pFDR=0.03)* 
CAMCOG ρ=-0.60 
(p=0.001, pFDR=0.003)* 
ρ=-0.47 
(p=0.01, pFDR=0.02)* 
ρ=-0.23 
(p=0.23, pFDR=0.23) 
AD, Alzheimer’s disease; CAF, Clinician Assessment of Fluctuation; CAF duration, Clinician Assessment of 
Fluctuation duration subscale; CAF freq, Clinician Assessment of Fluctuation frequency subscale; CAMCOG, 
Cambridge Cognitive Assessment; FDR, false discovery rate; LBD, Lewy body dementia; Mayo arousal, 
Mayo Fluctuations arousal subscale; Mayo total, Mayo Fluctuations scale; Mayo cogn, Mayo Fluctuations 
cognitive subscale; MMSE, Mini Mental State Examination; UPDRS, Unified Parkinson’s Disease Rating 
Scale III. 
3.3.4 Effect of dopaminergic medication in the LBD group 
There was no significant correlation between LEDD and mu (ρ=0.19, p=0.25) or tau (ρ=0.04, 
p=0.79) in the LBD group. However, there was a significant correlation between sigma and 
LEDD (ρ=0.38, p=0.02). 
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3.3.5 VBM analysis 
Three DLB and two AD patients did not have structural MRI scans available and were 
therefore not included in the VBM analysis.  
In AD, mu was negatively correlated with numerous clusters in widespread parts of the brain, 
including bilateral occipital, frontal, and temporal cortices (Figure 3.4 and Table 3.6). Two 
larger clusters in right frontal and left temporal regions survived correction for multiple 
comparisons. There was one very small cluster of positive correlation between mu and grey 
matter volume in the AD group. Sigma was negatively correlated with grey matter volume in 
right and left frontal pole and left supramarginal gyrus (after correction for multiple 
comparisons), and smaller clusters in left temporal and frontal regions, and the precuneus. 
There was a positive correlation between sigma and grey matter volume in bilateral temporal 
gyri and the cerebellum. Tau was negatively correlated with clusters in the right cerebellum 
while it was positively correlated with very small clusters in right temporal and frontal 
regions. 
Two larger clusters of negative correlation between sigma and white matter volume in the left 
temporal gyrus survived multiple comparison correction (Figure 3.4 and Table 3.7). Mu was 
negatively correlated with white matter volume in the middle temporal regions, and tau was 
negatively correlated with white matter volume in left lingual regions. However, none of these 
clusters remained significant after correcting for multiple comparisons. 
In the LBD group, when considering clusters with p<0.001 (uncorrected) mu was negatively 
correlated with grey matter volume in a cluster at the right lingual gyrus and frontal pole and 
smaller clusters at the right paracingulate and thalamus (Table 3.8). Mu and sigma were both 
negatively correlated with grey matter volume in the right supplementary motor area. Sigma 
was also negatively correlated with bilateral frontal and subcortical regions (left and right 
thalamus, bilateral basal ganglia, and right amygdala), right temporal pole, and precuneus. 
There was one smaller cluster of positive correlation with sigma in the right frontal pole. Tau 
was positively correlated with grey matter volume in the bilateral cerebellum and left frontal 
pole.  
Mu and sigma were both negatively correlated with white matter volume in frontal regions 
and around the primary motor cortices and supplementary motor areas (Table 3.9). There was 
no significant correlation between white matter volume and tau. None of the grey matter and 
white matter clusters found in the LBD group survived correction for multiple comparisons. 
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Figure 3.3. Spearman’s correlations between global cognition and the three ex-Gaussian 
parameters in the AD group. All p-values are FDR-corrected for multiple comparisons.  
FDR, false discovery rate; MMSE, Mini Mental State Examination; CAMCOG, Cambridge 
Cognitive Examination. 
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Table 3.6. Correlations between ex-Gaussian parameters and grey matter volume in AD. All 
clusters are larger than five voxels and significant at p<0.001, uncorrected. Correction for 
multiple comparisons was performed using AlphaSim at p<0.05 which resulted in a minimum 
cluster size of 232 voxels for mu, 241 voxels for sigma, and 236 voxels for tau. Clusters 
surviving multiple comparison correction are highlighted with an asterisk. Anatomical labels 
were determined from the Harvard-Oxford Structural Atlas in FSL. 
Cluster location size MNI (X,Y,Z) 
Mu, negative correlation   
R frontal pole 422* 42, 36, 14 
L planum polare 316* -48, -4, -4 
L middle temporal gyrus 156 -54, -45, -6 
L lingual gyrus 127 -18, -62, -6 
R inferior lateral occipital cortex 90 48, -66, 12 
L postcentral gyrus 71 -56, -15,32 
L posterior temporal fusiform cortex 61 -40,-40,-30 
L paracingulate cortex 52 -14, 50,-3 
R inferior lateral occipital cortex 52 33, -81, 10 
L angular gyrus 37 -46, -50,22 
R inferior lateral occipital cortex 34 40, -66,-4 
R occipital pole 33 34, -94, 6 
L posterior cingulate gyrus 32 -2, -38, 42 
R frontal pole 29 27, 52, -20 
R posterior middle temporal gyrus 21 54, -34, 0 
R white matter 19 52, -34, 12 
L posterior supramarginal gyrus 17 -58, -45,27 
R middle temporal gyrus 14 46, -57, -2 
L angular gyrus 10 -54, -57,36 
L precentral gyrus 7 -62, -3, 6 
R white matter 6 14, -78, 22 
R cerebellum IX 6 9, -46, -38 
L frontal pole 5 -18, 57, 28 
Sigma, negative correlation   
R frontal pole 689* 42, 48, 12 
L posterior supramarginal  428* -60, -50, 12 
L frontal pole 245* -18, 52, 12 
L frontal operculum cortex 178 -39, 28, 6 
L middle temporal gyrus 97 -54, -44, -8 
L precuneus 75 -15,-70, 24 
L frontal pole 65 -15, 70, -3 
L postcentral gyrus 40 -58,-18, 28 
L planum polare 30 -48, -2, -9 
L precentral gyrus 17 -46, 9, 30 
L posterior middle temporal gyrus 17 -60, -15, -9 
L frontal pole 10 -16, 62, 24 
L posterior middle temporal gyrus 10 -52, -32, -14 
L middle frontal gyrus 7 -34, 33, 44 
Sigma, positive correlation   
R middle temporal gyrus 28 64, 0, -24 
L anterior middle temporal gyrus 21 -66, -6,-16 
L cerebellum Crus II 6 -33,-86,-45 
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Table 3.6 (continued). Correlations between ex-Gaussian parameters and grey matter 
volume in AD. 
Cluster location size MNI (X,Y,Z) 
Tau, negative correlation   
R cerebellum Crus I 143 18, -84,-24 
L temporal occipital fusiform cortex 34 -28, -62,-9 
Tau, positive correlation   
R post. superior temporal gyrus 9 69, -18, 0 
R frontal pole 6 33, 34, -21 
MNI, Montreal Neurological Institute coordinates. 
 
 
Table 3.7. Correlations between ex-Gaussian parameters and white matter volume in AD. All 
clusters are larger than five voxels and significant at p<0.001, uncorrected. Correction for 
multiple comparisons was performed using AlphaSim at p<0.05 which resulted in a minimum 
cluster size of 204 voxels for mu, 224 voxels for sigma, and 231 voxels for tau. Clusters 
surviving multiple comparison correction are highlighted with an asterisk. Anatomical labels 
were determined from the Harvard-Oxford Structural Atlas in FSL and white matter regions 
were identified from the nearest grey matter structure. 
Cluster location size MNI (X,Y,Z) 
Mu, negative correlation   
L middle temporal gyrus 91 -54,-38,-10 
R middle temporal gyrus 80 42, -48, 9 
L occipital fusiform gyrus 30 -32, -69, 0 
Sigma, negative correlation   
L superior temporal  588* -54,-38, 12 
L inferior temporal gyrus 584* -45, -48,-8 
L postcentral gyrus 144 -56,-18, 28 
L cuneal cortex 125 -4, -87, 26 
R intracalcarine cortex 99 9, -80, 15 
R supramarginal gyrus 77 45, -44, 15 
R superior temporal  62 56, -6, -9 
L middle frontal gyrus 40 -28, 6, 42 
L central opercular  31 -34, 2, 15 
L middle frontal gyrus 25 -27, 28, 34 
R postcentral gyrus 19 42, -21, 51 
R lateral occipital cortex 15 28, -88, 6 
L lingual gyrus 13 -12, -78, -8 
L frontal pole 11 -24, 51, 10 
L frontal pole 10 -32, 52,-10 
R precentral gyrus 6 38, -2, 44 
L frontal pole 5 -36, 46, 6 
R intracalcarine cortex 5 21, -75, 10 
Tau, negative correlation   
L lingual gyrus 30 -10, -72, -6 
MNI, Montreal Neurological Institute coordinates. 
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Table 3.8. Correlations between ex-Gaussian parameters and grey matter volume in LBD. All 
clusters are larger than five voxels and significant at p<0.001, uncorrected. Correction for 
multiple comparisons was performed using AlphaSim at p<0.05 which resulted in a minimum 
cluster size of 228 voxels for mu, 220 voxels for sigma, and 229 voxels for tau. No clusters 
survived multiple comparison correction. Anatomical labels were determined from the 
Harvard-Oxford Structural Atlas in FSL. 
Cluster location size MNI (X,Y,Z) 
Mu, negative correlation   
R lingual gyrus 63 6, -92, -14 
R white matter 37 12, 30, 45 
R frontal pole 34 12, 54, 34 
R thalamus 20 3, -16, 10 
R paracingulate gyrus 16 3, 42, 34 
R supplementary motor area 14 12, 0, 54 
R thalamus 6 18, -34, 8 
L thalamus 5 -20, -34, 6 
Sigma, negative correlation   
R frontal pole 169 33, 40, 26 
L middle frontal gyrus 152 -39, 14, 45 
R superior frontal gyrus 116 14, 9, 56 
L inferior frontal gyrus 111 -50, 15, 24 
L frontal pole 91 -27, 39,-10 
R amygdala 32 22, -8, -9 
R supplementary motor area 31 3, -4, 62 
R temporal pole 29 26, 6, -21 
R precuneus 25 14, -48, 52 
R middle frontal gyrus 24 34, 12, 33 
R superior frontal gyrus 18 4, 33, 46 
R thalamus 16 12, -36, 4 
L middle frontal gyrus 14 -33, 14, 57 
L thalamus 12 -10, -36, 3 
R caudate 10 8, 18, 0 
L pallidum 9 -20, -8, -9 
L white matter 9 -40, 18, 14 
Sigma, positive correlation   
R frontal pole 12 36, 42, 39 
Tau, positive correlation   
L cerebellum Crus I  141 -39,-70,-34 
R cerebellum IX 89 12,-58,-39 
L frontal pole 64 -24,57,27 
R cerebellum IX 62 6,-46,-54 
MNI, Montreal Neurological Institute coordinates. 
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Table 3.9. Correlations between ex-Gaussian parameters and white matter volume in LBD. 
All clusters are larger than five voxels and significant at p<0.001, uncorrected. Correction for 
multiple comparisons was performed with AlphaSim at p<0.05 which resulted in a minimum 
cluster size of 253 voxels for mu, 244 voxels for sigma. No clusters survived multiple 
comparison correction. Anatomical labels were determined from the Harvard-Oxford 
Structural Atlas in FSL and white matter regions were identified from the nearest grey matter 
structure. 
Cluster location size MNI (X,Y,Z) 
Mu, negative correlation   
L precentral gyrus 186 -16,-27,57 
R superior frontal gyrus 26 14,4,63 
R superior frontal gyrus 26 22, 24, 40 
R superior frontal gyrus 10 9, 34, 44 
R frontal pole 9 15, 48, 34 
R supplementary motor area 7 10, -3, 48 
L cerebellum VIIb 6 -24,-69,-45 
Sigma, negative correlation   
L frontal pole 146 -22, 51,-14 
L frontal pole 71 -34, 46, -9 
R frontal pole 32 44, 42, -8 
L frontal pole 24 -38, 45, 4 
R supplementary motor area 19 8, -4, 58 
L middle frontal gyrus 14 -34, 12, 28 
L frontal pole 8 -42,40,-10 
L middle frontal gyrus 7 -36, 8, 42 
R superior frontal gyrus 6 9, 46, 33 
L precentral gyrus 5 -38, -16,63 
MNI, Montreal Neurological Institute coordinates. 
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Figure 3.4. Correlations between ex-Gaussian parameters and grey matter (GM) and white 
matter (WM) volume in AD. See Tables 3.6 and 3.7 for all uncorrected clusters. 
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3.4 Discussion 
In this chapter, using an ex-Gaussian modelling analysis, differences in RT distributions from 
an attentional task were investigated in LBD and AD patients compared to healthy controls. 
Differential effects were found for the different ex-Gaussian parameters, indicating that 
different aspects of RT distributions are differentially affected by the two forms of dementia. 
The two dementia groups could be distinguished by a relative lack of overall RT slowing in 
the AD group. While dementia in general led to more fluctuations in RT performance as 
indicated by an increased tau parameter, this did not appear to be associated with the clinical 
fluctuations observed in the LBD group. In AD patients, there were correlations between the 
Gaussian parameters and grey as well as white matter volume. In contrast, in LBD patients 
there was a relative lack of significant results with respect to correlations between RT 
performance and cortical volume. 
3.4.1 More extremely slow responses in AD compared to controls 
Results from the standard RT analysis described in Chapter 2 suggested a slowing of RT 
performance in both dementia groups as indicated by an increased mean RT (with more 
pronounced deficits in LBD compared to AD). The ex-Gaussian distributional analysis 
presented here allowed for a more detailed and specific characterisation of RT performance 
changes in dementia compared to standard RT analyses. The lack of a significant increase in 
the mean of the Gaussian component in AD compared to controls indicated that no major 
overall slowing of RTs occurred in the AD group. This was contrary to what had been 
suggested by the results of the standard RT analysis using arithmetic mean RTs. The 
increased tau parameter showed that the overall increase in mean RT in AD patients was 
being driven by an increase in extremely slow responses. These extremely slow responses 
could be seen as temporary attentional lapses in some but not all trials. They are thought to be 
more directly linked to attentional difficulties than an overall slowing of RTs (Hervey et al., 
2006). It has also been argued that the tau parameter reflects more dynamic processes of 
attention such as attentional control and working memory; in AD, an increase in tau might 
thus reflect a breakdown of attentional control systems and poorer working memory 
capacities (Schmiedek et al., 2007; Tse et al., 2010). The present result is in line with previous 
studies that have consistently associated mild AD with an increase in tau and no change in mu 
or sigma across different tasks (Jackson et al., 2012; Tse et al., 2010). The same has been 
reported in individuals without dementia who later developed AD. This suggests that an 
increase in tau might be a very early indicator of the disease (Balota et al., 2010). Hence, the 
present results show that the overall pattern observed in pre-clinical and early-stage AD, 
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seems to persist in patients at a mild to moderate stage of dementia. However, in addition to 
an increase in tau, I also found a trend for a larger mu in AD compared to controls, indicating 
that a more general slowing of RTs might develop in AD patients as the disease progresses. 
This hypothesis is supported by a negative correlation between mu and dementia severity as 
measured by MMSE and CAMCOG, suggesting that more severe dementia is related to 
slower overall RTs in the AD group. 
3.4.2 Overall RT slowing in LBD compared to AD and controls 
In addition to the increase in excessively slow responses that was observed in both dementia 
groups, LBD patients also showed an overall slowing (increased mu) and higher variability 
(increased sigma) of RTs compared to controls. In addition, this slowing of RTs in patients 
with LBD was significantly larger than in the AD group and might be linked to greater 
attentional impairment in LBD relative to AD (Ballard et al., 2001a; Bradshaw et al., 2006). 
However, there was no difference between the two dementia groups with respect to the slow 
tail of the distribution, i.e. there was no further increase in attentional lapses in LBD patients 
compared to patients with AD. This is in contrast to my hypothesis given that tau is thought to 
capture attentional fluctuations (Schmiedek et al., 2007) which are a core symptom of LBD 
and less common in AD (Bradshaw et al., 2004). However, correlation analysis with the 
clinical fluctuation scales did not reveal any significant correlation between the severity of 
cognitive fluctuations and any of the ex-Gaussian parameters, suggesting that tau, contrary to 
my hypothesis, might not be a suitable measure of cognitive fluctuations in LBD. It also 
suggests that the fluctuations that are commonly observed in LBD patients and that are 
measured by clinical scales might not correspond well to trial-to-trial fluctuations observed 
upon the execution of the ANT task. This is in contrast to early studies in DLB that found a 
positive relation between the severity of cognitive fluctuations and trial-to-trial fluctuations on 
choice RT tasks (Ballard et al., 2002a, 2001b; Walker et al., 2000a). However, LBD patients 
in earlier studies were more impaired than the present LBD group and in contrast to most of 
our patients, they were not taking acetylcholinesterase inhibitors (Ballard et al., 2002a, 2001b; 
Walker et al., 2000a). Cholinesterase inhibitors have been shown to reduce RT variability in 
patients with cognitive fluctuations (Onofrj et al., 2003); the discrepancy between the present 
results and previous studies could therefore indicate that the association between clinical 
fluctuation severity and trial-to-trial RT variability is specific to unmedicated LBD patients.  
There was a correlation trend between the Gaussian parameters, mu and sigma, and the 
severity of Parkinsonism, suggesting that motor problems in LBD might have an influence on 
the general slowing of RT performance (Ballard et al., 2002a). This was supported by the fact 
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that the PDD group which generally showed more severe motor impairment also seemed to be 
more impaired in terms of the ex-Gaussian parameters than the DLB patients. However, these 
differences did not remain significant after correcting for multiple comparisons. 
3.4.3 Structural correlates of RT deficits in LBD and AD 
This is the first investigation assessing the association between ex-Gaussian parameters and 
cortical volume in LBD. There were more significant correlations between grey and white 
matter loss and RT deficits in AD patients than in LBD patients, indicating that attentional 
deficits in AD might be more strongly linked to regional brain volume than in LBD. The AD 
group showed negative correlations between grey matter volume in widespread cortical 
regions, such as temporal, lingual, and left frontal cortex, and the Gaussian part of the RT 
distribution (mu and sigma). Furthermore, white matter loss in temporal regions was related 
to increased sigma which corroborates the grey matter results. Both mu and sigma also 
correlated with MMSE and CAMCOG in AD, suggesting that correlations between cortical 
volume and these ex-Gaussian parameters may be related to global cognition in AD. This is 
supported by the negative correlations between mu and sigma and grey matter volume in 
several brain regions related to the DMN such as the occipital cortex, temporal gyrus, 
paracingulate cortex, frontal pole, and the precuneus (Mevel et al., 2011). The DMN has been 
associated with memory recall and is highly affected by AD pathology (Agosta et al., 2012).  
When considering results at an uncorrected threshold, the LBD group showed negative 
correlations in the frontal cortex, more specifically, a negative correlation between grey 
matter volume of the right frontal pole and RT variability. This agrees with Sanchez-
Castaneda et al. (2009) who reported a relation between a reduction in cortical volume within 
frontal regions and worse performance on a test of maintained attention and response 
inhibition in patients with LBD. On the contrary, tau showed a positive correlation with grey 
matter volume of the left cerebellar Crus I. This region has been associated with the dorsal 
attention network (Peraza et al., 2014) and has been found to be structurally altered in patients 
with DLB (Colloby et al., 2014). The observed association of a higher number of extremely 
slow responses with an increase in grey matter volume might seem counter-intuitive, but may 
represent an imbalance within the attention system, where a structurally intact cerebellum 
may drive an “over-thinking” in the decision-making during the ANT task, causing higher 
values of tau. Although non-significant after multiple comparison correction, these regions 
showed some correspondence with the AD results and may deserve further investigation 
regarding their similarities and differences between both conditions. However, the overall 
lack of significant VBM correlations in the LBD group suggests that attentional dysfunction 
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in LBD might be more related to microstructural changes and functional changes that are not 
observable by volume estimators such as VBM (Kramer and Schulz-Schaeffer, 2007). 
3.4.4 Limitations 
Similar to Chapter 2 (Section 2.4.6), a possible limitation is the use of cholinergic and/or 
dopaminergic medication in many of the dementia patients. There was a positive correlation 
between LEDD and sigma in the LBD group, indicating that dopaminergic medication might 
have an influence on the variability of RT performance in LBD. Again, analysing the effect of 
cholinergic medication was not possible due to the small number of patients who were not 
taking acetylcholinesterase inhibitors.  
Furthermore, the two dementia groups were not completely matched in terms of overall 
cognitive impairment; however, restricting the analysis to subgroups of AD and LBD patients 
that were matched in terms of overall cognition did not change the results. 
As described in Chapter 2, the ANT was designed to probe three different aspects of attention 
– alerting, orienting, and executive conflict – by comparing RT performance between the 
different cue and target conditions (Fan et al., 2002). In the ex-Gaussian analysis, I combined 
trials from all conditions and could only consider overall effects on the three ex-Gaussian 
parameters. While the ex-Gaussian analysis provides a useful tool to separate different parts 
of the RT distribution, a problematic aspect is its need for a relatively high number of trials to 
obtain a good model fit. The low number of trials that was available for each cue and target 
condition did not allow for a successful fit of the ex-Gaussian distribution to trials from each 
condition individually. Therefore, it was not feasible to perform the ex-Gaussian analysis for 
the different components of the ANT. Future studies with a larger number of trials will be 
needed to study the effect of the different ANT conditions on the three ex-Gaussian 
parameters. 
3.4.5 Conclusion 
The ex-Gaussian analysis showed that different aspects of RT distributions are differentially 
affected by AD and LBD. Furthermore, the neural correlates of impaired attentional 
performance were shown to differ between the two forms of dementia. While impaired RT 
performance is linked to grey and white matter atrophy in AD, the more pronounced 
behavioural deficits that were observed in the LBD group did not exhibit strong correlations 
with brain structure, similar to what was shown in Chapter 2.  
The following chapters will therefore focus on the analysis of functional neuroimaging and 
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electrophysiological data to investigate possible brain functional correlates of attentional 
impairment and cognitive fluctuations in LBD.   
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Chapter 4. Within- and between-network analysis of fMRI functional 
connectivity 
4.1 Introduction 
Resting-state fMRI can be used to study brain functional connectivity and enables 
characterisation of resting-state networks (RSNs) which are sets of brain regions that are 
spatially distinct, but show coordinated activity in the absence of a specific task (Biswal et al., 
1995; Lowe et al., 1998). Several RSNs have been consistently found in healthy participant 
studies and involve brain regions that are related to different functions such as visual, motor 
and sensory processing, attention, salience, and memory (Damoiseaux et al., 2006). One RSN 
that has been of particular interest is the DMN which is typically active during rest and 
deactivated upon the execution of a task (Raichle et al., 2001).  
Most studies investigating resting-state functional connectivity in DLB have used seed-based 
approaches (Galvin et al., 2011; Kenny et al., 2013, 2012) or only considered a small set of 
RSNs based on a priori hypotheses (Franciotti et al., 2013; Lowther et al., 2014; Peraza et al., 
2014) and overall findings are somewhat inconsistent. While some studies have found that 
connectivity was generally decreased in DLB compared to age-matched healthy controls 
(Lowther et al., 2014; Peraza et al., 2014), other studies only report increased connectivity in 
DLB compared to controls (Kenny et al., 2013, 2012). Furthermore, the networks that have 
been found to be altered in DLB differ between studies. Decreased connectivity in DLB was 
reported for salience, executive (Lowther et al., 2014), frontoparietal, sensorimotor, and 
temporal networks (Peraza et al., 2014) whereas increased connectivity has been found for 
basal ganglia (Kenny et al., 2013; Lowther et al., 2014) and thalamic networks (Kenny et al., 
2013). While functional connectivity within the DMN has been consistently found to be 
reduced in AD patients compared to healthy controls (Binnewijzend et al., 2012; Greicius et 
al., 2004), the role of the DMN in DLB has been debated with different studies showing 
increased (Galvin et al., 2011; Kenny et al., 2012), decreased (Lowther et al., 2014) or 
unchanged connectivity within this network compared to controls (Franciotti et al., 2013; 
Peraza et al., 2014). In addition to reporting inconsistent findings, previous analyses have 
been limited to studying within-network connectivity without considering connectivity 
changes between different RSNs. Therefore, the first aim of this chapter is to investigate 
functional connectivity changes in DLB patients compared to healthy controls and patients 
with AD within and between a wide range of RSNs without a priori selection. I hypothesised 
that DLB patients will show functional connectivity alterations in the following networks: 
motor and basal ganglia networks because of previous evidence for their implication in 
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Parkinsonism (Szewczyk-Krolikowski et al., 2014), attentional networks based on previous 
results in DLB (Peraza et al., 2014) and the presence of a wide range of attentional deficits in 
DLB (Ballard et al., 2001a), and visual networks given DLB-related impairments in visual 
processing (Mosimann et al., 2004).  
Previous studies have found an association between resting-state functional connectivity 
measures and cognitive fluctuation severity, suggesting an involvement of connectivity 
alterations in attention-related networks (Franciotti et al., 2013; Peraza et al., 2014). The 
second aim of this chapter is therefore to investigate whether the observed connectivity 
changes in DLB are related to the clinical scores of cognitive fluctuations and test if this 
analysis could help in furthering our understanding of the etiological mechanisms underlying 
DLB core symptoms. 
4.2 Methods 
4.2.1 Participants 
Data from the CATFieLD and ARThippo studies were combined for this analysis. This 
analysis involved 102 participants: 33 were diagnosed with probable DLB, 36 with probable 
AD, and 33 participants were healthy controls. Because the ARThippo study did not include 
PDD patients, this analysis was restricted to the DLB group without PDD patients. 
4.2.2 Data acquisition 
MR imaging for the CATFieLD and ARThippo studies was performed on the same 3T Philips 
Intera Achieva scanner. The imaging acquisition protocol was the same in both studies except 
for a different resolution of the structural scans. To account for this, in the group analysis a 
dichotomous covariate of no interest for study membership was included. Structural images 
were acquired with a MPRAGE sequence, sagittal acquisition, echo time 4.6 ms, TR 8.3 ms, 
inversion time 1250 ms, flip angle = 8°, SENSE factor = 2, and in-plane field of view 256 x 
256 mm2 with slice thickness 1.2 mm, yielding a voxel size of 0.93 x 0.93 x 1.2 mm3 
(ARThippo study) and in-plane field of view 240 x 240 mm2 with slice thickness 1.0 mm, 
yielding a voxel size of 1.0 x 1.0 x 1.0 mm3 (CATFieLD study). Resting-state scans for both 
studies were obtained with a gradient echo echo-planar imaging sequence with 25 contiguous 
axial slices, 128 volumes, anterior-posterior acquisition, in plane resolution = 2.0 x 2.0 mm, 
slice thickness = 6 mm, TR = 3000 ms, echo time = 40 ms, and field of view = 260 x 260 
mm2. DLB patients who were taking dopaminergic medication were scanned in the motor ON 
state. 
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4.2.3 Preprocessing 
A first preprocessing step was carried out using FEAT (FMRI Expert Analysis Tool) version 
6.0 which is part of the FMRIB’s software library (FSL, www.fmrib.ox.ac.uk/fsl) including 
motion correction using FMRIB’s Linear Image Registration Tool (MCFLIRT), slice-timing 
correction, and spatial smoothing with a 6.0 mm full width at half maximum Gaussian kernel. 
Participants were excluded if the MCFLIRT-estimated motion parameters exceeded 2 mm 
translation and/or 2° rotation. To assess differences in movement between the three groups 
due to patients with Parkinsonian symptoms the following formula was used (Liao et al., 
2010): 
head motion/rotation = (𝑀 − 1)−1 ∑ √|𝑥𝑖 − 𝑥𝑖−1|2 + |𝑦𝑖 − 𝑦𝑖−1|2 + |𝑧𝑖 − 𝑧𝑖−1|2
𝑀
𝑖=2
, 
where M is the total number of volumes (M=128), index i denotes the time points, and xi, yi, 
and zi are the translations/rotations at the ith time point in x, y, and z direction. This analysis 
was done for translations and rotations separately. 
Denoising was performed with ICA-AROMA in FSL which performs single-subject 
independent component analysis (ICA) to remove motion components from each participant’s 
functional data (Pruim et al., 2015b, 2015a). Additionally, eroded CSF and white matter 
masks were estimated using FAST in FSL and the mean signal inside the mask was regressed 
out of each participant’s cleaned functional data. Functional and structural images were then 
coregistered using boundary based registration in FSL, and normalised to the standard MNI 
template using Advanced Normalization Tools (Avants et al., 2011; Klein et al., 2009). 
Finally, functional data were temporally high-pass filtered with a cutoff of 150 s and 
resampled to a resolution of 4 x 4 x 4 mm3. Grey matter probability maps were obtained from 
the FAST-segmented T1 images and included as voxel-wise spatial covariates in the group 
comparison analyses. 
4.2.4 Analysis of resting-state data 
To estimate independent healthy RSNs, 44 healthy control participants from the ICICLE and 
VEEG-Stim studies were selected. All participants were scanned on the same scanner as the 
participants from the main analysis. Eighteen of the additional HC participants were scanned 
with a slightly different scanner protocol with a change in the TR to 2072 ms and a change in 
the voxel size of the resting-state scans to 3 x 3 x 4 mm3. The resting-state data were 
preprocessed in the same way as described in Section 4.2.3. Two subjects were excluded 
because they exceeded the motion exclusion criteria resulting in 42 independent HC 
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participants that were included in the generation of the RSN templates. 
The temporally concatenated data from all independent HC participants were subjected to a 
group-ICA using FSL’s Multivariate Exploratory Linear Optimised Decomposition into 
Independent Components (MELODIC). To obtain more reliable components, a meta ICA 
approach was adopted (Biswal et al., 2010; Poppe et al., 2013). To this end, MELODIC was 
repeated 25 times on randomised subsets of 30 out of the 42 HC participants. Subsequently, a 
meta ICA run was performed on the concatenated components from all individual ICA runs. 
A model order of 70 independent components was chosen for the individual as well as the 
meta ICA as this has been shown to be optimal for assessing disease-related group differences 
(Abou Elseoud et al., 2011; Dipasquale et al., 2015). To identify reliable components, the 
spatial correlation of each meta component across the individual ICA runs was calculated and 
components with a correlation <0.6 across runs were excluded (Cerliani et al., 2015). 
Furthermore, the meta ICA procedure was repeated using all HC participants from the main 
analysis and compared to the components from the independent group to ensure that the 
selected RSNs were present in both cohorts. All meta ICA components from the independent 
cohort that survived these reliability checks were visually inspected with respect to their 
spatial maps (Kelly et al., 2010) and 27 were identified as being of biological interest 
according to the previous literature (Agosta et al., 2012; Beckmann et al., 2005; Damoiseaux 
et al., 2008) (Figure 4.1 and Table 4.1).  
Subsequently, within-network connectivity was assessed by running FSL-dual regression with 
all 27 identified RSNs concatenated in a single 4D image. First, for each participant, the RSN 
spatial maps were regressed (as spatial regressors in a multiple regression) into the 
participant’s 4D dataset, resulting in a subject-specific timeseries, one for each RSN. Second, 
these timeseries were regressed (as temporal regressors, again in a multiple regression) into 
the same 4D dataset, resulting in a set of subject-specific spatial maps, one for each RSN. 
These spatial maps represent the participant’s functional connectivity map for the respective 
RSN. Group differences in these functional connectivity maps between AD and HC, between 
DLB and HC, and between DLB and AD were assessed using FSL’s randomise function with 
10,000 permutations and family-wise error (FWE) correction for multiple comparisons using 
threshold-free cluster enhancement (TFCE). Covariates of no interest were included to control 
for age, sex, and study membership. Additionally, in order to reduce the impact of cortical 
atrophy differences between the participant groups, grey matter probability maps were also 
included as voxel-wise regressors in the linear model (Damoiseaux et al., 2012). To 
investigate between-network connectivity, the FSLNets package was applied to the subject-
specific time series from dual regression (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSLNets). Full 
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and partial correlations were calculated between all pairs of RSNs and the resulting 
correlation coefficients were converted to z-scores for further analysis. Partial correlations are 
computed as correlations between two RSNs while controlling for the effect of all other RSNs 
and are thought to reflect more direct connections (Smith et al., 2011). FSL-randomise with 
10,000 permutations was then applied to assess group differences in between-network 
connectivity including covariates for age, sex, and study membership. Results were FWE-
corrected for multiple comparisons. 
Table 4.1. List of all resting-state networks (RSNs) included in the analysis. Anatomical 
labels refer to bilateral areas if not stated otherwise. Locations of RSNs were estimated from 
the Harvard-Oxford Cortical and Subcortical Structural Atlases and the Cerebellar Atlas in 
FSL. 
RSN name  Brain regions 
Lateral sensorimotor network LSMN Pre- and postcentral gyrus 
Medial sensorimotor network MSMN Pre- and postcentral gyrus, supplementary 
motor area 
Supplementary motor area 
network 
SMAN Supplementary motor area, precentral gyrus 
Left motor network LMN Left post- and precentral gyrus 
Right motor network RMN Right post- and precentral gyrus 
Basal ganglia network BGN Putamen, caudate 
Thalamic network THN Thalamus 
Cerebellar network 1 CBN1 Cerebellum crus I, crus II 
Cerebellar network 2 CBN2 Cerebellum V, VI 
Medial visual network MVN Intracalcarine cortex, supracalcarine cortex, 
lingual gyrus 
Lateral visual network LVN Superior lateral occipital cortex, precuneus 
Occipital pole network OPN Occipital pole 
Lingual gyrus network LGN Lingual gyrus, intracalcarine cortex 
Superior visual network SVN Superior lateral occipital cortex, occipital pole 
Temporal network TN Planum temporale, Heschl’s gyrus 
Temporal pole network TPN Temporal pole 
Insular network 1 ISN1 Insular cortex, frontal operculum cortex 
Insular network 2 ISN2 Insular cortex, planum polare 
Anterior cingulate network ACN Anterior cingulate cortex 
Default mode network 1 DMN1 Precuneus, posterior cingulate cortex 
Default mode network 2 DMN2 Precuneus 
Default mode network 3 DMN3 Precuneus, superior lateral occipital cortex 
Supramarginal gyrus network SPGN Supramarginal gyrus 
Right fronto-parietal network RFPN Right superior lateral occipital cortex, right 
angular gyrus, right middle frontal gyrus, left 
superior lateral occipital cortex 
Left fronto-parietal network LFPN Left superior lateral occipital cortex, right 
angular gyrus, left middle frontal gyrus, right 
superior lateral occipital cortex 
Dorsal attention network DAN Superior parietal lobule, supramarginal gyrus, 
superior lateral occipital cortex 
Ventral attention network VAN Middle frontal gyrus, inferior frontal gyrus 
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Figure 4.1. Spatial maps of the 27 resting-state networks (RSNs) obtained from the 
independent healthy control group. RSN maps are thresholded at 3<z<12. Images are shown 
in radiological convention, i.e. the left side of the image corresponds to the right hemisphere. 
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4.2.5 Statistical analysis 
Statistical analyses were carried out in IBM SPSS version 23 and R version 3.5.1. In the DLB 
group, Spearman’s correlations were calculated to assess relations between functional 
connectivity and clinical fluctuation scores (CAF total and subscores). The Mayo fluctuation 
scale was not assessed in the ARThippo study and was therefore not included in this analysis. 
Additional correlation analyses were performed for measures of overall cognition (MMSE 
and CAMCOG), the UPDRS motor subscore for Parkinsonism, and the NPI hallucination 
subscale for visual hallucination severity. Correlations were computed between these clinical 
scores and the mean connectivity within clusters with significant differences between DLB 
and controls (from dual regression) and for between-network connectivity scores for 
connections with significant between-group differences (from FSLNets). In the AD group, 
correlations were computed between overall cognitive scores (MMSE and CAMCOG) and 
mean connectivity of dual regression clusters that showed significant differences between AD 
patients and controls as well as between-network connectivity scores for connections with 
significant between-group differences from the FSLNets analysis.  
In the DLB group, in addition to investigating correlations with mean connectivity within a 
cluster, voxel-wise correlations with cognitive fluctuation scores were also tested. To this end, 
the dual regression z-scores for all DLB participants were concatenated in one 4D image and 
correlations with clinical scores were tested using a GLM in FSL with the respective clinical 
score as covariate in the design matrix. Statistical significance was assessed using FSL 
randomise with 5,000 permutations including a mask for the significant clusters from the HC-
DLB group comparisons. This analysis was also repeated for the other clinical scores 
(MMSE, CAMCOG, UPDRS, and NPI hallucination score).  
To assess the effect of dopaminergic medication in the DLB group, a group comparison of the 
dual regression results was performed between patients who were taking dopaminergic 
medication (N=18) and those who were not on these medications (N=13) using FSL-
randomise with 10,000 permutations and TFCE-correction. 
4.3 Results 
One AD patient was excluded due to coregistration errors. Additionally, two HC, six AD, and 
two DLB participants were excluded because of excessive motion. Therefore, 31 DLB 
patients, 29 AD patients, and 31 healthy controls were included in the analysis. The overall 
motion for all included participants was not significantly different between the three groups 
(Kruskal-Wallis test; rotation, H2=1.93, p=0.38; translation, H2=1.13, p=0.57). 
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4.3.1 Demographics 
All three groups were matched for age and sex and the two dementia groups were matched in 
terms of overall cognition (MMSE and CAMCOG) and duration of dementia (Table 4.2). As 
expected, many DLB patients were taking dopaminergic medication whereas none of the AD 
patients were on these medications. The number of patients taking acetylcholinesterase 
inhibitors was not significantly different between the dementia groups. DLB patients were 
significantly more impaired in terms of Parkinsonism, visual hallucinations, and cognitive 
fluctuations than the AD patients. 
The 42 independent HC participants whose fMRI data were used to estimate the RSNs, were 
significantly younger than the HC participants in the main analysis, but matched in terms of 
overall cognition (Table 4.3). 
Table 4.2. Demographic and clinical variables, mean (standard deviation). 
 HC (N=31) AD (N=29) DLB (N=31) Between-group 
differences 
Male: female 22:9 20:9 19:12 χ2=0.73, p=0.70a 
Study 1: study 2 15:16 13:16 12:19 χ2=0.60, p=0.74a 
Age 76.4 (7.2)  75.2 (8.6) 78.13 (6.7) F2,88=1.16, p=0.32
b 
AChEI - 26 28 χ2=0.007, p=0.93c 
PD meds - 0 18 χ2=24.06, p<0.001c 
Duration  - 3.7 (1.7)f 3.4 (2.3) U=339, p=0.14d  
MMSE 28.9 (1.1) 21.8 (3.8) 22.03 (4.3) t58=0.20, p=0.85
e 
CAMCOG 96.7 (3.2) 70.3 (13.5) 73.29 (13.6) t58=0.86, p=0.39
e 
UPDRS III 1.94 (2.8) 3.5 (4.0) 18.1 (10.2) t58=7.32, p<0.001
e 
CAF total - 1.00 (2.51)f 4.8 (4.9)g t56=3.66, p=0.001
e 
NPI total - 5.9 (5.5)h 14.55 (11.03)i t54=3.68, p=0.001
e 
NPI hall - 0j 1.6 (1.8)i t53=4.53, p<0.001
e 
AChEI, number of patients taking acetylcholinesterase inhibitors; AD, Alzheimer’s disease; CAF total, 
Clinical Assessment of Fluctuations total score; CAMCOG, Cambridge Cognitive Examination; DLB, 
Dementia with Lewy bodies; Duration, duration of cognitive symptoms in years; HC, healthy controls; 
Mayo total, Mayo Fluctuations Scale; Mayo cognitive, Mayo Fluctuation cognitive subscale; Mayo 
arousal, Mayo Fluctuations arousal subscale; MMSE, Mini Mental State Examination; PD meds, number 
of patients taking dopaminergic medication for the management of Parkinson’s disease symptoms; 
UPDRS III, Unified Parkinson’s Disease Rating Scale III (motor subsection); NPI, Neuropsychiatric 
Inventory; NPI hall, NPI hallucination subscore 
a Chi-square test HC, AD, DLB; b One-way ANOVA HC, AD, DLB; c Chi-square test AD, DLB; d Mann 
Whitney U test AD, DLB; e Student’s t-test AD, DLB. 
f N=28; g N=30; h N=27; i N=29; j N=26. 
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Table 4.3. Demographics of the independent healthy control group that was used for the 
estimation of RSNs compared to the control group from the main analysis. 
 HC main analysis 
(N=31) 
HC for RSN template 
estimation  
(N=42) 
Between-group comparison 
Male: female 22:9 25:17 χ2=1.02, p=0.31a 
Age 76.4 (7.2) 69.0 (8.7) t70=3.85, p<0.001
b 
MMSE 28.9 (1.1) 29.2 (1.4) t70=1.08, p=0.29
b 
HC, healthy controls; MMSE, Mini Mental State Examination; RSN, resting state network. 
a Chi-square test; b Student’s t-test. 
4.3.2 Within-network connectivity  
Between-group comparisons of the dual regression results were performed across the whole 
brain space, i.e. they were not spatially bounded by the thresholded RSN spatial maps shown 
in Figure 4.1. This was done in order to be able to investigate connectivity between each RSN 
and the rest of the brain instead of only considering connectivity changes within the main 
spatial maps of the RSNs. 
Decreased connectivity in AD patients compared to controls was found for the default mode 
network 1, for the lingual gyrus network, and in very small clusters for the right motor 
network. Connectivity was increased in patients with AD compared to controls in a small 
cluster within the dorsal attention network (Figure 4.2 and Table 4.4).  
Decreased connectivity in DLB compared to controls was observed for ten RSNs including 
the lateral sensorimotor network, the medial sensorimotor network, the superior visual 
network, the temporal network, the basal ganglia network, the right motor network, the 
thalamic network, the insular network 1, the anterior cingulate network, and the temporal pole 
network (Figure 4.3 and Table 4.5). Increased connectivity in DLB compared to controls was 
found in very small clusters for the left motor network, the ventral attention network, and the 
insular network 2 (Figure 4.3 and Table 4.5).  
In the comparison between the two dementia groups, very small clusters of increased 
connectivity were found in patients with DLB compared to patients with AD for the default 
mode network 1 (Table 4.6). There were no clusters of decreased connectivity in DLB 
patients compared to patients with AD.  
Although decreased connectivity in the DLB group is reported for all clusters in panels A-F of 
Figure 4.3, it was evident that some of these results were due to correlations shifting from 
positive in the control group to negative in the DLB group (e.g. TN-1, Figure 4.4). Similarly, 
increased connectivity in the DLB group could also be due to correlations being negative in 
healthy controls, and shifting to positive correlations in DLB (e.g. ISN2-1).  
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Table 4.4. Dual regression results comparing AD and HC. All clusters are reported with 
p<0.05, TFCE-corrected. The table shows the number of significant voxels per cluster, the 
minimal p-value inside the cluster, the MNI coordinates of the voxel with minimal p-value, 
and the location of the cluster (estimated from the Harvard-Oxford Cortical and Subcortical 
Structural Atlases and the Cerebellar Atlas in FSL). 
 N  p-
value 
MNI  
(X, Y, Z) 
Location 
HC > AD     
Default mode network 1 
DMN1-1 61 <0.001 20, 22, 24 L posterior cingulate, R posterior cingulate 
DMN1-2 1 0.044 26, 13, 25 L precuneus 
Lingual gyrus network 
LGN-1 20 0.001 20, 37, 27 R paracingulate gyrus 
Right motor network 
RMN-1 1 0.03 10, 37, 15 R frontal orbital cortex 
RMN-2 1 0.048 12, 33, 24 R precentral gyrus, R inferior frontal gyrus 
AD > HC     
Dorsal attention network 
DAN-1 5 0.024 34, 17, 24 L angular gyrus 
AD, Alzheimer’s disease; HC, healthy controls; MNI, Montreal Neurological Institute coordinates. 
 
 
 
Figure 4.2. Dual regression results comparing AD and HC. RSN maps are shown in red-
yellow. A, B) Clusters with decreased connectivity in AD; HC>AD, p<0.05, TFCE-corrected, 
shown in blue. C) Cluster with increased connectivity in AD; AD>HC, p<0.05, TFCE-
corrected, shown in green. See Table 4.4 for more information on cluster locations and sizes. 
All images are shown in radiological convention. 
AD, Alzheimer’s disease; DAN, dorsal attention network; DMN 1, default mode network 1; 
HC, healthy controls; LGN, lingual gyrus network; TFCE, threshold-free cluster 
enhancement.  
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Table 4.5. Dual regression results comparing DLB and HC. All clusters are reported with 
p<0.05, TFCE-corrected. The table shows the number of significant voxels per cluster, the 
minimal p-value inside the cluster, the MNI coordinates of the voxel with minimal p-value, 
and the location of the cluster (from the Harvard-Oxford Cortical and Subcortical Structural 
Atlases and the Cerebellar Atlas in FSL). 
 N  p-
value 
MNI  
(X, Y, Z) 
Location 
HC > DLB     
Lateral sensorimotor network 
LSMN-1 1 0.046 24, 28, 30 L supplementary motor cortex 
Medial sensorimotor network 
MSMN-1 1 0.048 26, 21, 19 L hippocampus, white matter 
Superior visual network 
SVN-1  1 0.036 19, 11, 12 R cerebellum Crus I 
Temporal network 
TN-1 34 0.002 17, 12, 16 R lingual gyrus, R occipital fusiform gyrus 
TN-2 20 0.014 21, 21, 26 R posterior cingulate gyrus, R precuneus 
TN-3 10 0.02 26, 15, 15 L lingual gyrus 
TN-4 9 0.017 30, 8, 16 L inferior lateral occipital cortex 
TN-5 6 0.007 34, 18, 14 L inferior temporal gyrus 
TN-6 5 0.033 33, 11, 13 L inferior lateral occipital cortex 
TN-7 2 0.043 34, 14, 23 L superior lateral occipital cortex 
TN-8 1 0.04 37, 17, 13 L inferior temporal gyrus 
Basal ganglia network 
BGN-1 5 0.039 15, 29, 21 R putamen 
BGN-2 2 0.035 17, 32, 22 R caudate 
BGN-3 1 0.037 19, 31, 21 R caudate 
Right motor network 
RMN-1 142 0.001 15, 26, 30 R precentral gyrus 
RMN-2 54 0.003 14, 34, 24 R middle frontal gyrus, R inferior frontal gyrus 
RMN-3 22 0.007 25, 15, 23 L precuneus 
Thalamic network 
THN-1 5 0.039 30, 9, 24 L superior lateral occipital cortex 
Insular network 1 
ISN1-1 1 0.032 13, 34, 24 R inferior frontal gyrus 
Anterior cingulate network 
ACN-1 11 0.028 29, 37, 24 L superior and middle frontal gyrus 
ACN-2 4 0.044 20, 37, 25 R anterior cingulate cortex 
ACN-3 1 0.027 34, 18, 15 L inferior temporal gyrus 
Temporal pole network 
TPN-1 190 0.005 24, 40, 19 R/L anterior cingulate, R/L paracingulate 
TPN-2 100 0.003 31, 44, 16 L frontal pole, L inferior/orbital frontal gyrus 
TPN-3 3 0.041 21, 22, 30 R precuneus, R precentral gyrus 
DLB > HC     
Left motor network 
LMN-1 4 0.012 16, 26, 31 R precentral gyrus, white matter 
Ventral attention network 
VAN-1 1 0.036 27, 16, 22 L precuneus 
Insular network 2 
ISN2-1 6 0.021 29, 42, 24 L frontal pole 
DLB, dementia with Lewy bodies; HC, healthy controls; MNI, Montreal Neurological Institute coordinates. 
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Figure 4.3. Dual regression results comparing DLB and HC. RSN maps are shown in red-
yellow. A-F) Clusters with decreased connectivity in DLB; HC>DLB, p<0.05, TFCE-
corrected, shown in blue. G) Clusters with increased connectivity in DLB; DLB>HC, p<0.05, 
TFCE-corrected, shown in green. See Table 4.5 for more information on cluster locations and 
sizes. All images are shown in radiological convention. 
ACN, anterior cingulate network; AD, Alzheimer’s disease; BGN, basal ganglia network; 
DLB, dementia with Lewy bodies; HC, healthy controls; ISN 2, insular network 2; LMN, left 
motor network; RMN, right motor network; TFCE, threshold-free cluster enhancement; TN, 
temporal network; TPN, temporal pole network. 
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Figure 4.4. Mean z-scores for all dual regression clusters that showed significant group 
differences (see Tables 4.4 - 4.6). In each boxplot the central line corresponds to the sample 
median, the upper and lower border of the box represent the 25th and 75th percentile, 
respectively, and the length of the whiskers is 1.5 times the interquartile range. 
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; HC; healthy controls. 
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Table 4.6. Dual regression results comparing AD and DLB. All clusters are reported with 
p<0.05, TFCE-corrected. The table shows the number of significant voxels per cluster, the 
minimal p-value inside the cluster, the MNI coordinates of the voxel with minimal p-value, 
and the location of the cluster (estimated from the Harvard-Oxford Cortical and Subcortical 
Structural Atlases and the Cerebellar Atlas in FSL). 
 N  p-
value 
MNI  
(X, Y, Z) 
Location 
AD > DLB     
No significant clusters 
DLB > AD     
Default mode network 1 
DMN1-1 1 0.044 13, 12, 24 R superior lateral occipital cortex 
DMN1-2 1 0.025 13, 12, 27 R superior lateral occipital cortex 
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; Montreal Neurological Institute coordinates. 
4.3.3 Between-network connectivity 
When considering full correlations, there was a decrease in connectivity between the thalamic 
network and the default mode network 2 in AD patients compared to controls (Figure 4.5). 
Comparing DLB patients and controls, there was a change in connectivity between the 
temporal pole and the anterior cingulate networks. While this connection showed a negative 
correlation in controls, the mean correlation was around zero in the DLB group. There were 
no connections with decreased connectivity in AD or DLB patients compared to controls. 
When comparing the AD and DLB groups, a significant difference was found for the 
connection between the left fronto-parietal and the occipital pole networks which were 
positively correlated in the AD group, but showed a negative correlation in patients with DLB 
(Figure 4.5). There were no significant group differences for any comparison when 
considering partial correlations.  
4.3.4 Clinical correlations 
There was a negative correlation between the CAF total and its subscores and a cluster 
belonging to the temporal network in the left inferior temporal cortex (TN-8). A positive 
correlation was observed between MMSE and a cluster in the left supplementary motor cortex 
belonging to the lateral sensorimotor network (LSMN-1) in the DLB group (Table 4.7). 
However, both clusters only comprised one voxel and the correlations did not survive 
multiple comparison correction. Similarly, in the AD group there was a negative correlation 
between CAMCOG and mean connectivity within a very small cluster belonging to the right 
motor network which did not survive correction for multiple comparisons (Table 4.7).  
As an additional exploratory analysis, I also investigated voxel-wise correlations between 
clinical scores and connectivity within the clusters resulting from the group comparison.  
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Figure 4.5. Correlation matrices from FSLNets analysis for A) HC, B) AD, and C) DLB. 
Upper triangular matrices show full correlations while partial correlations are plotted in the 
lower triangular matrices. D) Boxplots of z-scores for edges with significant group differences 
for full correlations (black squares in panel A-C, p<0.05, FWE-corrected for multiple 
comparisons). In each boxplot the central line corresponds to the sample median, the upper 
and lower border of the box represent the 25th and 75th percentile, respectively, and the length 
of the whiskers is 1.5 times the interquartile range. 
ACN, anterior cingulate network; DMN2, default mode network 2; LFPN, left fronto-parietal 
network; OPN, occipital pole network; THN, thalamic network; TPN, temporal pole network. 
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There was one cluster of 4 voxels in the right occipital fusiform gyrus belonging to the 
temporal network that showed a negative correlation with the CAF total score (Table 4.8). 
Additionally, there was a very small cluster in the right motor network where connectivity 
was positively correlated with the CAF total and subscores. Furthermore, a one-voxel cluster 
in the lateral sensorimotor network showed negative correlations with CAF and UPDRS and a 
cluster in the anterior cingulate network exhibited a negative correlation with the MMSE. 
Table 4.7. Spearman's correlations between mean functional connectivity within significant 
clusters from dual regression and clinical scores in the DLB and AD groups. All correlations 
are shown that have an uncorrected p-value<0.05. 
LBD  
TN-8 – CAF totala ρ = -0.49 (p=0.006, pFDR=0.26) 
TN-8 – CAF durationa ρ = -0.49 (p=0.006, pFDR=0.26) 
TN-8 – CAF frequencya ρ = -0.46 (p=0.01, pFDR=0.30) 
LSMN-1 – MMSE  ρ = 0.37 (p=0.04, pFDR=0.94) 
AD  
RMN-1 – CAMCOG  ρ = -0.38 (p=0.04, pFDR=0.31) 
AD, Alzheimer’s disease; CAF, Clinician Assessment of Fluctuation; CAF duration, Clinician Assessment 
of Fluctuation duration subscale; CAF frequency, Clinician Assessment of Fluctuation frequency subscale; 
CAMCOG, Cambridge Cognitive Assessment; DLB, dementia with Lewy bodies; FDR, false discovery 
rate; LSMN, lateral sensorimotor network; MMSE, Mini Mental State Examination; RMN, right motor 
network; TN, temporal network 
a N=30.  
 
Table 4.8. Results from voxel-wise correlations between z-scores (from dual regression) and 
clinical scores in the DLB group. All correlations are shown that have an uncorrected p-
value<0.05. 
cluster 
name 
N  
voxels 
MNI 
(X,Y,Z) 
clinical correlations 
LSMN-1 1 24, 28, 30 negative correlation with CAF total (p=0.035), 
CAF duration (p=0.042), and UPDRS (p=0.018) 
TN-1 4 16, 11, 16 negative correlation with CAF total (p=0.022) 
RMN-1 1 13, 27, 30 positive correlation with CAF total (p=0.01), CAF 
duration (p=0.037), and CAF frequency (p=0.01) 
ACN-3 1 34, 18, 15 negative correlation with MMSE (p=0.045) 
ACN, anterior cingulate network; AD, Alzheimer’s disease; CAF, Clinician Assessment of Fluctuation; 
CAF duration, Clinician Assessment of Fluctuation duration subscale; CAF frequency, Clinician 
Assessment of Fluctuation frequency subscale; CAMCOG, Cambridge Cognitive Assessment; DLB, 
dementia with Lewy bodies; LSMN, lateral sensorimotor network; MMSE, Mini Mental State Examination; 
RMN, right motor network; TN, temporal network. 
4.3.5 Effect of dopaminergic medication in the DLB group 
There were no significant differences in connectivity between the DLB patients who were 
taking dopaminergic medication compared to those not taking these medications except for 
two very small clusters of increased connectivity in the medicated patients comprising one 
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voxel for the supplementary motor area network in left frontal orbital cortex and right 
superior frontal gyrus. 
4.4 Discussion 
In this chapter, I investigated within- and between-network connectivity in a wide range of 
RSNs in DLB compared to healthy controls as well as AD patients. With respect to within-
network connectivity more decreases than increases in connectivity were identified in the 
DLB group compared to controls, mainly in motor, temporal, and frontal networks. The 
analysis of between-network connectivity suggests that long-range functional connections are 
largely intact in DLB as there was only one connection between a frontal and a temporal 
network that showed altered between-network connectivity compared to controls. When 
directly comparing both dementia groups there were only very small differences, indicating 
that AD and DLB might not be that different with respect to their resting-state functional 
connectivity. Furthermore, there was no consistent relation between altered connectivity in 
DLB and any clinical variables, in particular with respect to cognitive fluctuations, suggesting 
that this analysis method might not be the most suitable to identify neural correlates of 
clinical DLB symptoms. 
4.4.1 Decreased connectivity in motor networks in DLB  
Connectivity was decreased in DLB compared to controls in several motor networks, 
including both sensorimotor, the basal ganglia, and the right motor networks. Overall, the 
observed changes in these networks correspond well to the clinical manifestation of DLB 
which is – among other core symptoms – characterised by Parkinsonian motor features 
(McKeith et al., 2005). Moreover, the results show substantial overlap with previous findings 
in PD and emphasise the significance of alterations in motor networks in DLB even though 
this condition is primarily characterised by cognitive decline and, frequently, significant AD 
co-pathology (Irwin et al., 2017). Decreased connectivity in the basal ganglia network has 
been found in patients with PD compared to healthy controls and patients with AD and has 
been suggested as a potential biomarker for early PD (Rolinski et al., 2015; Szewczyk-
Krolikowski et al., 2014). While I found similar results in the DLB group, the clusters of 
decreased connectivity were much smaller than in previous PD studies. This might be due to 
the use of dopaminergic medication in many DLB patients which has been shown to restore 
basal ganglia connectivity to near-normal levels (Szewczyk-Krolikowski et al., 2014). The 
finding of less impaired basal ganglia connectivity in the present DLB group compared to 
previous PD studies might also be related to the fact that Parkinsonism in DLB is often milder 
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and has been present for a shorter period than the motor symptoms in PD. The present results 
stand in contrast to previous studies in DLB that found increased basal ganglia connectivity 
compared to controls (Kenny et al., 2013; Lowther et al., 2014). The discrepancy between 
previous results in DLB and the present results and more recent PD studies is likely to be due 
to the use of different preprocessing methods, especially with respect to the removal of 
motion artefacts. It has recently been argued that motion correction approaches such as those 
used in previous DLB studies might have led to spurious findings and that prior results might 
have to be re-evaluated using more appropriate motion correction techniques such as those 
applied here (Ciric et al., 2017; Parkes et al., 2018; Power et al., 2015). This is especially 
crucial when studying elderly patients and comparing groups with different degrees of motor 
symptoms (van Dijk et al., 2012).  
In addition to decreased basal ganglia connectivity there was reduced connectivity within 
cortical motor networks. The right motor network showed large clusters of decreased 
connectivity in DLB within primary motor areas. Sensorimotor networks have been 
commonly shown to be altered in Lewy body diseases (Tessitore et al., 2014; Wu et al., 2011; 
Yu et al., 2013) and lower connectivity within the motor cortex has been reported previously 
in DLB (Peraza et al., 2016, 2014; Taylor et al., 2013). In addition to reduced connectivity 
within the motor network, itself, cognitive control areas, such as frontal and default mode 
areas, were also less strongly connected to this network in DLB, which might be related to 
impairments of voluntary movement control in this disease group. However, there were no 
significant correlations between the reduction in motor network connectivity and the severity 
of Parkinsonism. It might be that motor connectivity changes are related to the presence of 
Parkinsonian symptoms, but not their severity in DLB. 
4.4.2 DLB-related changes in non-motor networks 
With respect to non-motor networks, decreased connectivity in DLB compared to controls 
was observed mainly in temporal and frontal networks. The temporal network showed a 
general disconnection from different occipital regions which agrees with previous findings in 
DLB (Peraza et al., 2014; Taylor et al., 2012). The connections between occipital and 
temporal cortices represent the ventral visual stream which is involved in object recognition 
(Ungerleider and Haxby, 1994). A breakdown of this important visual pathway might thus be 
related to visuo-perceptual difficulties in DLB (Mosimann et al., 2004). However, similar to 
previous studies, there were no significant correlations with frequency or severity of visual 
hallucinations (Peraza et al., 2014). It may be that the observed connectivity changes foster a 
cortical state that is permissive for the occurrence of visual hallucinations, but that is not 
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directly related to their severity or frequency of occurrence. The temporal pole network 
demonstrated lower synchronisations in DLB compared to controls, mainly in frontal areas 
such as ACC and frontal pole. Similarly, the frontal anterior cingulate network showed a 
disconnection from inferior temporal regions. The observed reduced involvement of the ACC 
within the temporal pole network in DLB seemed to be compensated by an increase in 
between-network connectivity between the temporal pole and the anterior cingulate networks. 
The ACC is an important region involved in cognitive control and emotional processing 
(Bush et al., 2000) and abnormalities in this region have been associated with different 
aspects of Lewy body diseases. While reduced metabolism in the ACC has been found in both 
DLB and PDD (Yong et al., 2007), synaptic and pathological changes in this region have been 
implicated in visual hallucinations in DLB (Teaktong et al., 2005) and cognitive deficits in 
PD (Kövari et al., 2003). The present results provide further evidence for the importance of 
ACC abnormalities in Lewy body diseases and suggest that the previously described changes 
at the synaptic level might lead to more wide-range disruptions of the functional connectivity 
profile of this region.  
While the common finding of decreased DMN connectivity in the posterior cingulate cortex 
in AD could be replicated in the present analysis (Binnewijzend et al., 2012; Greicius et al., 
2004), there were no changes in DMN connectivity in DLB compared to controls. 
Additionally, DMN connectivity was increased in patients with DLB compared to AD 
patients, albeit only for very small clusters. These results confirm that the finding of DMN 
hypoactivity is rather specific to AD and does not seem to be present in DLB patients 
(Franciotti et al., 2013; Peraza et al., 2014).  
The results of this analysis suggest that long-range connections are largely intact in DLB 
which is somewhat contradictory to results from a previous graph-based analysis that found a 
relative loss of medium and long range connections in DLB (Peraza et al., 2015a). However, 
while the present analysis focuses on spatially distinct networks, the previous graph-theoretic 
approach is a more global analysis. It might thus be that connections between independent 
RSNs are relatively intact while this might not be true for long-distance connections in 
general. 
4.4.3 Comparison between the dementia groups 
In contrast to previous studies, I did not find large differences between the two dementia 
groups with respect to their within-network functional connectivity (Galvin et al., 2011; 
Lowther et al., 2014). An important difference to previous studies was the use of a more 
stringent motion correction technique and the inclusion of a covariate to control for voxel-
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wise grey matter differences. Previous studies on AD-DLB differences did not include a grey 
matter covariate even though grey matter loss is generally more severe in AD than in DLB 
(Watson et al., 2012) and might thus lead to spurious results in a group comparison 
(Damoiseaux et al., 2012). Furthermore, it has been shown that subtle differences in motion 
between groups can be mistaken for neuronal effects (van Dijk et al., 2012). In the present 
investigation, however, there was a between-network connectivity difference between patients 
with AD and patients with DLB for the left frontoparietal and occipital pole networks, which 
showed opposed synchronisations; positive in AD and negative in DLB. In the healthy control 
group, the correlation between these two networks was on average negative, which suggests 
that the positive correlation seen in the AD group is likely to represent an abnormal shift of 
connectivity from negative to positive correlation. Functional alterations in occipital and 
attentional systems have been previously reported in AD (Li et al., 2012; Sorg et al., 2007) 
although not between these two systems. Further research will be needed to corroborate their 
altered functional inter-relations. 
4.4.4 Limitations 
Similar to the previous chapters, the use of cholinergic and/or dopaminergic medication might 
have had an influence on the functional connectivity measures presented here. However, 
dopaminergic medication has been shown to normalise connectivity towards more healthy 
levels (Szewczyk-Krolikowski et al., 2014; Tahmasian et al., 2015), suggesting that the 
observed group differences were not due to medication. Furthermore, there were only very 
small differences in terms of functional connectivity measures between DLB patients who 
were taking dopaminergic medication compared to those not on these medications. However, 
as mentioned before, a comparison between patients on and off acetylcholinesterase inhibitors 
was not possible due to small numbers in the latter group. 
4.4.5 Conclusion 
Functional connectivity differences between AD and DLB were subtle and suggest that these 
two dementias may have more similarities than differences with respect to overall functional 
connectivity in patients with mild disease. Additionally, this analysis revealed a general 
decrease in functional connectivity in DLB compared to healthy ageing in motor, frontal, and 
temporal networks with a relative sparing of the DMN. The observed functional connectivity 
alterations may be related to the presence of motor and cognitive impairment in DLB as the 
networks that are commonly associated with these functions showed lower connectivity. 
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Chapter 5. Dynamic fMRI functional connectivity analysis 
5.1 Introduction 
To date, most functional connectivity studies have focussed on mean connectivity over the 
duration of a scan of several minutes (see Chapter 4), thereby implicitly assuming that 
functional connectivity remains stationary during that time. However, it has recently been 
shown that functional connectivity can vary substantially in both strength and directionality 
on a timescale of seconds to minutes (Chang and Glover, 2010; Hutchison et al., 2013b) and 
that studying these dynamics provides important complementary information to the traditional 
analysis of stationary functional connectivity (Calhoun et al., 2014; Hutchison et al., 2013a). 
Several methods have been developed to analyse dynamic functional connectivity in resting-
state fMRI, including sliding window approaches (Allen et al., 2014), time-frequency analysis 
(Chang and Glover, 2010), and change point detection (Cribben et al., 2013). The 
interpretation, functional significance, and origin of dynamic functional connectivity have 
been the subject of an extensive debate (Hindriks et al., 2016; Laumann et al., 2016; Lehmann 
et al., 2017). However, recent studies using concurrent fMRI and EEG measurements point 
towards a neuronal origin of dynamic functional connectivity (Chang et al., 2013; 
Tagliazucchi et al., 2012b). Additionally, several studies have provided support for a 
cognitive role of dynamic connectivity by showing that changes in connectivity are related to 
changes in behavioural or vigilance states (Jia et al., 2014; Kucyi et al., 2017; Thompson et 
al., 2013). Finally, the study of dynamic functional connectivity in clinical populations has led 
to the identification of specific dynamic connectivity alterations associated with specific 
disorders which provides further evidence of the neurocognitive significance of time-varying 
functional connectivity (Damaraju et al., 2014; Jones et al., 2012; Kaiser et al., 2015; Rashid 
et al., 2016, 2014; Sourty et al., 2016). 
As discussed in Chapter 1, LBD is characterised by transient clinical symptoms, in particular 
cognitive fluctuations that occur spontaneously in the absence of clear environmental triggers 
(Ballard et al., 2001a; Bradshaw et al., 2004). This suggests that cognitive fluctuations in 
LBD are internally driven and that dynamic changes in brain activity and connectivity might 
play a role in their aetiology (Sourty et al., 2016). Cognitive fluctuations can occur over days 
and hours, but variations on shorter timescales occur, with a strong association between sub-
second RT variability and cognitive fluctuations over longer time periods (Walker et al., 
2000a). Often coupled with fluctuations in LBD is marked slowing of information processing, 
and mental slowness, also known as bradyphrenia, a phenomenon distinct from motor 
slowness (Vlagsma et al., 2016).  
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It is not clear whether there is a pathologic increase or decrease in brain dynamical function 
associated with cognitive fluctuations. In regard to the former, early studies in LBD posited 
that a second by second temporal instability in the spectral power of the EEG of DLB patients 
was associated with the severity of cognitive fluctuations (Bonanni et al., 2008; Walker et al., 
2000c). In contrast, a recent study has provided support for the counter-argument of a 
decrease in brain dynamical function. Firbank et al. (2017) demonstrated that LBD patients 
who have marked cognitive slowing or bradyphrenia had prolonged cognitive processing on 
fMRI. These findings suggest that a less dynamic brain may be apposite for the cognitive 
phenotype of fluctuations that occurs in LBD. This is in alignment with the broader literature 
which indicates that a dynamic brain, as evidenced by temporal variability and flexibility of 
brain activity, is important for cognitive functioning (Deco et al., 2011; Garrett et al., 2013b; 
Zalesky et al., 2014) whereas less dynamic brain activity is associated with worse 
performance on cognitive tasks (Jia et al., 2014; McIntosh et al., 2008) and ageing (Grady and 
Garrett, 2018; Guitart-Masip et al., 2016). 
The aims of this chapter are therefore to (1) identify the differential dynamic connectivity 
profile of DLB patients compared to healthy controls, (2) investigate how functional 
connectivity dynamics in patients with DLB differ from AD patients, and (3) test a possible 
relation between abnormal connectivity dynamics and the severity of clinical symptoms in the 
DLB group, especially with respect to cognitive fluctuations. Based on previous evidence for 
the importance of brain dynamics for healthy cognitive functioning, I hypothesised to find a 
decrease in the dynamics of functional connectivity in patients with DLB compared to 
controls. Furthermore, I hypothesised this reduction in variability to be related to the severity 
of clinical symptoms in DLB, especially with respect to cognitive fluctuations. 
5.2 Methods 
5.2.1 Participants 
This analysis involved the same 102 participants as in Chapter 4, again combining data from 
CATFieLD and ARThippo studies: 33 were diagnosed with probable DLB, 36 with probable 
AD, and 33 were healthy controls. 
5.2.2 Data acquisition and preprocessing 
The analyses in this chapter were conducted with the same resting-state fMRI data that is 
presented in Chapter 4 (see Sections 4.2.2 and 4.2.3 for details on data acquisition and 
preprocessing). 
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5.2.3 Postprocessing 
As dynamic functional connectivity measures are especially vulnerable to different non-
neuronal artefacts (Hutchison et al., 2013a), several postprocessing steps were applied to the 
data to remove remaining noise sources. To this end, the subject-specific time courses 
resulting from dual regression (see Section 4.2.4) were further processed in Matlab (R2016b) 
using functions from the Group ICA of fMRI toolbox (GIFT, 
http://mialab.mrn.org/software/gift/index.html). Postprocessing included (1) detrending to 
remove linear, quadratic, and cubic trends, (2) outlier detection based on AFNI’s 3dDespike 
function (http://afni.nimh.nih.gov/afni) and interpolation of outliers using a third-order spline 
fit to the clean parts of the time courses, and (3) low-pass filtering using a fifth-order 
Butterworth filter with a cutoff frequency of 0.15 Hz. 
5.2.4 Sliding window analysis 
The postprocessed dual regression time series were analysed with a sliding window method to 
assess changes in between-network connectivity over time (Figure 5.1C). The sliding window 
approach was chosen because of its relative simplicity and computational efficiency compared 
to other dynamic connectivity methods which ensures that the results are interpretable and 
thus makes this approach especially suitable for the investigation of clinical questions. This 
analysis was performed in Matlab (R2016b) based on functions from GIFT (Allen et al., 
2014). A tapered window was created by convolving a rectangle of 22 TR (66 s) with a 
Gaussian with sigma of 3 TR and moved in steps of 1 TR. Since there were 128 volumes 
available, this resulted in a total of 107 overlapping time windows for each participant. To 
assess the robustness of the results with respect to different window sizes, all analyses were 
repeated for window sizes ranging from 18 to 28 TR.  
A covariance matrix between all RSN-to-RSN pairs was estimated for each window 
separately. Following Allen et al. (2014), regularised inverse covariance matrices were 
estimated using the graphical LASSO approach because it has been shown that estimation of 
covariance based on relatively short time series can otherwise be noisy. To achieve 
regularisation and promote sparsity, an L1-norm constraint was imposed on the inverse 
covariance matrix. The L1 regularisation parameter λ was optimised for each participant 
individually by evaluating the log-likelihood of unseen time windows from the same 
participant using 20-fold cross-validation. All covariances were subsequently converted to 
correlation values and transformed into z-scores using Fisher r-to-z transformation. To control 
for the effect of possible covariates, the z-scores were then residualised with respect to age, 
sex, and study membership using multiple linear regression (Damaraju et al., 2014).  
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Figure 5.1. Explanation of sliding window and k-means analysis. A) Data from all healthy 
control subjects from the independent cohort is concatenated in time and subjected to group 
ICA to identify RSN spatial maps. Subject-specific time courses of each RSN are estimated 
using dual regression (see Chapter 4). B) Static functional connectivity analysis by calculating 
correlation between each pair of RSNs using the whole time course (see Chapter 4). C) 
Sliding window approach and estimation of standard deviation of connectivity over time. D) 
K-means clustering. 
FC, functional connectivity; ICA, independent component analysis; RSN, resting state 
network; SD, standard deviation. 
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The variability of the connection strengths between RSNs (dynamic functional connectivity) 
was assessed by calculating the standard deviation of the RSN-to-RSN correlations across 
time windows. To assess whole-brain dynamics the mean standard deviation across all 
connections between RSN pairs was computed. Additionally, the mean standard deviation for 
each network across all other networks was considered and each RSN-to-RSN connection was 
also tested separately. 
5.2.5 K-means clustering 
To assess patterns of functional connectivity that reoccur over time across different 
participants, k-means clustering was applied to the windowed covariance matrices from all 
windows and all participants using the Manhattan (L1) distance function (Figure 5.1D). The 
optimal number of clusters k was chosen based on the elbow criterion of the cluster validity 
index, computed as the ratio of within-cluster to between-cluster distance, calculated for k 
between 2 and 14 (Allen et al., 2014). The clustering algorithm was repeated 500 times in 
Matlab with random initialisations of cluster centroid positions to get a stable solution. In 
addition to using the optimal value for k, the analyses were repeated for k ranging from 2 to 8 
to assess the robustness of the results regarding different values of k.  
Group differences were assessed with respect to (1) frequency: proportion of windows 
assigned to a state, (2) mean dwell time: average number of consecutive windows assigned to 
a state, (3) intertransition interval: average number of consecutive windows before a state 
transition occurs, and (4) number of transitions: overall number of transitions between 
different states (Hutchison and Morton, 2015; Marusak et al., 2016). 
5.2.6 Dynamic network analysis 
To examine the temporal variability of the brain network’s topological organisation, I also 
considered a graph-theoretic approach studying the dynamics of global and local efficiency 
using the Brain Connectivity Toolbox (Rubinov and Sporns, 2010). For each time window, a 
graph was constructed using the 27 RSNs as nodes and the correlation between the RSNs 
within the respective time window as edge strength. Binarised, unweighted, and undirected 
graphs were created by thresholding the absolute value of the individual time window 
correlation matrices to achieve different edge densities. The edge density of a graph is defined 
as the number of existing edges divided by the maximum number of possible edges (351 in 
this case). Edge density thresholds ranging from 3.7% to 39.3% were used based on previous 
network studies (Peraza et al., 2015b; van Wijk et al., 2010). Global and local efficiency were 
computed for each time window separately (Achard and Bullmore, 2007; Latora and 
101 
 
Marchiori, 2001). Variability of efficiency was then assessed by integrating over all edge 
density thresholds and computing the standard deviation of the respective measure over time 
(Kim et al., 2017). The same analysis was repeated in a static way by calculating local and 
global efficiency from the whole time course. 
5.2.7 Statistical analysis 
Statistical analyses were performed in IBM SPSS version 23 and in R version 3.5.1. The 
variability of functional connectivity of each network and each connection was compared 
between the groups using a non-parametric multivariate ANOVA (MANOVA) (Burchett et 
al., 2017) with diagnosis as between-subject factor. The different k-means measures were also 
compared between the groups using non-parametric MANOVAs followed by Kruskal-Wallis 
ANOVAs and post-hoc Dunn’s tests using FDR-correction for multiple comparisons. 
Spearman’s rank correlations were calculated to assess the relation between dynamic 
functional connectivity measures that showed significant group differences and cognitive 
fluctuation scores (CAF total and subscores) in the DLB group. Additional correlation 
analyses were performed for the MMSE and CAMCOG as measures of overall cognition, the 
UPDRS motor subscale, and the NPI hallucination subscale in DLB. In the AD group, 
correlations with MMSE and CAMCOG were calculated. P-values from the correlation 
analyses were FDR-corrected for multiple comparisons.  
To assess the effect of dopaminergic medication on dynamic connectivity measures, DLB 
patients were divided into those patients who were taking dopaminergic medication and those 
who were not on these medications and all dynamic connectivity measures were compared 
between the two groups using Mann-Whitney U-tests. 
Additionally, to investigate the effect of motion on the dynamic connectivity measures, mean 
framewise displacement was calculated following the approach of Power et al. (2012) and 
Spearman’s correlations between mean framewise displacement and the dynamic connectivity 
measures were tested across all participants. 
5.3 Results 
As described in Section 4.3, one AD patient was excluded due to coregistration errors. 
Additionally, two controls, six AD, and two DLB participants were excluded because of 
excessive motion. Thus, 31 DLB, 29 AD, and 31 HC participants were included in the 
analysis. The overall motion for all included participants did not differ between the groups 
(see Section 4.3). Furthermore, mean framewise displacement was not different between the 
groups (HC, mean (SD)=0.24 (0.11); AD, mean (SD)=0.25 (0.15); DLB, mean (SD)=0.24 
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(0.09); Kruskal-Wallis ANOVA, H2=1.22, p=0.54). See Section 4.3.1 and Table 4.2 in 
Chapter 4 for a comparison of group demographics. 
5.3.1 Group differences in dynamic connectivity 
The subject-specific values for the regularisation parameter λ that resulted from the 
optimisation procedure did not differ between the three groups (Kruskal-Wallis ANOVA, 
H2=0.06,p=0.97).  
Figure 5.2 (A-C) shows matrices representing the mean standard deviation of the strength of 
each RSN-to-RSN connection within each group. The mean variability of RSN connectivity, 
across all networks, is shown in Figure 5.2D. When considering average variability of each 
RSN, the overall MANOVA did not show a significant effect of diagnosis (F(10,442)=1.39, 
p=0.18). Similarly, when considering each individual RSN-to-RSN connection, the 
MANOVA did not reveal a significant group difference across all variables (F(96,4221)=1.02, 
p=0.43). 
Standard deviation matrices were re-estimated using different window sizes from 18 to 28 TR 
showing that the overall appearance of the standard deviation matrices was not dependent 
upon the specific choice of window size (Figure 5.3). Furthermore, repeating the analysis of 
connectivity variability for different window sizes did not show any significant group 
differences (all p>0.05). 
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Figure 5.2. Results from dynamic functional connectivity analysis. A-C) Matrices represent 
mean standard deviation over time for all HC, AD, and DLB participants. D) Boxplot of 
group comparison of mean standard deviation across all connections. In the boxplot the 
central line corresponds to the sample median, the upper and lower border of the box 
represent the 25th and 75th percentile, respectively, and the length of the whiskers is 1.5 times 
the interquartile range. 
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; HC, healthy controls; SD, 
standard deviation; see Table 4.1 in Chapter 4 for the abbreviations of the RSN names. 
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Figure 5.3. Mean standard deviation matrices for healthy controls, AD, and DLB for different 
window sizes ranging from 18 TR to 28 TR. 
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; HC, healthy controls; TR, 
repetition time. 
5.3.2 K-means clustering 
An optimal number of k=3 clusters was determined by the elbow criterion (Figure 5.4). State 
1 was characterised by relatively strong positive and negative between-network correlations 
(Figure 5.5). Especially strong positive correlations were present within the visual and the 
motor networks and between these two groups of networks (Figure 5.6). Additionally, the 
motor and visual networks showed negative correlations with cognitive control, salience, and 
temporal networks, and there was a strong connection between two components of the DMN. 
In contrast, state 2 was characterised by much sparser connections, with weaker connectivity 
within visual and motor networks and a relative lack of connections between the two groups 
of networks. There were a few positive connections between visual and default mode 
networks and additional positive connections between DMN and attention networks. State 2 
was the most common state, being present in almost all participants and accounting for 50% 
of all time windows across all participants. Similar to state 2, state 3 was characterised by 
weaker connections and a relative absence of strong anti-correlations. In addition to some 
within-module connections in the visual, motor, and default mode networks, there were weak 
connections between visual and DMN and attention networks. 
Non-parametric MANOVAs revealed that there was a significant effect of diagnosis on 
frequency and mean dwell time across all three states (Table 5.1). Follow-up univariate 
Kruskal-Wallis ANOVAs and pairwise post-hoc tests demonstrated that state 1 occurred less 
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frequently in the AD and DLB groups compared to controls with no difference between the 
dementia groups (Figure 5.7A and Table 5.1). In contrast, state 2 occurred more often in DLB 
patients compared to controls. However, there was no difference between controls and 
patients with AD or between AD and DLB patients for frequency of state 2. The mean dwell 
time of state 1 and 2 followed the same pattern as the frequency, i.e. DLB patients spent 
shorter periods of time in state 1 and longer periods of time in state 2 than controls; AD 
patients spent shorter times in state 1 than controls with no difference for state 2, and there 
was no difference between the dementia groups (Figure 5.7B). For state 3 there were no group 
differences in frequency or dwell time (Table 5.1). 
 
Figure 5.4. Elbow plot of the cluster validity index, i.e. ratio of within-cluster distance to 
between-cluster distance, for k=2 to 14. 
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Table 5.1. Results from overall non-parametric multivariate ANOVA (MANOVA) and 
follow-up Kruskal-Wallis ANOVAs per state for group comparison of k-means characteristics 
and static and dynamic efficiency measures between HC, AD, and DLB. 
 Three-group 
comparison 
Post-hoc tests (p-value) 
HC-AD HC-DLB AD-DLB 
Frequency 
MANOVA  F=2.69 (p=0.034) 
 
 
 
State 1 H=8.61  
(p=0.014, 
pFDR=0.040) 
p=0.02 
(pFDR=0.04) 
p=0.01 
(pFDR=0.03) 
p=0.69 
(pFDR=0.74) 
Post-hoc 
ANOVAs 
State 2 H=6.95 
(p=0.031, 
pFDR=0.046) 
p=0.1 
(pFDR=0.17) 
p=0.01 
(pFDR=0.03) 
p=0.29 
(pFDR=0.39) 
 State 3 H=0.98 
(p=0.61, 
pFDR=0.61) 
- - - 
Mean dwell time 
MANOVA  F=2.85 (p=0.023) 
 State 1 H=8.49 
(p=0.014, 
pFDR=0.043) 
p=0.03 
(pFDR=0.04) 
p=0.01 
(pFDR=0.04) 
p=0.75 
(pFDR=0.76) 
Post-hoc 
ANOVAs 
State 2 H=6.05 
(p=0.048, 
pFDR=0.072) 
p=0.1 
(pFDR=0.12) 
p=0.02 
(pFDR=0.04) 
p=0.57 
(pFDR=0.66) 
 State 3 H=2.71 
(p=0.26, 
pFDR=0.26) 
- - - 
Number of transitions F=3.16 
(p=0.21) 
- - - 
Intertransition interval F=3.21 
(p=0.20) 
- - - 
SD of local efficiency F=0.89 
p=(0.64) 
- - - 
SD of global efficiency F=6.08 
p=(0.047) 
p=0.28 
(pFDR=0.28) 
p=0.01 
(pFDR=0.041) 
p=0.18 
(pFDR=0.28) 
static local efficiency F=2.30 
(p=0.32) 
- - - 
static global efficiency F=2.01 
(p=0.37) 
- - - 
AD, Alzheimer’s disease; ANOVA, analysis of variance; DLB, dementia with Lewy bodies; FDR, false 
discovery rate; MANOVA, multivariate ANOVA; SD, standard deviation. 
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Figure 5.5. Results from the k-means analysis. A) Centroids resulting from clustering on all 
windows and participants. B) Cluster medians in the healthy control group. C) Cluster 
medians in the AD group. D) Cluster medians in the DLB group. 
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; HC, healthy controls. 
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Figure 5.6. Network representation of cluster centroids resulting from k-means analysis. The 
graphs are showing only the 5% strongest positive (red) and negative (blue) connections.  
See Table 4.1 in Chapter 4 for the abbreviations of the RSN names. 
 
 
 
Figure 5.7. A) Comparison of frequency of occurrence between the three groups for each 
state. B) Comparison of mean dwell time in each state between the three groups. Solid lines 
represent the means per group, shaded areas represent error bars of the standard error. FDR-
corrected p-values<0.05 (from post-hoc tests) are marked with an asterisk (see Table 5.1 for 
detailed statistics). 
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; FDR, false discovery rate; HC, healthy 
controls. 
 
 
Table 5.2. Correlations between time and the occurrence of the three states from Spearman’s 
rank correlations across all participants. 
Correlation with time ρ puncorrected pFDR 
Occurrence of state 1 -0.03 0.78 0.78 
Occurrence of state 2 0.05 0.62 0.78 
Occurrence of state 3 -0.19 0.045 0.13 
FDR, false discovery rate. 
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Several further analyses were performed to assess the robustness of the k-means analysis. 
Figure 5.8 shows results for different numbers of clusters demonstrating that the main result 
of differences in frequency and dwell time of state 1 and 2 persisted when using a higher k. 
Additionally, repeating the k-means analysis with k=3 for different window sizes confirmed 
that the specific choice of window length did not influence the state identification (Figure 
5.9). I also repeated the k-means analysis on split-half and bootstrap resamples of the data. 
Bootstrapping was performed by randomly selecting 31 HC, 29 AD, and 31 DLB participants 
with replacement and was repeated five times. Split-half resampling was performed by 
splitting the whole group of participants in half, with the constraint that each half contained 
approximately the same number of participants from each of the three groups. This analysis 
showed that states 1 and 2 were consistently identified in both split-half and all bootstrap 
resamples, while state 3 failed to be identified in some of the bootstrap resamples (Figure 
5.10). 
There were no significant differences between AD, DLB, and healthy control groups in the 
number of state transitions or the intertransition interval (Table 5.1). The frequency of 
occurrence of the three states was not correlated with time, i.e. there was no increase or 
decrease in the occurrence of any state over the duration of the scan (Table 5.2). 
5.3.3 Dynamic network measures 
Global efficiency variability differed significantly between the groups (Table 5.1). Post-hoc 
tests revealed that it was less variable in DLB compared to controls with no significant 
difference between AD patients and controls as well as between the two dementia groups 
(Figure 5.11A). In contrast, there was no difference between the groups in terms of variability 
of local efficiency (Figure 5.11B and Table 5.1). Also, the static analysis of global and local 
efficiency did not reveal any group differences (Table 5.1). 
5.3.4 Clinical correlations 
There were no significant correlations between the dynamic connectivity measures and 
cognitive fluctuation scores in DLB, even before correcting for multiple comparisons (all 
uncorrected p>0.5). Frequency of state 2 was positively correlated with the UPDRS in DLB 
(ρ=0.39, p=0.03). However, this correlation did not survive correction for multiple 
comparisons (pFDR=0.61). There were no significant clinical correlations in the AD group (all 
uncorrected p>0.1). 
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Figure 5.8. Results from k-means analysis (cluster centroids, frequency, and mean dwell time 
for the different states) for different values of k. FDR-corrected p-values<0.05 (from post-hoc 
tests) are marked with an asterisk. 
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; FDR, false discovery rate; HC, 
healthy controls. 
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Figure 5.9. States from k-means analysis with k=3 for different window sizes ranging from 
18 TR to 28 TR. 
TR, repetition time. 
 
 
Figure 5.10. K-means analysis with k=3 on A) bootstrap resamples of the data and B) split-
half samples. Bootstrapping was performed by randomly selecting 31 HC, 29 AD, and 31 
DLB participants with replacement and was repeated five times. Split-half resampling was 
performed by splitting the whole group of participants in half with the constraint that each 
half contained approximately the same number of participants from each of the three groups. 
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5.3.5 Effect of dopaminergic medication in the DLB group 
Comparing DLB patients who were on dopaminergic medication to those who were not, did 
not reveal any significant differences between the two groups with respect to the k-means 
parameters and the variability of local and global efficiency (Table 5.3). 
Table 5.3. Group comparison between DLB patients who were on dopaminergic medication 
(DLB on PD meds, N=18) and those patients not taking dopaminergic medication (DLB not 
on PD meds, N=13) using independent samples Mann-Whitney U-tests. 
 mean (SD) group comparison 
 DLB on PD meds DLB not on PD 
meds 
 
overall SD 0.18 (0.01) 0.18 (0.01) U=111.00 (p=0.83) 
frequency state 1 0.04 (0.08) 0.07 (0.16) U=111.00 (p=0.83 
frequency state 2 0.65 (0.36) 0.59 (0.23) U=95.50 (p=0.40) 
frequency state 3 0.31 (0.37) 0.33 (0.22) U=90.00 (p=0.30) 
mean dwell time state 1 4.22 (8.30) 3.95 (8.42) U=115.00 (p=0.95) 
mean dwell time state 2 43.38 (36.05) 34.50 (23.68) U=112.00 (p=0.86) 
mean dwell time state 3 17.78 (25.78) 16.03 (7.72) U=82.50 (p=0.17) 
number of transitions 2.67 (1.88) 3.85 (1.52) U=5.00 (p=0.10) 
intertransition interval 41.65 (36.40) 24.77 (11.50) U=88.50 (p=0.26) 
SD of local efficiency 0.04 (0.006) 0.03 (0.01) U=86.00 (p=0.23) 
SD of global efficiency 0.02 (0.009) 0.02 (0.005) U=110.00 (p=0.80) 
DLB, dementia with Lewy bodies; PD meds, dopaminergic medication; SD, standard deviation. 
5.3.6 Effect of motion 
There were no significant correlations between the dynamic connectivity measures that 
showed group differences and mean framewise displacement (Table 5.4).  
Table 5.4. Spearman’s correlations between dynamic connectivity measures and mean 
framewise displacement across all participants. 
 ρ p-value 
frequency state 1 -0.08 0.43 
frequency state 2 0.14 0.18 
mean dwell time state 1 -0.06 0.56 
mean dwell time state 2 0.12 0.27 
SD of local efficiency 0.07 0.49 
SD of global efficiency -0.09 0.42 
SD, standard deviation. 
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Figure 5.11. Results from dynamic network analysis. Comparison of the variability of A) 
global efficiency (p-values FDR-corrected) and B) local efficiency between groups (all post-
hoc p-values>0.05) (see Table 5.1 for detailed statistics). 
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; FDR, false discovery rate; HC, 
healthy controls. 
5.4 Discussion 
In this chapter, I investigated differences in functional connectivity dynamics and dynamic 
brain network topology between patients with DLB, patients with AD, and healthy controls. 
In terms of dynamic changes in overall network structure, there was a reduction in variability 
of global efficiency in the DLB group compared to controls which was not observed in the 
AD group. Using a state-based analysis, it became evident that both dementia groups spent 
less time in a state of strong inter-network connectivity than controls, indicating transiently 
reduced functional connectivity in both dementia groups. Additionally, DLB patients spent 
more time in a more sparsely connected state characterised by the relative loss of strong anti-
correlations and an isolation of motor networks relative to other networks. While dynamic 
connectivity measures of the AD group were often between those of the control and DLB 
groups, there were no significant differences in the direct comparison between both dementia 
groups. 
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5.4.1 State-based analysis 
While the number of visited states and the number of state changes were not altered in the 
dementia groups, there was a significant difference in the type of state changes in the 
dementia patients compared to controls. The frequency with which the control participants 
visited each of the three states was relatively balanced, i.e. they spent about a third of their 
time in each state. In contrast, the distribution of states in the AD and DLB groups was more 
out of balance compared to controls with a clear decrease in frequency of state 1 in both 
dementia groups accompanied by an increased frequency of state 2 in DLB. In addition to 
visiting state 1 less often, the dementia patients also switched out of this state more rapidly 
and DLB patients stayed in state 2 for longer consecutive periods of time. In accordance with 
previous reports in healthy participants (Allen et al., 2014), brain development (Marusak et 
al., 2016), ageing (Viviano et al., 2017), and PD (Kim et al., 2017), the most common state in 
the present analysis (state 2) was characterised by a sparse connectivity profile with relatively 
weak inter-network connections and the absence of strong anti-correlations. The frequency of 
this state has been linked to the amount of self-focused thought (Marusak et al., 2016) and it 
has been suggested to represent a general connectivity pattern that participants spend most of 
their time in, with other states reflecting temporary deviations that might be due to cognitive, 
physiological, or motion-related processes (Viviano et al., 2017). State 1 deviated from this 
state by stronger positive and negative connections. It seems that AD as well as DLB patients 
remain in states of low inter-network connectivity and switch less often into more highly and 
specifically connected network configurations. This may relate to the presence of dementia in 
general even though there were no specific correlations between the time spent in different 
states and the severity of cognitive impairment. A specific hallmark of state 1 is strong 
connectivity within visual and motor networks and between these two groups of networks that 
is not present in state 2. A reduced ability to switch into this state thus accords with Sourty et 
al. (2016), who found dynamic connectivity changes in DLB for networks related to visual 
processing using Hidden Markov Models. Another important characteristic of state 1 that 
differentiates it from state 2 is the existence of strong anti-correlations in the former. 
Furthermore, while the DMNs do not show strong correlations with task-positive networks in 
state 1, the other two states are characterised by positive connections between DMN and 
visual and attention networks. Anti-correlation between default mode and task-positive 
networks has been shown to be important for attentional function (Fox et al., 2005) and a loss 
of anti-correlations has been associated with ageing, MCI, and cognitive impairment in PD 
(Baggio et al., 2015; Esposito et al., 2017). The present results further suggest that an absence 
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of this antithetic relationship between default mode and task-positive networks might also be 
a feature of more established neurodegenerative disease in the case of AD and DLB. 
5.4.2 DLB-related changes in dynamic network topology 
Regarding dynamic network topology, global efficiency was found to be less variable in DLB 
compared to controls. Global efficiency is a measure of communication efficiency across the 
whole brain network (Latora and Marchiori, 2001). In general, more pronounced variability of 
functional connectivity has been shown to be related to superior performance on a range of 
behavioural tests including attention and memory tasks (Jia et al., 2014), indicating that the 
dynamic and flexible engaging and disengaging of different brain regions seems to be crucial 
for efficient and adaptable communication within the brain (Zalesky et al., 2014). Reduced 
dynamics in turn can lead to less flexible and ineffective communication as well as a reduced 
ability of the network to respond to situational demands. The reduced variability of global 
efficiency in DLB might thus indicate a disease-related and abnormal rigidity of the brain 
network which might relate to the cognitive slowing (bradyphrenia) that is observed in DLB 
patients (Firbank et al., 2018). In contrast, in healthy brains efficiency is temporally 
modulated, which has been shown to represent more economical network dynamics allowing 
for a more specific response to situational demands (Zalesky et al., 2014). In contrast to the 
dynamic analysis, there were no significant group differences when considering efficiency 
across the whole time course. This finding stands in contrast to a previous study which 
reported increased global efficiency in DLB patients compared to patients with AD (Peraza et 
al., 2015b). However, while Peraza et al. (2015b) analysed a brain network that was based on 
individual atlas-defined regions of interest, the network nodes in the present analysis were 
large-scale RSNs themselves, thereby assessing the interconnections between different 
networks. There is no complete correspondence between the two approaches (Rosazza et al., 
2012) which might explain this difference in findings. Nevertheless, similar to the present 
results, Peraza et al. (2015b) reported no difference between patients with AD and controls 
with respect to global efficiency which indicates that static and dynamic changes in efficiency 
might be a specific feature of DLB that might not be associated with dementia per se. In 
contrast to the present results, Kim et al. (2017) have found increased variability of global 
efficiency in patients with PD. However, this finding was not replicated in another study in 
PD patients with mild cognitive impairment (Díez-Cirarda et al., 2017) and thus further 
research will be needed to identify the specific changes related to these different Lewy body 
diseases. 
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5.4.3 Relation to clinical symptoms in DLB 
Given the transient nature of clinical DLB symptoms such as visual hallucinations and 
cognitive fluctuations, I expected symptom severity to be related to some extent to dynamic 
connectivity measures. However, there were no significant correlations between dynamic 
connectivity measures and cognitive fluctuations, even before correcting for multiple 
comparisons. A possible reason for this might be the difference in timescales: while the fMRI 
data only allowed the characterisation of dynamics during a 6-minute resting-state scan, the 
timescale of cognitive fluctuations can be on the order of minutes to hours and even days. 
Performing repeated scans with DLB patients at different times of the day or over several 
days might thus help to understand more about the relation between functional connectivity 
dynamics and clinical symptom severity. There was a trend for an association between 
frequency of state 2 and severity of Parkinsonism in DLB, i.e. an increased time spent in this 
sparsely connected state might relate to more severe Parkinsonism. Relative to state 1, this 
state was characterised by a disconnection of motor networks from other networks and the 
observed correlation might thus indicate that the isolation of motor networks might contribute 
to the severity of clinical motor symptoms. However, this is only an exploratory result that 
did not survive multiple comparison correction and further research will be needed to confirm 
this conjecture. 
5.4.4 Reliability of dynamic connectivity results 
The interpretation, functional significance, and origin of dynamic functional connectivity 
have been the subject of an extensive debate (Hindriks et al., 2016; Laumann et al., 2016). 
However, recent studies using concurrent fMRI and EEG measurements point towards a 
neuronal origin of dynamic functional connectivity (Chang et al., 2013). Additionally, several 
studies have provided support for a cognitive role by showing that temporary changes in 
connectivity are related to changes in behavioural or vigilance states (Jia et al., 2014; Kucyi et 
al., 2017; Thompson et al., 2013) and cognitive performance in healthy older adults (Cabral et 
al., 2017). Finally, the study of dynamic functional connectivity in clinical populations has led 
to the identification of specific dynamic connectivity alterations associated with specific 
disorders which provides further evidence of the neurocognitive significance of time-varying 
functional connectivity (Damaraju et al., 2014; Jones et al., 2012; Sourty et al., 2016). 
Although the sliding window approach has been widely applied to study dynamic functional 
connectivity (Allen et al., 2014; Damaraju et al., 2014; Hutchison and Morton, 2015; Jones et 
al., 2012; Marusak et al., 2016), its validity has been debated (Hindriks et al., 2016). 
Advantages are its interpretability and computational efficiency which make this kind of 
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analysis especially suitable for the investigation of clinical questions. However, problematic 
aspects include the need for an a priori specification of parameters such as window length and 
the number of states for the k-means analysis and the possibility of spurious connectivity 
fluctuations which can arise due to noise sources such as head motion (Hutchison et al., 
2013a). In the present analysis, I applied several pre- and postprocessing steps to reduce the 
effect of these noise sources (see Section 5.2.3). It was also ensured that the groups did not 
differ with respect to motion which makes it unlikely that the observed group differences 
were merely motion artefacts. Additionally, there was no significant relation between 
dynamic connectivity measures and mean framewise displacement, indicating little influence 
of motion on the dynamic connectivity measures in the present analysis. Regarding the choice 
of window length, I showed that the results can be reproduced using windows of different 
lengths. While most previous studies examined a larger number of states (Allen et al., 2014; 
Damaraju et al., 2014; Hutchison and Morton, 2015; Marusak et al., 2016; Viviano et al., 
2017), I focused on a smaller set of three states which was determined as the optimal number 
of states in the present dataset and is comparable to a previous report in PD (Kim et al., 2017). 
The states tended to get more unstable as more states were added with states appearing that 
were specific to certain participants (see Figure 5.8). This might be due to the small number 
of participants and large heterogeneity in the present sample. Nevertheless, I showed that the 
observed group differences in terms of frequency and dwell time remained largely unchanged 
for different values of k, and states were reproducible on split-half and bootstrap resamples of 
the data which confirms the robustness of this approach. Notably, adding more states did not 
result in more significant group differences, indicating that these three states represent the 
most important states in terms of dementia-related changes in connectivity dynamics. 
5.4.5 Limitations 
Many of the DLB patients were on dopaminergic medication and scanned in the ON state 
which might have influenced their dynamic functional connectivity measures. However, 
dopaminergic medication has been shown to normalise connectivity towards more healthy 
levels (Tahmasian et al., 2015), suggesting that the observed group differences were not due 
to medication. Furthermore, there were no differences in terms of dynamic connectivity 
measures between DLB patients who were taking dopaminergic medication compared to 
those not on these medications. 
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5.4.6 Conclusion 
The loss of variability of global efficiency in DLB indicates an abnormally rigid brain 
network. This might be associated with less economical dynamics that can lead to disruptions 
of normal brain functioning and prevent specific and effective responses of the brain network 
to situational demands. This loss of dynamics was not observed in AD patients and seems to 
represent a DLB-specific abnormality that might relate to the cognitive phenotype of DLB. In 
contrast, the inability to transiently switch out of states of low inter-network connectivity into 
more highly and specifically connected network configurations was observed in both 
dementia groups and might thus be related to the presence of dementia in general rather than 
symptoms that are specific to AD or DLB. 
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Chapter 6. EEG Microstate Analysis 
6.1 Introduction 
Brain dynamics can be assessed with different methodologies and on different timescales: 
while fMRI allows the characterisation of slower brain dynamics with high spatial resolution 
(see Chapter 5), dynamical changes on a sub-second timescale can be studied using EEG 
microstate analysis (Michel and Koenig, 2017). Previous research has shown that the EEG 
signal can be segmented into a number of short, non-overlapping, quasi-stable topographies – 
the microstates –  that remain transiently stable for about 80-120 ms before abruptly 
transitioning into a new state (Khanna et al., 2015; Lehmann et al., 1987; Michel and Koenig, 
2017). Even though there is a large number of possible topographies in multi-channel EEG, 
more than 70% of its variance can be explained by only a few distinct and stereotypical 
topographies (Koenig et al., 1999). These microstates have been described as the basic 
building blocks of human information processing or the “atoms of thought” (Lehmann, 1990) 
and it has been shown that their temporal dynamics, especially in terms of microstate 
duration, are important for cognitive functioning (Van De Ville et al., 2010). Furthermore, it 
has been suggested that investigating temporal aspects of microstate sequences can provide 
insight into the brain’s dynamic repertoire across different timescales. Studying microstate 
dynamics on a sub-second timescale can therefore provide information about brain dynamics 
in general with implications for fast and slow dynamic processes (Van De Ville et al., 2010). 
Thus, interrogation of microstate dynamics in LBD may provide a novel perspective in 
understanding the basis of cognitive fluctuations and more broadly the LBD cognitive 
phenotype. These investigations form the first part of this chapter.  
In the second part, I address the potential mechanisms of microstate transition and their 
disruption in LBD. While there is evidence for a relation between specific microstates and the 
well-known RSNs that can be obtained from fMRI (Britz et al., 2010; Custo et al., 2017; 
Musso et al., 2010), it remains unclear which processes in the brain drive the abrupt global 
transitions between different microstates, i.e. the neural correlates of microstate dynamics 
(Michel and Koenig, 2017). However, subcortical-cortical networks represent one putative 
system which could globally alter brain dynamics given their significant and widespread 
cortico-petal connectivity. In particular, both the thalamus and the basal ganglia have 
extensive connections to various parts of the cortex and form part of the cortical-basal 
ganglia-thalamic loop which is an important contributor to large-scale network 
communication within the brain (Bell and Shine, 2016). The thalamus has been suggested to 
play a role in modulating the cortical EEG signal (Lopes da Silva, 1991) and its activity has 
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been shown to relate to cortical microstate characteristics (Schwab et al., 2015). From a LBD 
perspective, structural and functional abnormalities of the thalamus are a common feature in 
Lewy body diseases (Watson et al., 2017). In particular, microstructural changes and 
cholinergic imbalance in the thalamus have been suggested to play a role in the aetiology of 
cognitive fluctuations in DLB (Delli Pizzi et al., 2015b; Pimlott et al., 2006). Similarly, 
dopaminergic dysfunction of the basal ganglia is a hallmark of Lewy body diseases (McKeith 
et al., 2007) and aberrant functional connectivity of the basal ganglia network has been found 
in DLB and PD (Rolinski et al., 2015; Szewczyk-Krolikowski et al., 2014, see also Chapter 
4). Both the basal ganglia and the thalamic networks are therefore potential candidate 
networks whose dynamic interaction with cortical networks might influence microstate 
dynamics in LBD. 
I hypothesised that a less dynamic brain, as evidenced by slowing of microstate dynamics is a 
feature of LBD which is related to the cognitive phenotype, and in particular, cognitive 
fluctuations, and that disturbances in microstate dynamics in LBD will be contingent upon a 
loss of dynamics within cortical-basal ganglia-thalamic connections. 
6.2 Methods 
6.2.1 Participants 
This analysis involved 96 participants from the CATFieLD study comprising 46 diagnosed 
with probable LBD (25 DLB and 21 PDD), 32 with probable AD, and 18 healthy controls. 
Patients who were taking dopaminergic medication were assessed in the “ON” motor state. 
6.2.2 EEG acquisition and preprocessing 
Resting-state EEG recordings were acquired from all participants using Waveguard caps 
(ANT Neuro, The Netherlands) comprising 128 sintered Ag/AgCl electrodes that were placed 
according to the 10-5 system. Participants were seated during the recording and were 
instructed to remain awake, but keep their eyes closed. Electrode impedance was kept below 5 
kΩ and 150 s of continuous EEG data were recorded at a sampling frequency of 1024 Hz. The 
ground electrode was attached to the right clavicle and all EEG channels were referenced to 
Fz during recording.  
Preprocessing of EEG data was performed by Dr Luis Peraza, blinded to group membership 
and methods applied were the same as described in (Peraza et al., 2018). Data were filtered 
between 0.3 and 54 Hz using a second order Butterworth filter, noisy EEG segments with 
artefacts affecting all channels were deleted, and ICA was used for artefact removal. Data 
were then recomputed against the average reference, bandpass filtered between 2 and 20 Hz, 
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and split into non-overlapping epochs of 2-second length. For each participant the first 30 2-
second long artefact-free epochs were selected for the microstate analysis. Participants with 
less than 30 artefact-free epochs were excluded from further analysis. 30 epochs were chosen 
because this allowed to include a large number of patients and is comparable to the number of 
epochs that is typically used in microstate studies.   
6.2.3 Microstate analysis 
The microstate analysis was conducted using the Cartool software (Brunet et al., 2011) and 
functions from the EEGLAB plugin for Microstates 
(http://www.thomaskoenig.ch/index.php/software/microstates-in-eeglab) in Matlab R2017a. 
As a first step, the global field power (GFP) was calculated which is equivalent to the 
standard deviation of the average-referenced signal across all electrodes and whose local 
maxima represent instants of highest field strength (Lehmann and Skrandies, 1980). EEG 
topographies tend to remain stable during periods of high GFP and change rapidly around the 
local minima of the GFP (Lehmann et al., 1987). Thus, topographies at GFP peaks are 
representative of topographies at surrounding time points and restricting the microstate 
analysis to these GFP peaks provides optimal topographic signal-to-noise ratios (Lehmann et 
al., 1987). For each subject separately, topographies at GFP peaks were subjected to a 
topographic atomize and agglomerate hierarchical clustering (TAAHC) algorithm (Murray et 
al., 2008) (Figure 6.1A). The optimal number of microstate classes k was determined for each 
participant individually using the meta-criterion described in Custo et al. (2017), testing the 
entire range from 1 to 12 classes. The individual maps were then averaged across all 
participants within each group using a permutation algorithm (Koenig et al., 1999) and overall 
mean maps across all participants were obtained by averaging the group-specific average 
maps across groups (Figure 6.1B).  
The group microstate maps were then fitted back to the original data at GFP peaks assigning 
each GFP peak to one microstate class based on the maximal spatial correlation between 
topographies (Figure 6.1C). Microstate labels for data points between GFP peaks were 
interpolated with microstates starting and ending halfway between two GFP peaks. Potentially 
truncated microstates at the beginning and end of each epoch were excluded from the 
analysis. Microstate duration was thus calculated as the time during which all successive 
maps were assigned to the same microstate. Additionally, the mean number of occurrences of 
each microstate class per second (microstate occurrence) and the percentage of total analysis 
time covered by each microstate (microstate coverage), i.e. the sum of the durations of each 
occurrence of a certain microstate class across the whole time course, were calculated. 
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Figure 6.1. Explanation of EEG microstate analysis. A) For each subject, data at global 
maxima of the GFP are clustered using the TAAHC algorithm to obtain individual microstate 
maps. B) The individual maps are combined to obtain group maps within each clinical group 
using a permutation algorithm. C) Group maps are fit back to the data at GFP peaks assigning 
each GFP peak to the microstate class with the highest topographical correlation. Microstates 
in-between GFP peaks are interpolated. 
AD, Alzheimer’s disease; GFP, global field power; HC, healthy controls; LBD, Lewy body 
dementia; TAAHC, topographic atomize and agglomerate hierarchical clustering. 
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6.2.4 Microstate statistics 
The topographies of the different microstate classes were compared between the groups using 
topographical analysis of variance (TANOVA) implemented in the Ragu software (Koenig et 
al., 2011). For this, a non-parametric randomisation test was performed on global map 
dissimilarity with a within-subject factor of microstate class and a between-subject factor of 
group.  
Microstate duration, occurrence, coverage, and observed transition probabilities were 
compared between the groups using separate multivariate ANOVAs in IBM SPSS Statistics 
version 23. In the case of an overall significant test, follow-up univariate ANOVAs were 
performed to determine which microstate classes showed group differences followed by post-
hoc tests with Bonferroni-correction for multiple comparisons. 
Transition probabilities between different microstate classes were assessed by counting the 
number of transitions from each microstate class to any other class and normalising by all 
between-class transitions for each subject separately. If the transition from one microstate 
class to the next occurred randomly, i.e. irrespective of the class of the preceding microstate, 
transition probabilities would be proportional to the relative occurrence of the microstate 
classes. Under the null hypothesis of random transitions between microstates, the expected 
transition probability for transitions from microstate class X to class Y is therefore given by 
(Lehmann et al., 2005): 
PX→Y
exp
=  
occurrenceX × occurrenceY 
1− occurrenceX
  
To assess the randomness of transition probabilities, a non-parametric randomisation test was 
applied as described in Lehmann et al. (2005). Within each group, the observed and expected 
transition probabilities were averaged across participants and the overall difference between 
observed and expected transition probabilities was calculated using the χ2-distance (Lehmann 
et al., 2005). Individual observed and expected transition probabilities were then randomly 
permutated 5,000 times to obtain the distribution of χ2-distance values under the null 
hypothesis of random transition probabilities. The p-value was calculated as the fraction of 
permutations in which the χ2-distance was larger than the distance using non-permuted 
transition probabilities. 
6.2.5 Clinical and behavioural correlations 
Correlation analyses were performed in R version 3.5.1. Spearman’s correlations between 
mean microstate duration and the Mayo fluctuation scale (overall score, cognitive subscore, 
and arousal subscore) were tested in the combined LBD group as well as in the two subgroups 
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separately. P-values were FDR-corrected for multiple comparisons. To check whether these 
correlations were influenced by dopaminergic medication, a linear regression analysis was 
also performed adding LEDD (Tomlinson et al., 2010) as a covariate in the model. 
Supplementary correlation analyses were performed for the CAF score, global cognitive 
scores (MMSE and CAMCOG), the UPDRS motor subscale, and NPI visual hallucinations 
subscores in the LBD group. In the AD group, correlations were calculated between mean 
microstate duration and global cognition (MMSE and CAMCOG). 
Given that previous studies have reported a relation between a loss of brain dynamics and 
slower and less consistent RT performance (McIntosh et al., 2008), I was also interested in 
investigating correlations between mean microstate duration and the ex-Gaussian parameters 
reported in Chapter 3. To this end, a Spearman’s correlation analysis was performed across all 
groups to test correlations between mu, sigma, and tau and mean microstate duration. 
6.2.6 Effect of dopaminergic medication in the LBD group 
To assess the effect of dopaminergic medication usage in the LBD group, microstate duration 
and microstate occurrence per second were compared between LBD patients who were taking 
dopaminergic medication (N=29) and those LBD patients who were not taking dopaminergic 
medication (N=13). In addition, Spearman’s correlations were calculated between LEDD and 
mean microstate duration and occurrence in the LBD group. 
6.2.7 FMRI dynamic connectivity 
Resting-state fMRI was recorded from a subset of the participants included in the EEG 
analysis (non-concurrent, performed between one and three weeks apart). This subset 
comprised 12 healthy controls, 14 AD patients, and 29 patients with LBD (17 DLB and 12 
PDD). Details on the analysis of dynamic functional connectivity can be found in Section 
5.2.4. In the present analysis, given my a priori hypothesis, I focussed on dynamic 
connectivity between two subcortical networks (basal ganglia and thalamic networks) and all 
other networks (see Table 4.1 in Chapter 4 for a list of all included networks and Figure 4.1 in 
Chapter 4 for a depiction of the network maps). 
6.2.8 Combining EEG microstates and dynamic fMRI connectivity 
The mean variability of connectivity (standard deviation over time) between the two 
subcortical networks of interest – basal ganglia and thalamus – and all other networks was 
calculated and correlated with mean microstate duration in each group separately using 
Pearson’s correlations. To assess which of the individual network connections contributed 
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most to the overall correlation, mean microstate duration was correlated with the dynamic 
connectivity of each connection separately, correcting the resulting p-values for multiple 
comparisons using FDR-correction. 
6.3 Results 
6.3.1 Demographics 
Data from five AD and four PDD patients were excluded from the microstate analysis 
because they had fewer than 30 2-second long epochs of cleaned EEG data after 
preprocessing. Therefore, 18 healthy controls, 27 AD, and 42 LBD (25 DLB and 17 PDD) 
participants were included in the analysis. 
Healthy control, AD, and LBD participants were similar in age and sex (Table 6.1). 
Additionally, the two dementia groups did not differ significantly in terms of dementia 
duration. However, the LBD group was significantly less impaired in terms of overall 
cognition (MMSE and CAMCOG) compared to the AD group. The percentage of patients 
taking acetylcholinesterase inhibitors did not differ between the dementia groups. As expected 
the majority of LBD patients were taking dopaminergic medication compared to none of the 
AD patients. The LBD patients were more impaired than the AD patients with respect to the 
core LBD symptoms of Parkinsonism, cognitive fluctuations, and visual hallucinations.  
To ensure that the difference in overall cognition between the two dementia groups did not 
influence the results, all analyses described below were rerun with AD and LBD subgroups 
that were matched for MMSE and CAMCOG. These were created by excluding three AD 
patients with MMSE<14 and six LBD patients (five DLB and one PDD) with MMSE>27. 
The two resulting groups did not differ significantly with respect to dementia duration (Mann-
Whitney U test, U=322, p=0.19), MMSE (Student’s t-test, t58=0.65, p=0.52), and CAMCOG 
(Student’s t-test, t58=0.62, p=0.54).   
Demographics for those participants that were included in the combined EEG-fMRI analysis 
are shown in Table 6.2. All three groups were matched for age and sex, while the two 
dementia groups were matched in terms of overall cognition.   
Table 6.1 shows a comparison of clinical symptoms between DLB and PDD. Both LBD 
subgroups were matched in terms of age, sex, overall cognition, the percentage of patients 
taking acetylcholinesterase inhibitors, and cognitive fluctuation and visual hallucination 
severity. More PDD patients were taking dopaminergic medication and they had worse 
Parkinsonism than the DLB patients. DLB and PDD patients were combined into one LBD 
group as preliminary analyses showed that there were no group differences with respect to 
microstate characteristics (Table 6.3).
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Table 6.1. Demographic and clinical variables, mean (standard deviation). 
 HC (N=18) AD (N=27) LBD (N=42) Group differences DLB (N=25) PDD (N=17) Group differences 
Male: 
female 
11:7 20:7 36:6 χ2=4.5, p=0.11a 20:5 16:1 χ2=1.65, p=0.20k  
Age 76.3 (5.5)  74.9 (7.0) 74.8 (6.4) F(2,84)=0.35, 
p=0.70b 
76.2 (6.2) 72.8 (6.2) t40=1.71, p=0.10
l  
AChEI - 25 36 χ2=0.76, p=0.38c 23 13 χ2 =2.00, p=0.16k  
PD meds - 0 29 χ2=32.16, p<0.001c 12 17 χ2 =12.80, p<0.001k  
Duration  - 3.9 (2.1)f 3.2 (2.1)g U=399, p=0.12d  3.5 (2.3) 2.8 (1.5)p U =174, p=0.48
m  
MMSE 29.2 (0.9) 20.7 (4.3) 23.1 (3.7) t67=2.51, p=0.01
e 22.7 (4.3) 23.8 (2.6) t40 =0.92, p =0.36
l 
CAMCOG 96.7 (3.7) 67.4 (15.7) 75.7 (11.1) t67=2.57, p=0.01
e 74.8 (12.8) 77.1 (8.2) t40 =0.63, p =0.53
l  
UPDRS 
III 
1.3 (1.5) 2.4 (3.0) 20.4 (8.5) t67=10.6, p<0.001
e 16.2 (7.5) 26.6 (5.5) t40 =4.88, p<0.001
l 
CAF total - 0.38 (0.98)g 5.0 (4.3)h t64=5.31, p<0.001
e 4.1 (4.1)o 6.3 (4.4)p t38 =1.55, p=0.13
l 
Mayo total - 9.4 (4.7)g 14.0 (5.7)h t64=3.41, p=0.001
e 13.3 (5.9)o 14.9 (5.4)p t38=0.88, p=0.39
l 
Mayo 
cogn 
- 1.9 (1.8)g 2.8 (1.8)h t64=2.06, p=0.043
e 2.5 (1.8)o 3.2 (1.9)p t38=1.10, p=0.28
l 
NPI total - 6.8 (6.6)g 14.3 (10.5)j t65=3.23, p=0.002
e 10.2 (6.3)o 20.1 (12.6) t39=3.31, p=0.002
l 
NPI hall - 0.04 (0.20)g 1.9 (2.0)j t65=4.90, p<0.001
e 1.7 (1.9)o 2.2 (2.1) t39=0.85, p=0.40
l  
AChEI, number of patients taking acetylcholinesterase inhibitors; AD, Alzheimer’s disease; CAF total, Clinician Assessment of Fluctuation total score; CAMCOG, Cambridge 
Cognitive Examination; DLB, Dementia with Lewy bodies; Duration, duration of cognitive symptoms in years; HC, healthy controls; LBD, Lewy body dementia; Mayo total, 
Mayo Fluctuations Scale; Mayo cognitive, Mayo Fluctuation cognitive subscale; MMSE, Mini Mental State Examination; PDD, Parkinson’s disease dementia; PD meds, number 
of patients taking dopaminergic medication for the management of Parkinson’s disease symptoms; UPDRS III, Unified Parkinson’s Disease Rating Scale III (motor subsection); 
NPI, Neuropsychiatric Inventory; NPI hall, NPI hallucination subscore 
a Chi-square test HC, AD, LBD; b One-way ANOVA HC, AD, LBD; c Chi-square test AD, LBD; d Mann Whitney U test AD, LBD; e Student’s t-test AD, LBD. 
f N=25, g N=26, h N=40, j N=41 
k Chi-square test DLB, PDD; m Mann Whitney U test DLB, PDD; l Student’s t-test DLB, PDD. 
o N=24, p N=16. 
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Table 6.2. Demographic and clinical variables for all participants that were included in the 
combined EEG-fMRI analysis, mean (standard deviation). 
 HC (N=12) AD (N=14) LBD (N=29) Between-group 
differences 
Male: female 9:3 11:3 24:5 χ2=0.34, p=0.84a 
Age 76.4 (6.2)  75.0 (8.3) 74.5 (6.6) F(2,52)=0.33, p=0.72b 
AChEI - 13 27 χ2=0.01, p=0.98c 
PD meds - 1 21 χ2=16.1, p<0.001c 
Duration  - 3.9 (1.7) 3.4 (2.2)g U=151, p=0.22d  
MMSE 29.2 (0.8) 21.8 (4.1) 23.1 (3.5) t41=1.13, p=0.27
e 
CAMCOG 96.3 (2.9) 70.6 (16.4) 75.6 (11.4) t41=1.15, p=0.26
e 
UPDRS III 1.3 (1.5) 1.1 (1.2) 20.0 (8.3) t41=8.37, p<0.001
e 
CAF total - 0.38 (1.12)f 5.1 (4.5)g t39=3.66, p=0.001
e 
Mayo total - 8.9 (4.1)f 14.5 (5.4)g t39=3.31, p=0.002
e 
Mayo cogn - 2.2 (1.9)f 2.9 (1.9)g t39=1.05, p=0.30
e 
NPI total - 5.1 (4.3)f 15.2 (10.9) t40=3.23, p=0.003
e 
NPI hall - 0 (0)f 1.9 (1.7) t40=3.96, p<0.001
e 
AChEI, number of patients taking acetylcholinesterase inhibitors; AD, Alzheimer’s disease; CAF total, 
Clinical Assessment of Fluctuations total score; CAMCOG, Cambridge Cognitive Examination; Duration, 
duration of cognitive symptoms in years; HC, healthy controls; LBD, Lewy body dementia; Mayo total, 
Mayo Fluctuations Scale; Mayo cognitive, Mayo Fluctuation cognitive subscale; MMSE, Mini Mental State 
Examination; PD meds, number of patients taking dopaminergic medication for the management of 
Parkinson’s disease symptoms; UPDRS III, Unified Parkinson’s Disease Rating Scale III (motor 
subsection); NPI, Neuropsychiatric Inventory; NPI hall, NPI hallucination subscore 
a Chi-square test HC, AD, LBD; b One-way ANOVA HC, AD, LBD; c Chi-square test AD, LBD; d Mann 
Whitney U test AD, LBD; e Student’s t-test AD, LBD. 
f N=13, g N=28, h N=13. 
 
 
Table 6.3. Mean [95% confidence interval] of microstate duration and microstate 
occurrence per second in the DLB and PDD subgroups and results from group comparison 
using two-sample t-tests. 
 DLB PDD t-test 
duration    
mean 78.53 [74.9,82.2] 74.86 [69.1,80.6] t(40)=1.2, p=0.24 
A 71.00 [66.9,75.1] 70.93 [65.7,76.2] t(40)=0.02, p=0.98 
B 71.11 [67.2,75.0] 70.77 [64.1,77.5] t(40)=0.1, p=0.92 
C 76.98 [72.2,81.7] 73.89 [68.3,79.4] t(40)=0.9, p=0.39 
D 83.58 [78.0,89.2] 74.92 [67.9,82.0] t(40)=2.0, p=0.05 
E 79.2 [72.3,86.2] 74.26 [67.8,80.7] t(40)=1.0, p=0.30 
occurrence    
mean 13.25 [12.7,13.8] 13.95 [12.8,15.1] t(40)=1.2, p=0.22 
A 2.47 [2.2,2.7] 2.76 [2.4,3.1] t(40)=1.6, p=0.13 
B 2.40 [2.3,2.5] 2.67 [2.4,2.9] t(40)=2.0, p=0.053 
C 2.63 [2.5,2.8] 2.86 [2.6,3.2] t(40)=1.5, p=0.14 
D 3.03 [2.8,3.2] 2.83 [2.5,3.2] t(40)=1.0, p=0.32 
E 2.72 [2.6,2.9] 2.83 [2.6,3.1] t(40)=0.9, p=0.38 
DLB, dementia with Lewy bodies; PDD, Parkinson’s disease dementia. 
 
 
  
128 
 
6.3.2 Cluster evaluation 
The optimal number of microstate classes for each participant was determined to be between 
four and eight. The median within each clinical group as well as the overall median was five, 
with no significant differences between the groups (Kruskal-Wallis ANOVA, H(2)=0.93, 
p=0.63). The number of microstate classes was therefore set to five for all subsequent 
analyses.  
Across all participants the mean global explained variance (GEV) of five microstate classes 
was 70% (SD=6%). The mean and standard deviation in each group was 71% (SD=8%) for 
healthy controls, 68% (SD=5%) for AD, and 71% (SD=5%) for LBD. A univariate ANOVA 
showed that there were no significant group differences (F(2,84)=3.01, p=0.06). Post-hoc tests 
(Bonferroni-corrected) showed that there were no differences between patients with AD and 
controls (p=0.20) or between LBD patients and controls (p=1.0). However, there was a trend 
for smaller GEV in the AD compared to the LBD group (p=0.07). 
6.3.3 Microstate topographies 
Group microstate maps and the overall maps across all participants are shown in Figure 6.2. 
Microstate classes A to D corresponded well to the canonical microstate maps that have been 
reported in the literature (Michel and Koenig, 2017). There was an additional microstate class 
E that resembles a slightly lateralised version of class D and might be comparable to the 
deviant microstate topography of class C that has been described in Grieder et al. (2016) in a 
group of patients with semantic dementia. 
The overall TANOVA revealed a significant main effect of microstate class (p=0.0002) and a 
main effect of group (p=0.0002), but no interaction between the two factors (p=0.45). Follow-
up TANOVAs for each microstate class showed that the AD topographies were different from 
both the healthy controls and LBD topographies for all microstate classes (see Figure 6.2 and 
Table 6.4). In contrast, there were no significant differences between healthy controls and 
LBD topographies for any microstate class. These results did not change when analysing 
matched dementia subgroups (Table 6.5). 
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Table 6.4. P-values from TANOVA test of microstate topographies for microstate classes A 
to E between groups. The overall two-way TANOVA with microstate class as within-subject 
factor and group as between-subject factor resulted in a main effect of group (p<0.001), a 
main effect of microstate class (p<0.001), but no interaction between the two factors (p=0.45). 
 all groups HC-AD HC-LBD AD-LBD 
A <0.001 <0.001 0.15 <0.001 
B <0.001 <0.001 0.36 <0.001 
C 0.014 0.021 0.38 0.009 
D 0.036 0.049 0.40 0.027 
E 0.006 0.048 0.37 <0.001 
AD, Alzheimer’s disease; HC, healthy controls; LBD, Lewy body dementia. 
 
 
Table 6.5. P-values from TANOVA test of microstate topographies for microstate classes A 
to E for matched dementia subgroups. The overall two-way TANOVA with microstate class 
as within-subject factor and group as between-subject factor resulted in a main effect of group 
(p<0.001), a main effect of microstate class (p<0.001), but no interaction between the two 
factors (p=0.47). 
 all groups HC-AD HC-LBD AD-LBD 
A <0.001 <0.001 0.11 <0.001 
B <0.001 <0.001 0.22 <0.001 
C 0.013 0.017 0.45 0.009 
D 0.039 0.034 0.47 0.031 
E 0.004 0.027 0.46 <0.001 
AD, Alzheimer’s disease; HC, healthy controls; LBD, Lewy body dementia 
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Figure 6.2. Group comparison of microstate topographies. P-values result from comparing 
microstates topographies between groups using TANOVA. For the comparison between HC 
and LBD all p-values were above 0.1 (see Tables 6.4 and 6.5).  
AD, Alzheimer’s disease; HC, healthy controls; LBD, Lewy body dementia. 
6.3.4 Microstate temporal characteristics 
The mean number of GFP peaks per second was 21.3 in HC, 19.7 in AD, and 17.2 in LBD. 
There was a significant difference between groups (univariate ANOVA, F(2,84)=26.6, 
p<0.001) with Bonferroni-corrected post-hoc tests demonstrating that the number of GFP 
peaks was lower in patients with AD compared to controls (p=0.034), and lower in LBD 
patients compared to controls (p<0.001) and patients with AD (p<0.001).  
Across all microstate classes mean microstate duration was 65 ms in controls, 67 ms in AD 
patients, and 77 ms in the LBD group. A univariate ANOVA followed by post-hoc group 
comparisons showed that mean microstate duration was increased in patients with LBD 
compared to controls and AD patients with no significant difference between AD patients and 
controls (see Figure 6.3A and Table 6.6). Correspondingly, the mean number of unique 
microstate occurrences per second was 16 in controls, 15.5 in AD, and 13.5 in LBD. 
Univariate ANOVA and post-hoc tests showed that the number of unique microstate 
occurrences per second was significantly decreased in patients with LBD compared to 
controls and AD patients with no significant difference between the AD and the control 
groups (Figure 6.3A and Table 6.7). 
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Multivariate ANOVAs followed by post-hoc univariate ANOVAs were conducted to test for 
group differences in mean microstate duration and occurrence for microstate classes A to E 
(see Figure 6.3B and Tables 6.6 and 6.7). Microstate A duration was increased in both 
dementia groups compared to controls with a trend for a further increase in patients with LBD 
compared to AD patients. Occurrence of microstate A was reduced in LBD patients compared 
to controls and patients with AD with no difference between controls and AD patients. The 
other microstates (B to E) showed similar patterns in terms of duration with increased 
duration in LBD patients compared to patients with AD and controls and no difference 
between AD patients and controls. The occurrence of microstates B and C was decreased in 
the LBD group compared to the AD and healthy control groups with no difference between 
controls and AD patients. In contrast, microstate D occurrence was only reduced in patients 
with LBD compared to controls, but there was no difference between controls and AD 
patients and between the dementia groups. The occurrence of microstate E was reduced in 
both dementia groups compared to controls with no difference between the dementia groups.  
To test whether group differences in microstate duration and occurrence were merely due to 
group differences in the number of GFP peaks per second, the microstate analysis was 
repeated, but this time fitting group microstates to each time point of the individual subject 
data instead of only fitting to data at GFP peaks. This analysis was performed in Cartool using 
default smoothing parameters (smoothing half window size of 3 time frames, smoothing 
strength λ=10, and rejecting small segments below 3 time frames). Subsequently, microstate 
characteristics were computed in the same way as described above removing possibly 
truncated microstates from the epoch boundaries. Mean microstate duration and occurrence 
were compared between the groups using univariate ANOVAs. There was an overall group 
effect for microstate duration (F(2,84)=38.66, p<0.001). Post-hoc tests with Bonferroni 
correction for multiple comparisons revealed that microstate duration was longer in the LBD 
group compared to both controls (p<0.001) and AD patients (p<0.001) whereas there was no 
significant difference between healthy controls and patients with AD (p=0.40). There was also 
an overall group effect for microstate occurrence (F(2,84)=50.26, p<0.001). Post-hoc tests 
showed that microstate occurrence per second was lower in the LBD group compared to 
healthy controls (p<0.001) and patients with AD (p<0.001) with no significant difference 
between controls and AD patients (p=0.07). 
Repeating the group comparison analyses with matched dementia groups did not change the 
overall results, but enhanced some of the differences between the AD and LBD groups (Table 
6.8 and 6.9).   
To test whether the marginal group differences in GEV (see Section 6.3.2) had an effect on 
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the results from the group comparison of microstate characteristics, the analyses were 
repeated including GEV as covariate. There was a group difference for mean microstate 
duration (F(2,83)=17.51, p<0.001) and microstate occurrence (F(2,83)=17.14, p<0.001). Post-
hoc tests revealed that microstate duration was increased in the LBD group compared to 
controls (p<0.001) and patients with AD (p=0.001) with no difference between AD patients 
and controls (p=0.13). Microstate occurrence per second was reduced in patients with LBD 
compared to healthy controls (p<0.001) and AD patients (p=0.003) with no significant 
difference between the AD group and healthy controls (p=0.07). Thus, including GEV as a 
covariate did not change the overall significance of the results.  
Microstate coverage, i.e. the percentage of time spent within each microstate, was not 
different between the groups (MANOVA, F(8,164)=1.79, p=0.08); this was further confirmed 
with univariate post-hoc analysis which showed that the total time spent in microstate E was 
slightly reduced in patients with AD compared to controls (p=0.05) while there were no other 
significant differences with respect to microstate coverage (Table 6.10). 
Table 6.6. Mean microstate duration [95% confidence intervals] for microstate classes A to E 
and the three clinical groups, and results from group comparison using univariate ANOVAs 
and pairwise post-hoc tests. Post-hoc p-values are Bonferroni-corrected for multiple 
comparisons. 
 HC AD LBD ANOVA post-hoc (p-value) 
HC-
AD 
HC-
LBD 
AD- 
LBD 
mean 64.7 66.6 77.0 F(2,84)=15.5, 1.0 <0.001 <0.001 
[60.2,69.1] [63.0,70.3] [74.2,79.9] p<0.001 
A 56.6  65.4 71.0 F(2,84)=14.2 0.01 <0.001 0.06 
[52.1,61.1] [61.7,69.1] [68.0,73.9] p<0.001 
B 57.6 62.3 71.0 F(2,84)=12.9 0.38 <0.001 0.003 
[52.9,62.4] [58.5,66.2] [67.9,74.1] p<0.001 
C 60.8 66.9 75.7 F(2,84)=16.0 0.14 <0.001 0.002 
[56.1,65.4] [63.1,70.7] [72.7,78.8] p<0.001 
D 64.2 65.6 80.1 F(2,84)=13.9 1.0 <0.001 <0.001 
[57.9,70.4] [60.5,70.7] [76.0,84.2] p<0.001 
E 67.6 66.7 77.2 F(2,84)=5.7 1.0 0.05 0.01 
[61.0,74.2] [61.3,72.1] [72.9,81.5] p=0.005 
AD, Alzheimer’s disease; ANOVA, analysis of variance; HC, healthy controls; LBD, Lewy body dementia. 
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Figure 6.3. Group comparison of microstate duration and occurrence per second A) overall 
and B) for each microstate class separately. P-values result from pairwise post-hoc tests 
following univariate ANOVAs and are Bonferroni-corrected. See Tables 6.6 and 6.7 for 
detailed information on statistics.  
AD, Alzheimer’s disease; HC, healthy controls; LBD, Lewy body dementia. 
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Table 6.7. Mean microstate occurrence per second [95% confidence intervals] for microstate 
classes A to E and the three clinical groups, and results from group comparison using 
univariate ANOVAs and pairwise post-hoc tests. Post-hoc p-values are Bonferroni-corrected 
for multiple comparisons. 
 HC AD LBD ANOVA post-hoc (p-value) 
HC-
AD 
HC-
LBD 
AD- 
LBD 
mean 16.1 15.5 13.5 F(2,84)=15.1 0.99 <0.001 <0.001 
[15.2,17.0] [14.8,16.3] [12.9,14.1] p<0.001 
A 3.0 3.1 2.6 F(2,84)=5.6 1.0 0.17 0.005 
[2.6,3.3] [2.9,3.4] [2.4,2.8] p=0.005 
B 3.1 2.9 2.5 F(2,84)=8.3 0.87 0.001 0.01 
[2.8,3.3] [2.7,3.1] [2.3,2.7] p<0.001 
C 3.2 3.3 2.7 F(2,84)=8.2 1.0 0.03 <0.001 
[2.9,3.4] [3.1,3.5] [2.5,2.9] p<0.001 
D 3.4 3.2 3.0 F(2,84)=4.3 0.58 0.02 0.31 
[3.1,3.7] [3.0,3.4] [2.8,3.1] p=0.016 
E 3.5 3.0 2.8 F(2,84)=10.8 0.02 <0.001 0.16 
[3.2,3.8] [2.8,3.3] [2.6,2.9] p<0.001 
AD, Alzheimer’s disease; ANOVA, analysis of variance; HC, healthy controls; LBD, Lewy body dementia. 
 
 
Table 6.8. Mean microstate duration [95% confidence intervals] for microstate classes A to E 
for matched dementia subgroups (see Section 6.3.1), and results from group comparison using 
univariate ANOVAs and pairwise post-hoc tests. Post-hoc p-values are Bonferroni-corrected 
for multiple comparisons. 
 HC AD LBD ANOVA post-hoc (p-value) 
HC-
AD 
HC-
LBD 
AD- 
LBD 
mean 64.7 65.6 77.6 F(2,75)=16.0, 1.0 <0.001 <0.001 
[60.1,69.2] [61.7,69.6] [74.4,80.9] p<0.001 
A 56.6  64.7 71.9 F(2,75)=15.5 0.03 <0.001 0.02 
[52.1,61.1] [60.8,68.7] [68.7,75.2] p<0.001 
B 57.6 61.0 71.6 F(2,75)=14.4 0.86 <0.001 <0.001 
[52.9,62.3] [56.9,65.1] [68.2,74.9] p<0.001 
C 60.8 66.2 76.4 F(2,75)=16.6 0.26 <0.001 0.001 
[56.1,65.5] [62.1,70.3] [73.0,79.7] p<0.001 
D 64.2 64.7 79.7 F(2,75)=11.8 1.0 0.001 <0.001 
[57.7,70.7] [59.1,70.3] [75.1,84.3] p<0.001 
E 67.6 65.0 78.4 F(2,75)=7.2 1.0 0.03 0.002 
[60.9,74.3] [59.2,70.9] [73.6,83.1] p=0.001 
AD, Alzheimer’s disease; ANOVA, analysis of variance; HC, healthy controls; LBD, Lewy body dementia. 
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Table 6.9. Mean microstate occurrence per second [95% confidence intervals] for microstate 
classes A to E for matched dementia subgroups (see Section 6.3.1), and results from group 
comparison using univariate ANOVAs and pairwise post-hoc tests. Post-hoc p-values are 
Bonferroni-corrected for multiple comparisons. 
 HC AD LBD ANOVA post-hoc (p-value) 
HC-
AD 
HC-
LBD 
AD- 
LBD 
mean 16.1 15.8 13.5 F(2,75)=15.1 1.0 <0.001 <0.001 
[15.2,17.0] [15.0,16.6] [12.8,14.1] p<0.001 
A 3.0 3.2 2.6 F(2,75)=4.7 1.0 0.24 0.01 
[2.6,3.3] [2.9,3.5] [2.3,2.8] p=0.01 
B 3.0 2.9 2.5 F(2,75)=6.9 1.0 0.003 0.03 
[2.8,3.3] [2.7,3.1] [2.3,2.7] p=0.002 
C 3.1 3.4 2.7 F(2,75)=9.3 0.76 0.04 <0.001 
[2.9,3.5] [3.1,3.6] [2.5,2.9] p<0.001 
D 3.4 3.3 2.9 F(2,75)=6.1 1.0 0.006 0.05 
[3.2,3.7] [3.0,3.5] [2.7,3.1] p=0.004 
E 3.5 3.1 2.7 F(2,75)=10.5 0.08 <0.001 0.08 
[3.2,3.8] [2.9,3.3] [2.6,2.9] p<0.001 
AD, Alzheimer’s disease; ANOVA, analysis of variance; HC, healthy controls; LBD, Lewy body dementia. 
 
 
Table 6.10. Mean microstate coverage [95% confidence intervals] for microstate classes A to 
E and the three clinical groups, and results from group comparison using univariate ANOVAs 
and pairwise post-hoc tests. Post-hoc p-values are Bonferroni-corrected for multiple 
comparisons. 
 HC AD LBD ANOVA post-hoc (p-value) 
HC-
AD 
HC-
LBD 
AD- 
LBD 
A 0.18 0.20 0.18 F(2,84)=2.15 0.20 1.0 0.28 
[0.15,0.20] [0.19,0.22] [0.17,0.20] p=0.12 
B 0.18 0.18 0.18 F(2,84)=0.04 1.0 1.0 1.0 
[0.16,0.19] [0.16,0.19] [0.17,0.19] p=0.96 
C 0.19 0.22 0.20 F(2,84)=2.12 0.14 0.99 0.53 
[0.17,0.21] [0.20,0.23] [0.19,0.21] p=0.13 
D 0.22 0.21 0.23 F(2,84)=1.60 1.0 1.0 0.23 
[0.20,0.25] [0.19,0.23] [0.21,0.25] p=0.21 
E 0.24 0.20 0.21 F(2,84)=3.09 0.05 0.18 1.0 
[0.21,0.26] [0.18,0.22] [0.19,0.23] p=0.051 
AD, Alzheimer’s disease; ANOVA, analysis of variance; HC, healthy controls; LBD, Lewy body dementia. 
6.3.5 Analysis of transition probabilities  
The overall randomisation test showed that transition probabilities were non-random in all 
three groups (controls: p=0.011, AD: p=0.001, LBD: p=0.004). There were, however, no 
group differences in the transition probabilities between different microstate classes 
(MANOVA, F(38,134)=1.38, p=0.1) and these were therefore not examined further. 
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6.3.6 Clinical and behavioural correlations 
Figure 6.4 shows results from Spearman’s correlations between the Mayo fluctuation scales 
and mean microstate duration in the DLB patients with FDR-corrected p-values. There was a 
positive correlation between mean microstate duration and the Mayo total score in the 
combined LBD group (ρ=0.36, pFDR=0.06) which was mainly driven by the DLB patients 
(ρ=0.56, pFDR=0.038) and was not present in the PDD group (p>0.1). A similar pattern was 
observed for the Mayo cognitive subscale whereas correlations were weaker for the Mayo 
arousal subscale (Figure 6.4 and Table 6.11). There were non-significant trend associations 
with CAF total score and CAF duration score with mean microstate duration in the DLB 
group (uncorrected p≤0.10).  
The correlation between mean microstate duration and Mayo total score persisted when 
including LEDD as a covariate (ρ=0.36, p=0.02).  
There were no significant correlations between other clinical scores and mean microstate 
duration in LBD (all uncorrected p>0.05). In the AD group, there was a significant negative 
correlation between mean microstate duration and CAMCOG (ρ=0.56, p=0.03); however, this 
correlation did not survive FDR-correction for multiple comparisons.  
Eighteen HC, 23 AD, and 33 LBD (21 DLB and 12 PDD) participants were included in both 
the microstates and the ex-Gaussian analysis described in Chapter 3. Across these 
participants, mean microstate duration was positively correlated with mu (ρ=0.43, p=0.0002) 
and sigma (ρ=0.39, p=0.0006), but not with tau (ρ=0.12, p=0.32), see Figure 6.5. These 
correlations, however, did not persist when clinical diagnosis (HC, AD, LBD) was added as a 
covariate (mu: ρ=0.18, p=0.12; sigma: ρ=0.20, p=0.09;  tau: ρ=-0.12, p=0.31). 
Table 6.11. Spearman’s correlation between mean microstate duration and Mayo fluctuation 
scores in the combined LBD group and in DLB and PDD separately. 
 LBD DLB PDD 
Mayo total ρ=0.36  
(p=0.023, pFDR=0.06) 
ρ=0.56  
(p=0.004, pFDR=0.04) 
ρ=0.07  
(p=0.79, pFDR=0.88) 
Mayo cognitive ρ=0.33  
(p=0.035, pFDR=0.06) 
ρ=0.51  
(p=0.012, pFDR=0.05) 
ρ=0.17  
(p=0.54, pFDR=0.69) 
Mayo arousal ρ=0.27  
(p=0.10, pFDR=0.14) 
ρ=0.45  
(p=0.027, pFDR=0.06) 
ρ=0.04  
(p=0.88, pFDR=0.88) 
DLB, Dementia with Lewy bodies; FDR, false discovery rate; Mayo total, Mayo Fluctuations Scale; Mayo 
cognitive, Mayo Fluctuation cognitive subscale; Mayo arousal, Mayo Fluctuations arousal subscale; PDD, 
Parkinson’s disease dementia. 
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Figure 6.4. Spearman’s correlations between mean microstate duration and Mayo fluctuation 
scores in the DLB group. P-values are FDR-corrected for multiple comparisons (see Table 
6.11).  
FDR, false discovery rate; Mayo arousal, Mayo Fluctuations arousal subscale; Mayo total, 
Mayo Fluctuations Scale; Mayo cognitive, Mayo Fluctuation cognitive subscale. 
 
 
 
Figure 6.5. Spearman’s correlations between mean microstate duration and the three ex-
Gaussian parameters (see Chapter 3) across all participants. 
AD, Alzheimer’ disease; HC, healthy controls; LBD, Lewy body dementia. 
 
6.3.7 Effect of dopaminergic medication in the LBD group 
There were no significant differences between LBD patients who were taking dopaminergic 
medication compared to those who were not on these medications (Table 6.12). Furthermore, 
there was no significant correlation between LEDD and mean microstate duration (Pearson’s 
r=0.02, p=0.92) as well as mean microstate occurrence per second (Pearson’s r=-0.01, 
p=0.94). 
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Table 6.12. Mean [95% confidence interval] of microstate duration and microstate occurrence 
per second comparing LBD patients who were not on dopaminergic medication (no PD meds, 
N=13) to those LBD patients who were taking dopaminergic medication (PD meds, N=29) 
and group comparison using two-sample t-tests. 
 LBD,  
no PD meds  
LBD,  
PD meds 
t-test 
duration    
mean 80.3 [75.1,85.6] 75.6 [71.7,79.5] t(40)=1.5, p=0.16 
A 72.9 [66.9,78.9] 70.1 [66.3,73.9] t(40)=0.83, p=0.41 
B 73.2 [67.3,79.0] 70.0 [65.7,74.3] t(40)=0.88, p=0.38 
C 79.6 [74.1,85.0] 74.0 [69.5,78.5] t(40)=1.5, p=0.14 
D 82.1 [72.7,91.6] 79.1 [74.0,84.3] t(40)=0.63, p=0.53 
E 81.9 [70.2,93.5] 75.1 [70.2,80.1] t(40)=1.3, p=0.19 
occurrence    
mean 12.9 [12.2,13.7] 13.8 [13.0,14.5] t(40)=1.4, p=0.16 
A 2.5 [2.1,2.8] 2.6 [2.4,2.9] t(40)=0.91, p=0.37 
B 2.3 [2.2,2.5] 2.6 [2.4,2.8] t(40)=1.7, p=0.10 
C 2.6 [2.3,2.8] 2.8 [2.6,3.0] t(40)=1.3, p=0.19 
D 2.9 [2.6,3.1] 3.0 [2.7,3.2] t(40)=0.46, p=0.65 
E 2.7 [2.4,3.0] 2.8 [2.6,3.0] t(40)=0.84, p=0.41 
LBD, Lewy body dementia; PD meds, dopaminergic medication. 
6.3.8 Relation between dynamic connectivity and microstate duration 
In the LBD group, mean variability of connectivity between the basal ganglia network and all 
other networks was negatively related to mean microstate duration (r=-0.53, p=0.003, Figure 
6.6A). When considering each connection separately, there were six networks whose dynamic 
interaction with the basal ganglia network was negatively correlated with mean microstate 
duration: two motor networks (right motor network and medial sensorimotor network), three 
visual networks (medial visual network, superior visual network, and lingual gyrus network) 
and the default mode network 2 (all p<0.05, uncorrected, see Table 6.13). After correcting for 
multiple comparisons, the dynamic interaction between the basal ganglia network and the 
medial visual network was still significantly correlated with mean microstate duration.  
For the thalamic network, overall dynamic connectivity was also negatively related to mean 
microstate duration (r=-0.38, p=0.044, Figure 6.6B). When considering each connection 
separately, there were four networks whose dynamic interaction with the thalamic network 
was negatively correlated with mean microstate duration: the insular network 2, the lateral 
sensorimotor network, the occipital pole network, and the cerebellar network 2 (all p<0.05, 
uncorrected, see Table 6.14). After correcting for multiple comparisons, the dynamic 
interaction between the thalamic network and the lateral sensorimotor network was still 
significantly correlated with mean microstate duration. 
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Figure 6.7 shows correlations between overall dynamic connectivity of basal ganglia and 
thalamic networks in healthy controls and patients with AD, none of which were significant. 
 
Figure 6.6. Results from Pearson’s correlation analysis between mean microstate duration 
and dynamic functional connectivity of A) the basal ganglia network and B) the thalamic 
network in the LBD group. The panels on the right show results from correlating mean 
microstate duration with each individual network connection. Grey arrows indicate significant 
correlations at an uncorrected threshold of p<0.05 and red arrows indicate connections that 
survive Bonferroni correction for multiple comparisons (all significant correlations were 
negative). All correlation coefficients and corresponding p-values are shown in Tables 6.13 
and 6.14. All network names and locations can be found in Table 4.1 in Chapter 4. 
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Figure 6.7. Results from Pearson’s correlation analysis between mean microstate duration 
and mean dynamic functional connectivity of basal ganglia and thalamic networks in A) 
healthy controls and B) AD.
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Table 6.13. Pearson’s correlation coefficients and p-values from correlation between mean 
microstate duration and basal ganglia network dynamic connectivity for each network 
separately in the LBD group. 
Network name r puncorrected pFDR  
medial visual network -0.57 0.001 0.029 
superior visual network  -0.50 0.006 0.07 
default mode network 2 -0.46 0.013 0.11 
lingual gyrus network -0.39 0.037 0.18 
medial sensorimotor network  -0.38 0.045 0.18 
right motor network -0.37 0.047 0.18 
ventral attention network  -0.36 0.058 0.18 
right fronto-parietal network -0.35 0.059 0.18 
dorsal attention network  -0.31 0.10 0.23 
cerebellar network 1 -0.31 0.10 0.23 
insular network 1 -0.30 0.11 0.23 
default mode network 1  -0.30 0.12 0.23 
supplementary motor area network  -0.30 0.12 0.23 
insular network 2 -0.24 0.20 0.34 
left fronto-parietal network -0.24 0.21 0.34 
occipital pole network -0.24 0.22 0.34 
cerebellar network 2 -0.22 0.26 0.39 
anterior cingulate network  0.19 0.32 0.45 
default mode network 3 0.13 0.49 0.65 
temporal pole network  -0.11 0.56 0.70 
lateral sensorimotor network 0.05 0.79 0.90 
lateral visual network 0.05 0.79 0.90 
temporal network 0.04 0.84 0.91 
supramarginal gyrus network -0.02 0.90 0.94 
left motor network 0.002 0.99 0.99 
FDR, false discovery rate. 
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Table 6.14. Pearson’s correlation coefficients and p-values from correlation between mean 
microstate duration and thalamic network dynamic connectivity for each network separately 
in the LBD group. 
Network name r puncorrected pFDR  
lateral sensorimotor network -0.59 0.0008 0.019 
cerebellar network 2 -0.43 0.021 0.22 
insular network 2 -0.40 0.031 0.22 
occipital pole network -0.39 0.034 0.22 
ventral attention network -0.31 0.10 0.51 
cerebellar network 1 -0.26 0.17 0.58 
supramarginal gyrus network -0.25 0.20 0.58 
lateral visual network  -0.24 0.21 0.58 
right motor network  -0.24 0.22 0.58 
insular network 1 -0.23 0.23 0.58 
supplementary motor area network -0.19 0.32 0.73 
medial sensorimotor network  -0.18 0.35 0.73 
left fronto-parietal network -0.15 0.44 0.85 
default mode network 3 -0.12 0.52 0.94 
anterior cingulate network -0.08 0.69 0.98 
left motor network -0.07 0.70 0.98 
default mode network 1 0.05 0.78 0.98 
default mode network 2 -0.05 0.80 0.98 
medial visual network 0.04 0.82 0.98 
temporal pole network  -0.04 0.84 0.98 
lingual gyrus network -0.02 0.90 0.98 
right fronto-parietal network -0.02 0.93 0.98 
dorsal attention network  -0.01 0.96 0.98 
temporal network 0.01 0.96 0.98 
superior visual network   0.005 0.98 0.98 
FDR, false discovery rate. 
6.4 Discussion 
In this chapter, I investigated changes in brain dynamics in patients with LBD compared to 
healthy ageing and AD patients using an EEG microstate analysis to assess temporal 
characteristics of brain activity on a sub-second timescale and the relation between microstate 
dynamics and large-scale fMRI network dynamics within the cortical-basal ganglia-thalamic 
loop. 
6.4.1 Microstate dynamics 
There was a marked and generalised slowing of microstate dynamics in patients with LBD 
compared to both healthy controls and AD patients while temporal microstate characteristics 
in patients with AD were largely comparable to healthy control levels. Patients with LBD 
stayed in the same microstate class for longer consecutive periods of time and switched less 
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frequently between different states than healthy controls and AD patients. This was not 
specific to a certain microstate class as reported for other diseases (Kikuchi et al., 2011; 
Koenig et al., 1999; Nishida et al., 2013), but rather a general pattern observed for all classes 
which suggests that general microstate timing mechanisms are affected in LBD.  
The observed slowing of microstate dynamics in the LBD group indicates a relative loss of 
resting-state brain variability compared to healthy ageing and AD patients and is in line with 
the observation of a loss of brain network flexibility in DLB as evidenced by the dynamic 
fMRI network analysis in Chapter 5. The importance of variability in the brain has been 
confirmed in many studies (see Garrett et al. (2013b) for a review) relating less variability to 
ageing (Grady and Garrett, 2018; Guitart-Masip et al., 2016) and poorer performance on 
various cognitive tests (Jia et al., 2014; McIntosh et al., 2008). Reduced microstate dynamics 
in LBD could therefore be an indicator of less flexible, and ineffective, brain functioning.  
Apart from being an indicator of brain variability at rest, microstates show elaborate dynamic 
properties that are important for optimal brain functioning. In the healthy brain, microstate 
sequences have been shown to exhibit scale-free or fractal dynamics, i.e. the microstate time 
course is statistically self-similar across multiple timescales (Van De Ville et al., 2010). The 
observation of scale-free properties in a dynamic system indicates that the system operates 
near a point of criticality, fluctuating around a phase transition (Hesse and Gross, 2014; 
Tagliazucchi et al., 2012a). This state makes the system optimally adaptable enabling it to 
respond to incoming information and unpredictable stimuli by providing a self-organising 
mechanism and preventing the emergence of excessive periodicity at the same time 
(Goldberger et al., 2002). The extent of scale-free dynamics can also be used as an indicator 
of a system’s dynamic complexity with a reduction in fractal dimension indicating a loss of 
system complexity (Zappasodi et al., 2014). In the context of microstate sequences, it was 
shown that scale-free properties are preserved when the temporal sequence of the microstate 
labels is randomised, whereas these long-range dependencies are lost when equalising 
microstate duration (Van De Ville et al., 2010). This shows that the exact sequence of 
microstate classes is not crucial, but rather their duration seems to be the key parameter for 
the emergence of scale-free dynamics and thus optimal network properties. The observed 
abnormalities in microstate timing in LBD could therefore have significant consequences for 
the functioning of the whole brain network: disturbing its intricate fractal dynamics results in 
a less complex system that loses its adaptability and lacks flexibility when responding to 
external environmental stimuli. 
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6.4.2 Clinical and behavioural relevance of microstate dynamics in LBD 
In line with this hypothesis, there was a correlation between the severity of cognitive 
fluctuations and temporal microstate abnormalities in the DLB group, suggesting that more 
severe cognitive fluctuations are related to a greater slowing of microstate dynamics; this 
relationship was stronger for the cognitive/attentional dimensions of cognitive fluctuations as 
opposed to arousal or alertness (Bliwise et al., 2014). Additionally, microstate dynamics were 
found to be largely intact in an AD group of comparable dementia severity. This indicates that 
the alterations in dynamic properties in LBD might drive the brain network away from the 
point of criticality that is important for healthy cognitive functioning towards a state that 
allows for the emergence of cognitive symptoms that are specific to LBD such as fluctuating 
cognition (Ferman et al., 2004). However, the relationship between microstate dynamics and 
the severity of cognitive fluctuations was specific to the DLB group and was not observed in 
the PDD patients. This might suggest a different aetiology of cognitive fluctuations in PDD 
patients even though clinically they present very similarly to DLB (Ballard et al., 2002a; 
Varanese et al., 2010). Some of this may also relate to difficulties in assessing fluctuating 
cognition in patients with more advanced PD due to the confounding presence of motor 
fluctuations or the more significant levodopa load in these patients, although notably, in this 
investigation there was no association between LEDD and any of the microstate metrics. 
Furthermore, there was a relation between mean microstate duration and behavioural 
measures across all participants showing that slower microstate dynamics were associated 
with slower and less consistent RT performance on the attention task described in Chapter 3. 
This provides further evidence for the behavioural significance of brain dynamics in LBD and 
confirms previous studies showing a relationship between fMRI dynamics and RT 
performance (McIntosh et al., 2008). The present results indicate that this relationship also 
persists when considering dynamics on a faster timescale as measured by EEG. However, it 
has to be noted that the correlations were greatly attenuated when considering clinical 
diagnosis as a covariate, indicating that they were influenced by group differences in 
microstate duration and behavioural measures. 
6.4.3 Microstate dynamics in AD 
The observation of largely preserved microstate dynamics in patients with AD agrees with 
two previous studies that similarly reported no differences between AD patients and age-
matched controls in terms of the microstates’ temporal characteristics (Grieder et al., 2016; 
Nishida et al., 2013). In contrast to the present results, Nishida et al. (2013) found that 
transition probabilities in AD patients showed a pattern that was compatible with random 
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transitions. AD patients in this previous study showed a comparable level of cognitive 
impairment to the patients described here. However, patients in the Nishida et al. study were 
not taking any cholinergic medications whereas the large majority of patients in the present 
study were on acetylcholinesterase inhibitors which have been shown to alter resting-state 
EEG characteristics in AD (Babiloni et al., 2013) and might thus be an explanation for the 
different results.  
An alteration in the topographical structure of the microstates was only observed in the AD 
group while topographies in patients with LBD did not differ significantly from healthy 
controls. This highlights again that it is primarily microstate dynamics that seem to be 
affected by LBD. In contrast, the change in microstate topographies in the AD patients might 
be due to the greater structural abnormalities in this condition compared to LBD (Mak et al., 
2015b, 2015a). 
6.4.4 Relation to previous EEG findings in LBD 
With respect to previous EEG studies in LBD, a general slowing of oscillatory EEG activity 
as evidenced by a slowing of the dominant frequency is a well-established finding (Bonanni et 
al., 2016; Cromarty et al., 2015; Peraza et al., 2018; Stylianou et al., 2018) and thus it could 
be argued that this global change is driving the observed group differences in microstate 
dynamics. However, when testing the correlation between dominant frequency and mean 
microstate duration in the LBD group, there was only a weak negative correlation which was 
not statistically significant (Pearson’s r=-0.25, p=0.11) (see Peraza et al. (2018) for the 
estimation of dominant frequency). This indicates that while generalised EEG slowing might 
partially contribute to microstate slowing, it does not fully explain the relative loss of 
microstate dynamics in LBD. In contrast, the number of GFP peaks per second was positively 
correlated with dominant frequency in the LBD group (ρ=0.41, p=0.007), indicating that the 
group differences in the number of GFP peaks per second were influenced by differences in 
dominant frequency between the groups (Lehmann et al., 1987; Peraza et al., 2018). However, 
I showed that the results can be replicated when fitting the microstates on all data instead of 
the GFP peaks, further indicating that the well-established finding of EEG slowing in LBD is 
not equivalent to the slowing of microstate dynamics that is described here. 
6.4.5 Origins of microstate disturbances in LBD 
Even though previous studies have found a link between the rapidly changing EEG microstate 
sequences and slower changes of the fMRI signal (Britz et al., 2010; Custo et al., 2017; 
Musso et al., 2010), it remains largely unknown which processes in the brain might be 
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responsible for the emergence of the precise microstate timing and hence their complex 
dynamic properties (Michel and Koenig, 2017). In the present analysis, there was an 
association between less dynamic connectivity between basal ganglia and thalamic networks 
with large-scale cortical networks and a loss of microstate dynamics in the LBD group. These 
findings provide, for the first time, evidence to suggest that the dynamic interaction within the 
cortical-basal ganglia-thalamic loop plays a part in the modulation of global microstate 
dynamics. This is relevant from a LBD perspective as thalamic and basal ganglia dysfunction 
is a hallmark of Lewy body diseases (Delli Pizzi et al., 2015a, 2015b; McKeith et al., 2007; 
Pimlott et al., 2006; Watson et al., 2017). The results therefore support the conjecture that key 
subcortical abnormalities have broader impacts on the overall functioning of the whole-brain 
network in LBD. I speculate that structural and functional changes within subcortical 
structures associated with Lewy body disease contribute to an impairment in the dynamic 
interaction between these subcortical and large-scale cortical networks. This in turn might 
lead to the loss of crucial dynamic properties and hence a reduction in brain adaptability and 
efficiency as described above. Additionally, these results provide a possible explanation for 
how strategic pathology in subcortical structures in LBD can have more widespread impact on 
cognitive functions and symptom manifestation, especially with respect to cognitive 
fluctuations (Delli Pizzi et al., 2015b). 
Apart from being relevant to our understanding of brain abnormalities in LBD patients, the 
present study might also help to further our more general understanding of microstate 
dynamics by providing a first hint at how dynamic microstate properties might be modulated 
by subcortical-cortical dynamics. This has wider implications for a better mechanistic 
understanding of other diseases that are characterised by microstate abnormalities such as 
schizophrenia and depression (Koenig et al., 1999; Lehmann et al., 2005; Strik et al., 1995). 
6.4.6 Limitations 
As discussed in previous chapters, most patients were taking medication that might have 
influenced their fMRI and EEG signals (Babiloni et al., 2013; Szewczyk-Krolikowski et al., 
2014). Similar to previous chapters, dopaminergic medication did not seem to have an effect 
on microstate temporal characteristics whereas an analysis of the effect of 
acetylcholinesterase inhibitors was prevented by the small number of patients not taking these 
medications. More broadly this is relevant to the analyses presented in this chapter, given a 
priori evidence demonstrating a relationship between disruption of the cholinergic system and 
cognitive fluctuations (Ballard et al., 2002b; Colloby et al., 2017; Pimlott et al., 2006) as well 
as remediation of this symptom with acetylcholinesterase inhibitor treatment in LBD (Onofrj 
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et al., 2003). The intimate role of cholinergic efferents, for example from the 
pedunculopontine nucleus, in regulating cortico-thalamic outflow may therefore be apposite 
in shaping microstate dynamics and contribute to these observations. Further work will be 
required to unpick this conjecture.  
In addition, I used non-concurrent EEG-fMRI recordings in this analysis and thus it is only 
possible to draw limited conclusions with respect to a causal influence of network dynamics 
on microstate characteristics. While the present results provide an indication of a link between 
fMRI and EEG dynamics, studying concurrent EEG-fMRI data in the future will allow us to 
draw more concrete conclusions, especially with respect to the causal relation between 
microstate characteristics and large-scale network dynamics. 
6.4.7 Conclusion 
There was a profound slowing of microstate dynamics in LBD patients which clearly 
distinguished this form of dementia from AD and healthy ageing and which was related to the 
severity of cognitive fluctuations in the DLB patients. Disturbances to the precise timing of 
microstate sequences in LBD may lead to a breakdown of the fractal properties of the brain 
system therefore causing a loss of complexity and adaptability of the brain network that is 
crucial for its healthy functioning and which may in turn be related to the emergence of 
transient clinical symptoms such as cognitive fluctuations and impairment in attentional 
processing. Additionally, by using LBD as a probe pathology, I found a potential link 
between large-scale network fluctuations and microstate dynamics, suggesting that dynamic 
interactions within the cortical-basal ganglia-thalamic loop might play a role in the 
modulation of EEG dynamics. 
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Chapter 7. Conclusions and Future Directions 
The objective of this thesis was to combine clinical, behavioural, neuroimaging, and 
electrophysiological data to study how dynamic properties of the brain are differentially 
affected by AD and LBD and how abnormalities in brain dynamics relate to the cognitive 
phenotype of LBD, in particular with respect to attentional impairment and cognitive 
fluctuations. 
7.1 Summary of Main Findings 
7.1.1 Analysis of behavioural data 
Both dementia groups showed slower overall mean RTs than healthy controls, with additional 
slowing in LBD relative to AD. In AD, this RT slowing was related to a reduction in grey 
matter volume in occipital regions while the more pronounced behavioural deficits in LBD 
did not seem to be related to brain structural changes. This implies that either there were more 
specific structural deficits in LBD or that, in the main, deficits are driven by functional 
changes, for example in major neurotransmitter systems such as the cholinergic.  
There was a significant alerting effect in controls which was absent in the dementia groups. 
This inability of the dementia patients to benefit from the cueing effect is indicative of 
reduced efficiency of the alerting system in dementia irrespective of dementia type. In LBD, 
this finding fits with the idea of an association between alerting efficiency and deficiency of 
the noradrenergic system (Coull et al., 2001; Raz, 2004). In AD, however, this result 
contradicts previous findings of maintained alerting efficiency in this group (Fernandez-
Duque and Black, 2006). Given that previous studies included less impaired dementia 
patients, the absent alerting effect in the present analysis may suggest that there is a loss of the 
facilitating cue effect with dementia progression.  
The size of the orienting effect did not differ between AD and controls which agrees with 
previous studies that indicated a preservation of orienting efficiency in AD (Fernandez-Duque 
and Black, 2006). In LBD, there was a slight impairment in orienting efficiency which was 
expected given that the orienting aspect of the attention system is thought to be influenced by 
the basal forebrain cholinergic system which is markedly affected in LBD (Clerici et al., 
2007; Colloby et al., 2017; Grothe et al., 2014). The present study shows that this impairment 
might also be related to a reduction in white matter volume in occipital regions.  
The executive conflict effect was greater in both dementia groups compared to controls, i.e. 
both dementia groups showed an inability to resolve conflict amongst responses which is 
indicative of impaired executive function. This replicates previous findings in AD 
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(Fernandez-Duque and Black, 2006) and is in line with executive dysfunction in LBD (Noe et 
al., 2004) that might be related to degenerations within the dopaminergic system (Fan et al., 
2005; Kehagia et al., 2012). The relative absence of strong correlations between executive 
dysfunction and brain atrophy in both AD and LBD suggests that executive impairment in the 
dementia groups might be more related to functional rather than macrostructural 
pathophysiological changes. 
In the ex-Gaussian distributional analysis it became evident that both dementia groups 
showed an increase in the right tail of the distribution which represents extremely slow 
responses that can be seen as temporary lapses in attention. While there was no difference 
between AD and controls with respect to mean and variability of the Gaussian part of the RT 
distribution, both parameters were significantly increased in LBD patients, indicating a 
general slowing and higher trial-to-trial variability in LBD than in controls and AD. In AD, 
these finding are in agreement with previous studies in preclinical (Balota et al., 2010) and 
early-stage patients (Jackson et al., 2012; Tse et al., 2010), and the present results indicate that 
the same pattern seems to persist in patients at a mild to moderate stage of the disease. 
However, contrary to my hypothesis there was no further increase in LBD compared to AD 
with respect to the number of attentional lapses, and this parameter was not related to 
cognitive fluctuations in LBD, indicating that it is not suitable to capture cognitive 
fluctuations in LBD.  
There were widespread correlations between mean and variability of the Gaussian part and 
grey matter loss in AD, but not in LBD. Overall, the ex-Gaussian analysis showed that 
different aspects of RT performance are differentially affected by AD and LBD, with a 
difference in structural neural correlates underlying the observed behavioural deficits. While 
impaired attentional performance is linked to brain atrophy in AD, in LBD it does not seem to 
be strongly related to macrostructural changes. 
7.1.2 Static and dynamic functional connectivity analysis 
Within-network functional connectivity was generally decreased in DLB compared to healthy 
controls, mainly in motor, temporal, and frontal networks. Decreased connectivity in motor 
structures corresponded well with the clinical manifestation of DLB and agrees with previous 
studies in DLB and PD (Peraza et al., 2016, 2014; Rolinski et al., 2015; Szewczyk-
Krolikowski et al., 2014; Taylor et al., 2013). Reduction in connectivity in non-motor 
networks was mainly found in temporal and frontal regions which agrees with previous 
studies in DLB (Peraza et al., 2014; Taylor et al., 2012) and emphasises the role of 
abnormalities within the ACC in DLB.  
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With respect to DMN connectivity, the present analysis replicates previous studies in AD 
showing markedly reduced connectivity in patients with AD compared to controls 
(Binnewijzend et al., 2012; Greicius et al., 2004). In contrast, the relative sparing of the DMN 
in patients with DLB indicates that the finding of DMN hypoactivity is specific to AD and is 
not present in DLB (Franciotti et al., 2013; Peraza et al., 2014).  
Long-range connections between different networks were mainly intact in patients with DLB 
compared to controls; only the connection between a frontal and a temporal network showed 
increased connectivity in DLB, indicating that temporal/frontal regions are affected in this 
condition. Overall, differences in functional connectivity between AD and DLB were subtle, 
suggesting that AD and DLB may show more similarities than differences with respect to 
static functional connectivity in patients with mild to moderate disease when motion artefacts 
are adequately controlled. The lack of significant correlations between static connectivity 
measures and clinical scores indicates that the observed reduced connectivity within these 
networks might be related to the presence, but not to the severity of motor and cognitive 
impairment in DLB patients. 
When considering changes in functional connectivity over time, it was observed that AD and 
DLB patients spent more time than controls in sparse connectivity configurations with an 
absence of strong positive and negative connections and a relative isolation of motor networks 
from other networks. In contrast, they switched less often into states of high inter-network 
connectivity. This indicates transiently reduced functional connectivity in both dementia 
groups and an inability to temporarily switch out of states of low connectivity into more 
highly and specifically connected network configurations. The fact that this was observed in 
both AD and DLB indicates that this might be related to the presence of dementia in general 
rather than any symptom that is more specific to either dementia group. Additionally, the 
variability of global brain network efficiency was reduced in patients with DLB compared to 
controls which was not observed in the AD group. The dynamic and flexible engaging and 
disengaging of different brain regions has been shown to be important for efficient 
communication within the brain network (Zalesky et al., 2014) and brain variability is 
important for optimal cognitive performance (Jia et al., 2014). The relative loss of global 
efficiency variability that was found in the DLB group might thus indicate the presence of an 
abnormally rigid brain network and the lack of economical dynamics, factors which could 
contribute to cognitive slowing (Firbank et al., 2018) and an inability to respond appropriately 
to situational demands. 
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7.1.3 Dynamic EEG microstate analysis 
Microstate duration was increased in LBD for all microstate classes compared to AD and 
healthy controls with a corresponding reduction in the number of distinct microstates per 
second, indicating that microstate sequences in LBD are less dynamic over time. In contrast, 
microstate dynamics in AD were largely comparable to healthy levels, albeit with altered 
microstate topographies. Given the importance of brain dynamics for healthy cognitive 
functioning (Jia et al., 2014; McIntosh et al., 2008), the reduced microstate dynamics in LBD 
could be an indicator of less flexible and ineffective brain functioning. Additionally, it has 
been shown that microstate sequences exhibit important dynamic properties which can be lost 
when their intricate temporal structure is destroyed (Van De Ville et al., 2010). The observed 
abnormalities in microstate timing in LBD could therefore have significant consequences for 
the functioning of the whole brain network: disturbing its intricate dynamics may result in a 
less complex system that loses its adaptability and is less responsive to environmental 
demands, which might give rise to the apparent slowing in thinking and intermittent confusion 
which typify LBD. This is supported by the finding that a slowing of microstate dynamics 
was related to more severe cognitive fluctuations in the DLB group as well as to RT slowing 
and increased inter-trial variability across all participants as measured by the ex-Gaussian 
analysis, providing evidence for the clinical and behavioural relevance of microstate 
dynamics in LBD. In the LBD group, mean microstate duration was negatively correlated 
with fMRI dynamic functional connectivity between the basal ganglia and thalamic networks 
and large-scale cortical networks, suggesting that dynamic interactions within the cortical-
basal ganglia-thalamic loop may play a role in the modulation of EEG dynamics. The results 
therefore support the conjecture that key subcortical abnormalities may have broader impacts 
on the overall functioning of the whole-brain network in LBD.  
7.2 Strengths 
This thesis used clinical, behavioural, imaging, and electrophysiological data from a large 
group of well-characterised dementia patients and healthy controls by integrating data from 
several previous studies. Therefore, a particular strength of this work is its multimodal 
approach: Combining different data modalities allows to make use of specific advantages of 
each modality. While fMRI has high spatial resolution at the expense of relatively poor 
temporal resolution, the opposite is true for EEG. This makes the combination of both 
neuroimaging methods especially suitable for studying spatial as well as temporal aspects of 
brain function across different timescales. The confirmation of findings across different 
modalities and analyses strategies strengthens the robustness and reliability of the results and 
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makes it more likely that these are actual disease-related effects rather than artefacts specific 
to the type of data or analysis technique that was used.  
A strength of the fMRI analyses presented in this thesis is the application of rigorous motion 
correction techniques prior to the estimation of static and dynamic functional connectivity 
measures. It has recently been shown that motion can have a great influence on fMRI 
measures, in particular with respect to (dynamic) connectivity measures (Power et al., 2012) 
and new methods providing much more stringent control of motion artefacts have been 
developed (Ciric et al., 2017). While previous studies in DLB have relied on rather weak 
motion correction techniques, it has been shown that motion artefacts can mimic group 
differences in fMRI studies (Parkes et al., 2018; Power et al., 2015). Control of these 
confounds is therefore especially important when analysing differences between clinical 
groups (van Dijk et al., 2012) and insufficient control of motion artefacts in previous studies 
might partly explain why functional connectivity findings in DLB are inconsistent. The 
present study is therefore a first step towards more robust estimation of functional 
connectivity in LBD. Furthermore, the use of an independent healthy control group in 
conjunction with meta ICA for RSN estimation allowed to study the effect of DLB and AD on 
robustly estimated healthy networks instead of studying RSNs estimated from an average of 
all participants as commonly done in previous studies (Lowther et al., 2014; Peraza et al., 
2014). The current approach has also been shown to be more sensitive for finding functional 
connectivity differences between clinical groups (Griffanti et al., 2016).  
The EEG microstate analysis presented here provides a novel approach for studying EEG data 
that has not been applied to LBD before despite a large body of literature on EEG 
abnormalities in LBD (Cromarty et al., 2015). Microstates offer a conceptually simple, yet 
powerful tool to study brain dynamics on a sub-second timescale, they show high test-retest 
reliability, and can be reliably estimated from a short resting-state EEG recording with as few 
as eight electrodes (Khanna et al., 2014), which supports their potential use as biomarkers in 
clinical settings.  
Furthermore, combining EEG and fMRI data and using LBD as a probe pathology meant that 
it was possible to identify a potential link between the dynamic interaction of subcortical and 
cortical networks and the modulation of the cortical EEG signal. These results do not only 
provide a better understanding of LBD-related changes in dynamic brain processes, but might 
have wider implications for other diseases that are characterised by microstate abnormalities 
such as schizophrenia and depression (Koenig et al., 1999; Lehmann et al., 2005; Strik et al., 
1995). 
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7.3 Limitations 
A limitation that this study shares with all ante-mortem dementia studies is that diagnoses 
were based on clinical assessment rather than pathological confirmation. However, while a 
definite LBD/AD diagnosis cannot be obtained without post-mortem examination, it has been 
shown that the standardised clinical criteria used here show high specificity when validated 
against autopsy findings (McKeith et al., 2000a). In the future, as pathological information 
becomes available for more participants, it will be important to see how the results hold up 
and to investigate specific characteristics of mixed AD/DLB cases if possible.  
As mentioned in the individual chapters, a further potential limitation is that some of the DLB 
and PDD patients were on dopaminergic medication and scanned in the ON motor state which 
might have influenced their functional connectivity and EEG measures (Szewczyk-
Krolikowski et al., 2014). However, it has been shown that dopaminergic medication tends to 
normalise the signals towards more healthy levels (Szewczyk-Krolikowski et al., 2014; 
Tahmasian et al., 2015), which implies that the group differences that are reported here were 
not due to medication. Additionally, an analysis of the effect of dopaminergic medication was 
conducted in each chapter by comparing those patients taking dopaminergic medication to 
those patients who were not on these medications and by evaluating correlations with LEDD. 
Overall, these analyses showed that the results presented in this thesis did not seem to be 
influenced by the use of dopaminergic medication. However, in future studies it would be 
interesting to compare the same LBD patients on and off medication to better understand the 
effects of dopaminergic medication on fMRI and EEG dynamics.  
The majority of dementia patients were also taking acetylcholinesterase inhibitors which have 
been shown to influence RT measures (Onofrj et al., 2003), and modulate the EEG (Babiloni 
et al., 2013; Onofrj et al., 2003) and fMRI signal (Solé-Padullés et al., 2013). In contrast to 
dopaminergic medication, the influence of acetylcholinesterase inhibitors on the results could 
not be examined further due to the very small number of patients not on these medications 
and therefore remains as a potential limitation of this work. This is especially salient given 
that cognitive fluctuations are thought to be related to alterations within the cholinergic 
system (Ballard et al., 2002b; Colloby et al., 2017; Pimlott et al., 2006). From a research point 
of view, further work is therefore required in order to learn more about the influence of 
cholinergic medication on the results presented in this thesis. However, in clinical practice 
most dementia patients will be on acetylcholinesterase inhibitors and it is therefore also 
important to study medicated patients if a potential clinical application should be considered.  
Due to the fact that the ARThippo study did not recruit PDD patients, this condition was not 
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included in the fMRI analyses where data from the CATFieLD and ARThippo studies were 
combined. While a previous comparison of static fMRI functional connectivity between DLB 
and PDD patients found only subtle differences (Peraza et al., 2015a), it remains unknown 
how connectivity dynamics might differ between the two conditions and this will therefore 
form an important part of future work.  
Additionally, there were some limitations with respect to the quality of the fMRI data. In 
particular, the relatively long TR posed difficulties when trying to assess dynamic 
connectivity fluctuations. Furthermore, the relatively small number of volumes of the resting-
state scans might have resulted in difficulties regarding the robustness of the dynamic 
connectivity estimates as it has recently been recommended that at least 10 minutes of fMRI 
resting-state data should be used to obtain reliable dynamic connectivity estimates (Hindriks 
et al., 2016). The dynamic fMRI results presented in this thesis will therefore need to be 
replicated in a dataset with longer scan duration and lower TR. 
7.4 Conclusions 
To summarise, this thesis sought to characterise the brain dynamics of LBD in comparison to 
AD and healthy ageing and to investigate possible clinical and behavioural correlates. The 
results suggest that brain dynamics in LBD are dysfunctional and that a disturbance of the 
intricate temporal coordination of brain activity might give rise to clinical symptoms that are 
characteristic of LBD such as cognitive fluctuations and attentional impairment. More 
specifically, I showed that there is a relative loss of brain dynamics in LBD compared to 
healthy ageing which does not seem to be present in AD patients of comparable disease 
severity. This result indicates that the complex functional brain network might lose its 
temporal variability and flexibility when targeted by LBD pathology. The importance of a 
dynamic brain for healthy cognitive functioning is well-established (Garrett et al., 2011; Jia et 
al., 2014; McIntosh et al., 2008; Van De Ville et al., 2010; Zalesky et al., 2014); I would 
therefore argue that dysfunctional brain dynamics in LBD will have a great impact on brain 
function in these patients with wider consequences in terms of clinical and behavioural 
symptoms. Evidence for this claim is provided by the observation that a loss of brain 
dynamics was related to the severity of cognitive fluctuations in DLB and to attentional 
impairment across the whole study population. Additionally, I showed that dysfunctional 
whole-brain dynamics in LBD might be driven by abnormalities in subcortical structures that 
are characteristic of LBD (Delli Pizzi et al., 2015b; McKeith et al., 2007; Pimlott et al., 2006). 
This emphasises the importance of alterations in subcortical structures in Lewy body diseases 
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and raises the prospect that therapies targeted at these structures may also have a global effect 
on overall brain functioning in LBD including cognitive fluctuations.  
7.5 Future directions 
An important step of future work should be the replication of the results in larger and 
independent cohorts. This is especially important for the dynamic connectivity measures 
given potential concerns regarding the quality of the fMRI data as discussed above (see 
Section 7.3).  
Apart from this, several future directions can be taken based on the work presented in this 
thesis.  
This thesis has focussed solely on the analysis of resting-state fMRI and EEG data. An 
important next step is the extension of these analyses to task-based data which would allow a 
more direct assessment of the behavioural significance of brain dynamics in LBD. This could, 
for instance, involve assessing how brain dynamics during task execution are related to task 
performance and accuracy, or measuring how brain dynamics during pre-stimulus intervals 
can influence subsequent task performance. Another interesting aspect would be the 
comparison between brain dynamics during the resting state and upon task execution. In this 
context, it has been shown that younger and faster performing individuals show a larger 
increase in brain variability on task compared to rest than older and slower participants, 
emphasising the importance of an increase in brain variability for optimal task performance 
(Garrett et al., 2013a). It could thus be hypothesised that in addition to brain variability at rest 
being diminished in LBD, the increase in dynamics from rest to task may also be smaller in 
LBD patients compared to healthy individuals, and this might play a role in attentional 
impairment and cognitive fluctuations. 
Regarding dynamic fMRI connectivity measures, there have been rapid developments in new 
methods over the last few years introducing many emerging techniques that can be more 
robust and reliable than sliding window approaches (Cabral et al., 2017; Liégeois et al., 2017; 
Pedersen et al., 2018; Vidaurre et al., 2017). The main advantage of the sliding window 
approach that was used here is its simplicity and computational efficiency which makes it 
especially suitable for clinical applications. However, an important aspect of future work will 
be the application of other dynamic connectivity methods to the present dataset to check 
whether it is possible to replicate the results using more complex models of dynamic 
connectivity. 
Given the importance of the cholinergic system in the aetiology of cognitive fluctuations in 
LBD (Ballard et al., 2002b; Colloby et al., 2017; Onofrj et al., 2003; Pimlott et al., 2006), it 
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would be interesting to study the relationship between cholinergic system degeneration and 
the loss of brain dynamics described in this thesis. This could be achieved, for instance, by 
considering the relation between brain dynamics (e.g. microstate duration) and atrophy of 
cholinergic structures such as the substantia innominata (Colloby et al., 2017), by studying the 
effect of acetylcholinesterase inhibitors on brain dynamics, or by investigating the 
relationship between brain dynamics and an EEG-based marker of cholinergic activity 
(Johannsson et al., 2015). 
To better comprehend the relationship between EEG and fMRI dynamics and to further 
investigate possible drivers of EEG microstate dynamics, it would be interesting to study data 
from concurrent EEG and fMRI recordings. Importantly, this would allow to draw more direct 
conclusions about the causal relationship between subcortical functional connectivity 
alterations and slowing of EEG microstate dynamics in LBD. 
There has been a recent initiative in clinical neuroimaging to move away from simple 
comparisons of means between clinical groups towards more individualised and normative 
approaches to account for and better understand variability within clinical populations 
(Marquand et al., 2016). This is especially relevant in the context of dementia, and LBD in 
particular, where heterogeneity is large and clinical groups might be overlapping. Applying 
normative approaches to LBD would therefore be an important step towards a better 
understanding of this clinical heterogeneity and its neural correlates which could eventually 
pave the way for more personalised interventions and care. It would also help to learn more 
about the complicated relationship between AD, DLB, and PDD and would be especially 
helpful in cases of mixed pathologies that might lead to a clinical manifestation where there is 
no unambiguous assignment to a certain diagnostic group. More generally, while the analyses 
presented here are useful to provide an idea of overall group differences between LBD, AD, 
and healthy controls, it will be important to consider approaches that operate on a single-
subject level if the eventual goal is to translate these approaches to clinical practice.  
Finally, given that cognitive fluctuations have been suggested to be one of the most 
characteristic features of DLB patients at the preclinical stage (Donaghy et al., 2017), it would 
be of great interest to repeat the analyses presented here in a cohort of prodromal DLB 
patients. This would allow us to investigate whether the observed alterations in fMRI and 
EEG dynamics might already be present at an early stage of the disease and might potentially 
be used as an early biomarker of LBD and cognitive fluctuations. Additionally, while this 
thesis focussed on the analysis of cross-sectional data, it will be important to also study 
longitudinal data to understand how brain dynamics in LBD develop as the disease 
progresses.  
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